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Abstract
Yersinia pestis, the causative agent of plague, has killed millions throughout human
history. Today, it remains a significant threat for use as a bioweapon. Naturally occurring
antibiotic resistance has been observed in Y. pestis isolates, and resistant strains have been
engineered for use in biological warfare. Vaccines remain our best means of protection
against plague, as well as countless other global contagions.
We have developed a vaccine consisting of two Y. pestis virulence proteins, LcrV (V)
and F1, conjugated to Tobacco Mosaic Virus (TMV), a safe, non-replicating plant virus that
can be administered mucosally, providing complete protection against pneumonic plague, the
deadliest form of the disease and the one most likely to be seen in a bioterror attack. The goal
of this dissertation was to understand the mechanism(s) by which intranasal (i.n.)
administration of TMV-F1 and TMV-V conjugates enhanced vaccine-specific immunity in a
mouse model of pneumonic plague. I hypothesized that the recombinant TMV (rTMV) virion
was enhancing the immune response to the associated subunit proteins through direct uptake
of the virus by APCs and could induces responses analogous to VLP vaccines. The resulting
high-density display of antigens on the virus acts as an immunostimulant when compared to
their soluble forms, without the need for adjuvants.
My research was divided into three overarching aims: (1) APC uptake of TMV
conjugates, (2) T and B cell responses from TMV conjugate immunization, and (3) use of
TMV conjugates in a single dose plague vaccine and its efficacy in controlling inflammation
and bacterial dissemination. Challenge experiments utilized BSL-2 Y. pestis strains with the
chromosomal pgm locus deleted (CO92pgm−) or mutated (KIM5caf1A). We found TMV
conjugation to F1 and V increased their uptake into splenic and mucosal B-cells, and

xv

BMDCs in vitro, as well lung DCs in vivo, and was not due to any TMV-specific mechanism.
We could not show that these vaccines were immunostimulants, as both conjugates failed to
upregulate MHC II, CD80, or CD86 over that of unstimulated CD11c+ DCs in vitro.
We also demonstrated that generation of antibody‐based, but not T cell-based,
immunity could be attributed to vaccination with TMV conjugates. Mice immunized i.n. with
TMV-F1, specifically, predictably developed high F1-specific serum IgG titers after single
and multiple administrations. When applied to an infection model using F1+ Y. pestis
CO92pgm-, we observed that the protective memory response induced by TMV vaccination
did not require CD4+ or CD8+ T cells. This protection is lost against F1- Y. pestis, where
mice vaccinated with TMV-F1+TMV-V demonstrated poor protection.
Finally, TMV-F1+TMV-V vaccination showed significant reduction in
histopathology, bacterial burden, and inflammatory cytokine production in the days
following challenge with 100 LD50 Y. pestis CO92pgm-. Pneumonic challenge with this
strain resulted in systemic dissemination of the bacteria in all groups, but only TMVF1+TMV-V immunized mice rapidly cleared bacteria from the spleen and liver within 5
days. There was a direct correlation between pre-challenge serum F1 titers and protection in
all immunized mice, strongly suggesting a role for anti-F1 antibody in the neutralization
and/or opsonization of Y. pestis in this model. Furthermore, the TMV-F1+TMV-V i.n.
vaccine was capable of mediating single-dose protection.
Taken together, my data indicates the usefulness of rTMV – an inactivated virus – as
a carrier for VLP immunogenic presentation and mucosal delivery of whole protein antigens.
This particulate vaccine has the ability to target antigens to DCs at mucosal surfaces, which
elicits a potent antiviral-like immune response to the bound proteins in the form of

xvi

neutralizing IgG antibodies. T follicular helper (TFH) cells may be required in the activation
of naïve B cells and/or activation and maintenance of memory B cells in secondary lymphoid
organs. Further work should identify where vaccine-specific IgG+ memory B cells reside
(lymph nodes or spleen) after i.n. immunization with the TMV conjugates, the duration of B
cell memory in this model, and reasons for why TMV-V immunization cannot generate
100% protection against plague.
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Chapter 1. Introduction
Dissertation Premise and Rationale
In 2016, our laboratory reported a study comparing two mucosal plague vaccines: a
LcrV (V) antigen-expressing Lactobacillus plantarum (V-L.p.) live vectored vaccine, and a
subunit vaccine, consisting of Tobacco Mosaic Virus (TMV) covalently conjugated to F1
antigen, the Yersinia pestis capsule protein, and LcrV (V) antigen, the tip protein of the
Yersinia type 3 secretion system (T3SS) (Arnaboldi et al., 2016). The virion is a recombinant
TMV engineered to display a surface-exposed lysine on the CP, which allows for amine
conjugation of proteins to its surface. Mice were orally and intranasally (i.n.)-immunized
with V-L.p., and i.n.-immunized with TMV-F1 and TMV-V. For either vaccine, no adjuvant
was administered. In the case of i.n. immunization with V-L.p., mice were primed and
boosted twice (day 28 and 56). For i.n. immunization with the TMV conjugates, mice also
were primed and boosted twice (day 21 and 35). All immunized mice were challenged on day
70 with an i.n. lethal dose (10 LD50) of the pigmentation-deficient (pgm−) Y. pestis CO92
defined mutant. This attenuated strain enables us to work with the organism in our Animal
Biosafety Level (ABSL) 2 facility. Pgm− Y. pestis strains lack a 102 kb chromosomal
fragment (pgm locus) encoding iron binding and transport functions, and its deletion
attenuates virulence due to the bacterium’s inability to efficiently acquire host iron
(Buchrieser et al., 1998; Fetherston and Perry, 1994). Although this strain is considered safe
to most humans, we have verified that it maintains virulence in mice by the i.n. route.
Complete protection in our challenge experiments was only achieved using three
vaccine strategies: a mixture of TMV-F1 and TMV-V, TMV-F1 alone, and intramuscularly

(i.m.)-injected rV and rF1 in alum (positive control). This was surprising given the robust
humoral immune response generated by the i.n. V-L.p. vaccine; V-specific IgG1, IgG2b,
IgG2a, and mucosal IgA were all generated prior to challenge. Still, all V-L.p. vaccinees
succumbed to infection. Mice vaccinated with TMV-V also produced antigen-specific IgG.
V-specific IgG1 was strongly generated by immunization with TMV-V, and titers were
generally increased when TMV-F1 was co-administered with TMV-V. This pattern was also
observed with F1-specific IgG1, IgG2a, and IgG2b. All completely protected mice shared
one thing in common: an antibody response to the F1 protein. For these three groups, mean
titers were always in the thousands to tens of thousands for anti-F1 IgG1 and IgG2b, and in
the tens to hundreds for anti-F1 IgG2a. Higher V-specific titers, meanwhile, did not signify a
better survival outcome. Although mice vaccinated with i.n. TMV-V demonstrated higher
mean anti-V IgG1 and IgG2b titers compared with i.m. rF1+rV vaccination, only 60% of the
TMV-V vaccinated group survived while all mice in the rF1+rV vaccinated group survived.
Furthermore, conjugation to the TMV particle proved necessary for 100% survival, as the
mice i.n.-immunized with rF1+rV or individual rF1 and rV proteins never achieved higher
than 50% survival.
From these findings, we hypothesized that TMV was enhancing the immune response
to the associated subunit proteins through direct uptake of the virus and/or simulation of antiviral immunity. This mechanism of protection appeared to augment the humoral response to
the associated proteins, as F1-specific and V-specific pre-challenge titers were frequently
lower in mice i.n.-immunized with free recombinant protein compared to TMV-F1, TMV-V,
or both conjugates. L. plantarum is a Gram-positive commensal organism, and so it is
possible it does not induce the same level of activation as TMV – an RNA virus. Despite the
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marked difference in protection between mice given i.n. V-L.p. and i.m. rV + alum (positive
control), cytokine secretion was minimal and similar, as measured in ex vivo antigen recall
assays. Other than IL-17, no V-L.p. vaccine-specific cytokines were observed. IgA
production also proved nonessential for pneumonic plague protection. V-specific IgA was
detected in BAL washes of V-L.p.-immunized mice and not in rV + alum-immunized mice,
yet only the latter were protected from infection. The role of CD4+ and CD8+ T cells in
vaccine-induced protection was not assessed in this study, and still needs to be investigated
to rule out (or rule in) the possible contribution of cell-mediated immunity. The most
interesting observation was the synergetic effect of combining TMV-F1 and TMV-V, as
antigen-specific antibody was generally elevated in co-immunized mice compared to mice
that received each conjugate individually. Since the only additive component was the virus, I
speculated that TMV was responsible for this observed effect, although the mechanism was
unclear at the time.
Overall, our experiments provided more questions than it did answers. The study did
succeed in uncovering an effective mucosal plague vaccine. The difference in protection
between the TMV-based and V-L.p. vaccine was clear-cut: the viral particle vaccine
protected (100% survival) while the live vector did not (0% survival). However, vaccineinduced protection could not be discerned simply from antibody levels or any particular
cytokine profile (e.g. T helper 1 (Th1) response). The most logical lead of this investigation,
in my perspective, was to study the response to F1 antigen of Y. pestis, since this was not a
component of the failed V-L.p. vaccine. Clearly, the protective effects of the TMV conjugate
vaccine had something to do with a response to F1 but understanding this response would be
a major focus of this doctoral thesis. Through this body of research, I sought to define the
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immune correlates of protection of the TMV conjugates through studying innate and adaptive
immune responses, as well as the efficacy and application of this mucosal vaccine using a
mouse model of pneumonic plague.

Tobacco Mosaic Virus
1. Structure and Prevalence
According to the International Committee on Taxonomy of Viruses (ICTV), there are
nearly 1,000 different types of plant viruses known to our planet (King et al., 2012). These
viruses typically have simple structures: single-stranded (ss) or double-stranded (ds) DNA or
RNA packed neatly into a matrix of protein capsids. No plant virus, however, may be more
well-known, widely encountered, or relevant to human consumption than the Tobacco
Mosaic virus (TMV). TMV was the first virus discovered in 1898, after the advent of Louis
Pasteur’s Germ Theory and Robert Koch’s identifications of disease-causing bacteria
(Beijerinck, 1898). TMV is a positive (+) sensed ssRNA virus producing mosaic-like
mottling on leaves of infected plants, but namely, Nicotiana spp., or tobacco plants (Fig 1).
TMV belongs to the Tobamoviruses, a genus of closely related viruses that infect numerous
plant species. TMV, specifically, damages 125 different plant species, including common
crops like tomato, cucumber, and pepper plants, in addition to tobacco plants (Yang, Y. and
Klessig, 1996). This has contributed to its prevalence among human, wildlife, and
domesticated animal populations.
TMV is a rod-shaped virus with a capsid composed of 2,130 coat proteins (CP)
molecules surrounding its single ssRNA genomic core (6.3-6.5 kb) (Goelet et al., 1982;
Hwang et al., 1994) (Fig 1). The TMV genome encodes four open reading frames (ORFs),
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and the CP is self-assembled into a helical structure constituting 16.3 proteins per helix turn,
creating a hairpin loop structure of the RNA (Klug, 1999; Stryer et al., 1988). The CP
monomer (17kDa) is a small, compact protein, consisting of 158 amino acids which are
assembled into four main α-helices, and virions are 300 nm in length and 18 nm in diameter
(Klug, 1999). It is considered a highly thermo-stable virus, tolerating up to 120°F (50°C)
(Ashkin and Dziedzic, 1987). Because of its stability at high temperatures, TMV resists
manufacturing processes and is present in the tobacco of cigarettes, chewing tobacco, and
cigars, and also plant-based food products. TMV was found viable in 53% of all major
cigarette brands as shown by the development of lesions on leaves of Nicotiana tabacum
Xanthi after inoculation (Balique et al., 2012). Similar to bacterial infections, plant viruses
are transmissible by contact, such as from contaminated farm tools and human hands. Plant
viruses such as TMV cannot replicate in animal hosts, largely due to the lack of specific
receptors for recognition and entry into host cells (Liu et al., 2013). In addition, temperatures
above 34°C dramatically reduce the replication of TMV in tobacco leaf disks, although the
viral particle is still stable (Lebeurier and Hirth, 1966).
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Fig 1. Structure and natural hosts of Tobacco Mosaic Virus (TMV). TMV is consists of
2,130 identical coat proteins surrounding a ssRNA (+) genome of about 6,400 bases. Virions
are 300 nm in length and 18 nm in diameter. Here, an infected leaf of Nicotiana benthamiana
(tobacco plant) is shown discolored, indicating TMV as the pathogen. TMV can infect
common crops such as tomato and cucumber, which contributes to humans’ ubiquitous
exposure to this virus. TMV, tobacco mosaic virus; AA, amino acids; nm, nanometer;
ssRNA, single-stranded RNA. Image created on BioRender.com.
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Specific immune responses can be mounted against viral antigens, but it is generally
thought such responses are not elicited by plant viruses due to their inability to replicate in
mammalian cells, which thrive at 37°C (Mandal and Jain, 2010). Cytoplasmic or endosomal
replication of viruses normally elicits pathogen- and danger-associated molecular patterns
(PAMPs and DAMPs, respectively) that are sensed by animal host cell receptors (e.g. tolllike receptors, TLRs) that activate anti-viral signaling pathways. However, since plant
viruses cannot replicate in these cells, these pathways are typically not activated, and the
virus is perceived as innocuous (Balique et al., 2015). Limited data is available regarding
human immune responses elicited directly by TMV virions. Culturable TMV or TMV RNA
have been recovered in the feces (Zhang et al., 2006) and sputum (LeClair, 1967) of human
patients but has yet to be linked to any disease in humans. A recent study detected serum
antibodies to TMV within a range of ages, race/ethnicities, and tobacco use (smoke,
smokeless, and non-users), but not gender (only males were studied). These anti-TMV
antibodies were mainly of the IgG isotype, indicating class switching, and were detected in
all subjects (Liu et al., 2013). IgG1 was found to provide the dominant antibody response to
TMV, and smokers of all ages and ethnicities had a significantly higher total IgG (IgG1,
IgG3 and IgG4) against TMV than non-users (Liu et al., 2013). Interestingly, anti-TMV IgG
in smokeless tobacco users (i.e. chewing tobacco) did not significantly differ from those in
non-users. Caucasians specifically showed no difference in anti-TMV IgG among the three
subject groups, while African Americans did. Of note, Liu et al. compared absorbance of
antibodies in a sandwich ELISA assay and did not report titers in this study. Interpreting
these results as antibody “levels” is inaccurate and should instead be interpreted as avidity
and affinity of anti-TMV antibodies. Fortunately, TMV-antibody interactions have been
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extensively studied. Historically, the study of antibody binding kinetics to TMV made it
possible to describe the neutralization of viruses by antibodies well before in vivo systems
were used (Van Regenmortel et al., 1993; Van Regenmortel, 1999). TMV is one of the best
characterized plant viruses, and uniquely, almost all of its CP sequence has been shown to be
antigenic through recognition by monoclonal antibodies (Holzem et al., 2001).

2. Uses in Vaccination
TMV’s physical and antigenic attributes, as well as its simple genome, made it an
ideal candidate for study as a vaccine. In the last two decades, there has been significant
progress in this field of research. TMV has been utilized as an epitope display system for
numerous antigenic peptides, as well as biopharmaceutical protein production (Canizares et
al., 2005). One of the first published studies of peptide display on TMV reported the success
of co-assembly of chimeric CP-malaria epitope particles, and concluded: “recombinant plant
viruses have the potential to meet the need for scalable and cost effective production of
subunit vaccines that can be easily stored and administered” (Turpen et al., 1995). Beyond
TMV’s ability to serve as an epitope presentation system, it could also express exogenous
proteins. In one study, TMV was engineered to produce the F1 and V virulence proteins from
Yersinia pestis, that, when purified and administered to guinea pigs, were protective against
aerosolized Y. pestis challenge (Santi et al., 2006). The authors of that study concluded that a
TMV-based expression system was practical to areas of biodefense by offering speed in
production and scalability of vaccine proteins (Santi et al., 2006).
Remarkably, a TMV-peptide virion was able to break B-cell tolerance and induce
intentional production of autoreactive antibodies in vaccinated animals (Fitchen et al., 1995).
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This is not always easily achieved by vaccination. It was suggested that the ability of TMV to
break immune tolerance is likely due to the “high-density, quasi-crystalline array” in which
CP-peptide fusions are displayed on the virus, mimicking a PAMP (McCormick and Palmer,
2008). Koo et al. were the first to demonstrate that a TMV peptide-display vaccine for an
infectious disease (murine hepatitis virus, MHV) could induce neutralizing antibodies that
protected mice against MHV challenge (Koo et al., 1999). It was later demonstrated TMV
peptide-display vaccines did not have to be limited to one, or even two epitopes; their TMV
virion presented three different human papillomavirus (HPV) epitopes that could induce
cross-protective antibodies in a rabbit model of HPV (Palmer et al., 2006). At this point,
researchers anticipated that utility of TMV as a vaccine could be further developed. New
focus was placed on the viral surface to allow addition of larger protein moieties. However,
TMV CP surface residues naturally lack chemically reactive lysine and cysteine amino acids
(McCormick and Palmer, 2008). Kenneth Palmer and colleagues at Large Scale Biology
Corporation (Vacaville, CA) were the first to devise that simple addition of these amino acids
to the N terminus, loop, or C terminus of the CP could provide a scaffold for surface
conjugation (Smith et al., 2006). After several screens, their team succeeded in creating a
chemically stable virion with lysine as the surface-exposed residue – one that could
participate in amine conjugation and covalently link whole proteins containing cysteine or
lysine. Alison McCormick and Palmer’s colleagues noted the bond stability is “important in
inducing the maximum humoral immune response, possibly by generating a more stable
semi-crystalline array of peptide antigen on the surface of TMV” (McCormick and Palmer,
2008). Their first test of whole antigen conjugation was to TMV-biotin; their model antigens
were streptavidin (SA)-GFP and SA-COPV.L2 (L2 capsid of canine oral papillomavirus)
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(Smith et al., 2006). Mice and guinea pigs were immunized with SA-GFP and TMV-SAGFP, and SA-COPV.L2 and TMV-SA-COPV.L2. In each case, the TMV-biotin-SA
conjugates resulted in higher IgG titers in both species relative to the non-conjugated
antigens (Smith et al., 2006). Of note, GFP and the COPV L2 protein are 27kDa and 55kDa,
respectively, and much larger than the 17kDa TMV CP, yet still successfully bound the
virion. Continued observations of TMV-SA-GFP showed this model conjugate could also
stimulate cellular immune responses, further verifying its status as an immunogen
(McCormick and Palmer, 2008).
The feasibility of conjugating full-length antigens to TMV had now been realized.
The discovery made by Smith et al. paved the way for several studies utilizing TMV as a
vaccine delivery platform. Protein-TMV conjugate vaccines have now demonstrated
protection against tularemia (Banik et al., 2015; Mansour et al., 2018; McCormick et al.,
2018), pneumonic plague (Arnaboldi et al., 2016), and influenza H1N1 (Mallajosyula et al.,
2014) and H5N1 (Mallajosyula et al., 2016) (Table 1). In these particular studies, the TMVantigen conjugates were immunized by either subcutaneous (s.c.) or i.n. routes, and each time
induced stronger antigen-specific IgG responses in mice compared to unbound proteins.
Importantly, pre-exposing the mice to TMV did not reduce antigen-specific titers
(Mallajosyula et al., 2014). The adjuvant CpG was mixed with conjugates to boost Th1
responses for Francisella tularensis, an intercellular bacterial pathogen. Alum (Alhydrogel®)
or a squalene-based oil-in-water emulsion (AddaVax™) were mixed with TMVhemagglutinin (HA) conjugates. Each study offered unique observations, yet, this made it
difficult to draw conclusive statements about the mechanism of protection. In the H1N1
study, AddaVax™ adjuvant was needed achieve 100% survival with the TMV-HA vaccine,
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presumably by increasing total anti-HA IgG ((Mallajosyula et al., 2014). In the study by
Arnaboldi et al., co-administration of two TMV-protein conjugates (TMV-F1 + TMV-V)
without any adjuvant augmented antigen-specific IgG titers compared to mice that received
each conjugate individually. This mixture protected all mice from Y. pestis challenge, but
TMV-F1 immunization also elicited 100% protection (Arnaboldi et al., 2016). In this case,
protection from TMV was antigen-specific and did not directly correlate with total IgG
levels. T-cells were also thought to contribute to vaccine-induced protection. In the study by
Mansour et al., immunization of IFN-γ-deficient mice with a tetravalent TMV conjugate
mixture (TMV-DnaK + TMV-OmpA + TMV-Tul4 + TMV-SucB) showed IFN-γ was
necessary for protection against lethal respiratory challenge with F. tularensis LVS (live
vaccine strain) (Mansour et al., 2018). In normal mice, the tetravalent conjugate mixture with
CpG provided 100% protection after three doses (Mansour et al., 2018). In support of these
data, McCormick et al. had demonstrated previously that TMV conjugates to murine
melanoma peptide epitopes stimulated IFN-γ-producing T-cells after vaccination and
protected against tumors in mice (McCormick, Corbo, Wykoff-Clary, Palmer et al., 2006;
McCormick, Corbo, Wykoff-Clary, Nguyen et al., 2006). Thus, TMV conjugate vaccines
were capable of supporting both Th1 (IFN-γ-inducible) responses and antibody responses,
but it was still not clear if both responses were always initiated after immunization. Was the
virus itself an immunogen, skewing the immune response regardless of the antigen, or was it
simply a scaffold for whatever antigen was bound to its surface?

3. Immune Targeting and Activation
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The particulate nature of TMV is also thought to play a role in its immunogenicity. In
early studies, dissembled TMV CP generated lower titers in comparison with intact virions,
and TMV virions were more readily taken up by APCs and transported to secondary
lymphoid organs and the spleen in rabbits (Loor, 1967; Marbrook and Matthews, 1966). The
size of TMV makes it different from most other assembled virus-like particle (VLP)
structures, which are between 10 and 100nm (Bachmann and Jennings, 2010). For this
reason, immunized VLP either enter the lymphatic vessels and drain downstream of the
immunization site or are taken up by antigen presenting cells (APCs). TMV at 300 nm is
larger than most VLP and only suited for uptake and processing by APCs to reach the
lymphatics (Fig 2). Unlike proteins, it is imperative that pathogens make contact with APCs
early on in infection to mount an appropriate immune response. Professional APCs of the
immune system (macrophages, dendritic cells, and B cells) are able to efficiently take up
pathogens into the micrometer range (Fig 2) through phagocytosis or via receptor
internalization (Bachmann and Jennings, 2010). Dendritic cells (DCs) uniquely can
internalize, process, and present antigens through both major histocompatibility complexes
(MHC) I and II and play the predominant role in priming naïve T-cells and initiating immune
responses out of all APCs (Foged et al., 2002). According to various studies, DCs can
efficiently process 20-300nm particles by phagocytosis or macropinocytosis (Fifis et al.,
2004; Gamvrellis et al., 2004; Woodrow et al., 2012).
The particulate nature of VLP and high density of epitopes on their surface allow
them to induce potent T-cell mediated immune responses through interaction with DCs
(Chen and Lai, 2013). Studies led by McCormick have confirmed TMV’s ability to be taken
up by mammalian DCs both in vivo (following injection) and in vitro. Viable TMV was

12

capable of targeting DCs in murine lymph nodes (LN) and localizing in DC phagosomes,
indicating the virus is indeed phagocytized (Kemnade et al., 2014). Specifically, CD11c+
DCs isolated from popliteal LN that had taken up TMV following s.c. footpad injection had
increased surface expression of the T-cell costimulatory molecules CD54, CD40, CD86,
MHC I, and MHC II, compared to DCs from PBS-injected mice (Kemnade et al., 2014).
McCormick et al. next tested if TMV could be taken up by splenocytes and LN cells in vitro
(McCormick et al., 2006). Indeed, over 90% of cells had taken up fluorescently labeled TMV
particles in 1 hour in vitro, and DCs that had taken up TMV had increased expression of the
CD86 surface maker, a prerequisite for naïve T-cell priming (McCormick et al., 2006). It was
suggested that this set of features– the particulate size, repetitive structure, and ssRNA – was
responsible for the observed immune-activating effects of TMV as a VLP platform
(McCormick and Palmer, 2008). Like mammalian viruses, the ssRNA may stimulate innate
immunity in DCs via endosomal TLR7/8 recognition and downstream signaling. However,
whether TMV RNA activates TLR7/8 has yet to be formally established. As of now, the
immune-activating effects are largely attributed to that fact that particulates like TMV virions
are taken up naturally by APCs based on its size and repetitive surface structure.
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Table 1. List of protective vaccines comprising whole protein antigen-TMV conjugates.
Respiratory
Pathogen
Influenza (H1N1,
H5N1)

Antigen(s)

Vaccine
Route
s.c.

Adjuvant(s)

Reference(s)

Alhydrogel®,
AddaVax™

DnaK, OmpA,
Tul4, SucB

s.c., i.n.

CpG

Yersinia pestis

LcrV, F1

i.n.

---

Pseudomonas
aeruginosa

PcrV

i.n.

di-cyclic GMP

Mallajosyula et al.,
2014; Mallajosyula et
al., 2016
Banik et al., 2015;
McCormick et al.,
2018; Mansour et al.,
2018
Arnaboldi et al.,
2016; D’Arco et al.,
in review
Arnaboldi,
unpublished

Francisella
tularensis (LVS)

HA
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Fig 2. TMV as an APC-targeting delivery system. The size ranges of various vaccine
delivery systems and different pathogenic agents are indicated on a nanometer (nm) log
scale. The range of particle sizes that allow uptake by APCs and the size of macromolecules
that enter the initial lymphatic vessels are shown. TMV (300nm) is in the particle size range
ideal for APC uptake, while VLP fall into both ranges. ISCOMs, immune-stimulating
complexes; VLP, virus-like particles; TMV, tobacco mosaic virus; APC, antigen-presenting
cell. Image created on BioRender.com. Image and description adapted from: Bachmann M.
and Jennings G. Nat Rev Immunol. 2010;10:787–796.
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Yersinia pestis
1. The Disease and Historical Perspective
In 1894, Alexandre Yersin first described bacilli that were faintly Gram-negative
bacteria with “rounded ends,” cultured from buboes of cadavers during a plague outbreak in
Hong Kong (Butler, 2014; Hawgood, 2008; Yersin, 1894). Yersin later inoculated guinea
pigs with the bubo fluid, and all died within a few days (Yersin, 1894). The bacilli isolated
from the guinea pigs resembled the initial inoculum, and thus, Yersin had discovered the
agent of plague. Baron Shibasaburō Kitasato, a renowned Japanese physician-scientist and
bacteriologist, also made the same observations in Hong Kong right before Yersin. Although
his samples became contaminated, resulting in conflicting reports, it is believed Kitasato
should be given credit for accurately isolating and characterizing the plague bacilli (Bibel
and Chen, 1976). Yersin later made a major discovery – that rats were the pervasive source,
as their lymph nodes also contained the bacilli (Solomon, 1995). Paul-Louis Simond
eventually determined it was the fleas on infected rats that were the actual source of
transmission to human hosts (Gross, 1995; Simond, 1898). Yersinia pestis was later formally
given its name to honor its discoverer, Alexandre Yersin, although Kitasato is now
acknowledged as a co-discoverer.
Y. pestis is most commonly transmitted to humans via a bite from a flea which
previously fed on an infected rodent, resulting in bubonic plague (Perry and Fetherston,
1997). The distinctive clinical sign of this form of plague is a bubo, a gross enlargement of a
lymph node that drains the site of the flea bite. If left untreated, bacteria within the buboes
are left to multiply and disseminate throughout the lymphatic system, causing a bacteremia
that can eventually lead to a fatal septicemia (Perry and Fetherston, 1997). Bubonic plague
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has a mortality of ~60% in humans if left untreated. In rare cases, direct blood dissemination
can occur, resulting in primary septicemic plague. Septicemic plague is often associated with
a blackening of the hands and feet (necrosis) and is universally fatal if antibiotics are not
given (Koirala, 2006). Thrombosis, hemorrhaging, and gangrenous necrosis of acral regions
can also result from bubonic plague, if septicemia follows initial lymph node infection (Fig
3) (Demeure et al., 2019). Primary septicemic plague accounts for roughly 10% of all cases
of plague and is the least common form of the disease (Cornelis, 2000). Plague septicemia,
whether primary or secondary, typically progresses to metastatic infection of organ systems
and organ failure if left untreated.
Y. pestis was the notorious etiologic agent of the “Black Death” or “Black Plague” in
the Middle Ages when approximately 30-60% of Europe’s population succumbed to this
disease during the mid-14th century (Butler, 2014; Perry and Fetherston, 1997). This Second
Pandemic lasted 130 years, and smaller, recurrent outbreaks continued well into the 17th
century (Riedel, 2005). Historical records indicate other plagues, both before and after the
Black Death, decimated human populations. In the 6th century, the Plague of Justinian (First
Pandemic) of Eurasia is suspected to have started in Constantinople (the epicenter) after
ships from Egypt arrived carrying grain and infected rats (Wagner et al., 2014). An estimated
25-50 million people died in North Africa, Europe, and central and southern Asia during two
centuries of recurrence – an estimated 13-26% of the world population at the time (Riedel,
2005; Wagner et al., 2014). Numbers vary wildly based on source, as much as 60% of the
population of Europe may have died. Newly surfaced anthropological evidence suggests the
Great Plague of Justinian contributed to the decline of the Roman Empire (Harbeck et al.,
2013). In the 19th century, plague returned to civilization with a vengeance, and episodes of
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bubonic transmission arose and spread to all inhabited continents (except Australia),
collectively known as the Third Pandemic. During this worldwide series of plagues, China
and India saw a total of 12 million deaths (Riedel, 2005). The U.S. also saw the introduction
of plague on its soil, which likely originated in the rats of steamships docked at ports along
the Pacific coast. The city of San Francisco experienced a plague epidemic resulting in over
100 deaths at the turn of the 20th century (LINK, 1955). It was not until the mass production
and distribution of antibiotics in the 1950s that the reign of the Third Pandemic finally
ceased, or, at the very least, was suppressed.
Post-antibiotic discovery, sporadic outbreaks of plague continue to occur in many
parts of the world, particularly in central Asia, central sub-Saharan Africa, and the island of
Madagascar (Donaires et al., 2010; Koirala, 2006; Randremanana et al., 2019). The disease
is endemic in rodent populations in much of Asia, parts of Africa, and the Americas. Plague
remains endemic in prairie dogs in the western U.S. (Boone et al., 2009; Richgels et al.,
2016). Approximately 5-15 human cases of plague are reported in the U.S. each year, usually
in rural areas of the Southwest (New Mexico, California, Colorado, and Texas) where people
accidentally come into contact with infected animals (CDC, 2019; Runfola et al., 2015). The
U.S. Centers for Disease Control and Prevention (CDC) has repeatedly assured the public
that plague is not an emerging threat to the American population (CDC, 2019). Certainly,
other countries report worse outbreaks. Madagascar experienced a large urban outbreak in
2017; 76% of the nearly 2,400 reported cases were confirmed, probable, or suspected
pneumonic plague (Andrianaivoarimanana et al., 2019; Nguyen et al., 2018; Rabaan et al.,
2019; Randremanana et al., 2019; WHO, 2017). Thus, although bubonic plague is
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responsible for most cases of naturally occurring human plague, pneumonic transmission is
often what drives modern-day outbreaks in concentrated or urban populations.
Primary pneumonic plague results from infection of the lungs with Y. pestis. While
bubonic plague is transmitted via an insect bite, primary pneumonic plague is acquired
through aerosols generated from the coughing of infected humans within 2 meters of
proximity (Cornelis, 2000). This enables direct host-to-host transmission of the bacterium,
and a low inoculum is needed to cause disease (Perry and Fetherston, 1997). Secondary
pneumonic plague results from hematogenous spread of Y. pestis to the lungs, after bubonic
or septicemic infection. Primary pneumonic plague, however, is the most virulent form, with
death occurring within 48 hours of infection in the absence of treatment (100% mortality)
(Koirala, 2006). This is due to a unique biphasic response in the lungs (Fig 3). During a long
pre-inflammatory phase, Y. pestis bacteria replicate to high levels while suppressing and
evading host immune defenses (Pechous et al., 2013); 24-36 hours later, the proinflammatory phase occurs, characterized by extensive neutrophil influx and cytokine storms
that severely damage lung tissue and prove too late to control the infection (Demeure et al.,
2019). Complicating matters, pneumonic plague can be confused with several other acute and
community-acquired pneumonias, such as pneumococcal pneumonia, influenza viral
pneumonia, as well as Haemophilus influenza pneumonia. In addition, diagnosis could be
mistaken as pulmonary anthrax, tularemia, Legionella pneumophila, and Hantavirus
syndrome (Cornelis, 2000). For an early and accurate diagnosis of plague, reasonable
suspicion is required of the clinician, especially when biowarfare is suspected (Franz et al.,
1997). In cases where pneumonic plague is suspected, antibiotics must be administered
within 24 hours of symptoms to prevent imminent death.
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The extreme lethality of plague and history of weaponization have led to the
assignment of Y. pestis as a Tier 1 Select Agent, and fears of its release as a bioterrorist
weapon (Carus, 2015; Inglesby et al., 2000). During World War II, the Japanese army (Unit
731) is reported to have dropped plague-infected fleas in “flea bombs” over populated areas
in China and Manchuria by aircraft (Eitzen and Takafuji, 1997; Riedel, 2004). Following
World War II, the U.S., Great Britain, and the former Soviet Union (U.S.S.R.) established
biowarfare programs during the Cold War, researching Y. pestis as a potential biological
weapon and expanding on studies of Unit 731. These efforts focused on the study of plague
in aerosolized form, thereby eliminating the need for flea vectors. In 1970, the World Health
Organization (WHO) published a comprehensive report on the outcome of the possible use of
biological weapons. The report predicted that the release of 50 kg of Y. pestis in aerosolized
form over a city of 5 million could result in (worst case scenario) 150,000 cases of
pneumonic plague, 80,000-100,000 cases of hospitalization, and 36,000 victims (WHO
Group of Consultants, 1970). Furthermore, plague bacilli would remain viable in the air for 1
hour and up to a distance of 10 km (WHO Group of Consultants, 1970). The expert panel
was concerned that in such a scenario, significant numbers of city inhabitants would likely
flee, further spreading the agent. Unlike other biowarfare agents, plague is contagious and
can be spread from person-to-person. Today, the possibility of plague being unleashed onto
an unsuspecting city is still too nightmarish to comprehend but has yet to occur. Y. pestis can
also be easily genetically manipulated to create strains with specific traits, such as
engineering strains to be resistant to antibiotics commonly used to treat plague patients
(streptomycin, gentamicin, tetracyclines, ciprofloxacin, and chloramphenicol) (Riedel, 2005).
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Fig. 3. Pathogenesis of bubonic and primary pneumonic plague. Schematic representation
of Y. pestis transmission and migration in the human body during bubonic (upper panel) and
pneumonic plague (lower panel). The effect of temperature on the regulation of bacterium
virulence factors are indicated at various steps. Innate immunity host cells encountered by the
pathogen and involved in immune evasion mechanisms are shown. Image and description
credit: Demeure CE, et al. Genes and Immunity. 2019;20(5):357–370.
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Multidrug-resistant Y. pestis isolates have been recovered from human plague patients,
suggesting the bacterium continues to evolve mechanisms of survival in the mammalian host
(Galimand et al., 1997; Guiyoule et al., 2001; Welch et al., 2007). For several decades,
researchers in government and academia have studied Y. pestis with the hope of developing
preventative countermeasures to these scenarios, primarily in the form of vaccines.

2. Evolution and Virulence Factors
The pathogenicity of Y. pestis stems from its remarkable ability to overcome defense
mechanisms of the mammalian immune system and quickly overwhelm the host. The rapid
multiplication of the bacteria occurs mainly extracellularly, but can occur intracellularly
initially, typically in macrophages (McNally et al., 2016; Perry and Fetherston, 1997). The
entrance of the organism into a mammalian host (37°C) induces the expression of several
virulence factors (discussed below) that perturb or “paralyze” cells, enabling subversion of
host immune responses. Y. pestis is highly similar on a genomic level to Yersinia
pseudotuberculosis, which evolved from Yersinia enterocolitica, an infrequent enteric
pathogen in humans (yersiniosis). However, a series of genetic gains and losses led to
different mechanisms of disease and niche preference between Y. pestis and Y.
pseudotuberculosis (Achtman et al., 2004; Chain et al., 2004; McNally et al., 2016) that
forever separated them in the Yersinia evolutionary tree.
It is now estimated that Y. pestis diverged from Y. pseudotuberculosis around 5700–
6000 years ago, based on the recent recovery of Y. pestis DNA from the teeth of Neolithic
peoples in Eurasia (Andrades Valtuena et al., 2017; Rascovan et al., 2019; Rasmussen et al.,
2015; Spyrou et al., 2018). It is probable that Y. pestis existed prior to this in wild animal
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populations. Its emergence was characterized by the acquisition of the two key plasmids:
pFra/pMT1 and pPla/pPCP1. The acquisition of ymt (Yersinia murine toxin) in the
pFra/pMT1 plasmid (Sun, Y. C. et al., 2014) as well as inactivation of ureD, rcsA, flhD, pde2
and pde3 – all virulence-associated genes – enabled the transmissibility of Y. pestis by fleas
(Chouikha and Hinnebusch, 2014). The aftermath of these changes gave rise to the ability to
cause bubonic plague, which can be traced to the Bronze Age (Spyrou et al., 2018). The
plasminogen-activating protease, Pla, encoded by the pPla/pPCP1 plasmid, was carried by
earlier lineages of Y. pestis and led to the ability to cause pneumonia. However, a random
mutation in the pla gene, altering a single amino acid (I259  I259T), enabled invasive and
rapid extrapulmonary dissemination of the bacterium (Lathem et al., 2007; Zimbler et al.,
2015). Taken together, this deadly repertoire – a set of exceptional virulence factors, the
ability to infect lungs, and extreme invasiveness – made plague a death sentence. Y. pestis
could multiply to high numbers since it was no longer restricted to the site of infection,
thereby increasing its chances of transmission, and transforming a bacterium capable of
causing local outbreaks into the mass killer we know today.
In primary pneumonic plague, it is believed the bacteria first infect macrophages –
and then neutrophils – where they proliferate and produce factors in phagosomes in response
to drops in [Ca++] and pH (acidity) (McNally et al., 2016). Within alveolar macrophages, Y.
pestis persists in autophagosomes, and is capable of inhibiting phagosomal maturation by
perturbing the host endosomal recycling pathway, allowing intracellular replication (Connor
et al., 2015; Connor et al., 2018; Pujol et al., 2009; Spinner et al., 2014). Inflammasomedependent IL-1β/IL-18 release occurs early after bacteria enter the lung but fails to cause
inflammation due to the simultaneous release of anti-inflammatory IL-1RA blocking IL-1
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receptors (Sivaraman et al., 2015). Y. pestis can also directly evade phagocytosis by alveolar
macrophages. Absence of the LpxL/HtrB acyltransferase in Y. pestis yields a tetra-acylated
LPS, which prevents innate immune recognition by antagonizing TLR4 receptors (Montminy
et al., 2006). Fraction 1 (F1), the pFra/pMT1-encoded capsular antigen, prevents bacterial
uptake by inhibiting adhesion (Liu et al 2006). The Psa fimbriae (pH 6 antigen) also inhibits
phagocytosis by macrophages and mediates bacteria attachment to epithelial cells (Bao et al.,
2013). The Pla protease has been shown to cleave multiple host cell substrates in vivo and/or
in vitro including plasminogen, plasminogen activator inhibitor 1, urokinase plasminogen
activator, C3 complement, Fas ligand, as well functions as a critical adhesin to regulate
activity of the T3SS (Lathem et al., 2007; Zimbler et al., 2015). The expression of such
outer-membrane proteins is normally induced during transition from the flea midgut (26°C)
to that of the mammalian host (37°C) (Fig 3). However, in primary pneumonic plague, there
is no lag since many of these factors are already in abundance upon entering the lung. Indeed,
the Y. pestis T3SS mediates activity in the lung as early as 6 hours following pneumonic
infection (Pechous et al., 2013).
The best characterized virulence factors of Y. pestis are associated with its T3SS,
which is encoded in the pYV/pCD1 plasmid and shared with Y. pseudotuberculosis and Y.
enterocolitica. Among them are the effector Yersinia outer membrane proteins (Yops), which
are translocated via the T3SS directly into host cells. These effectors include YopH, YopE,
YopT, YopJ, YpkA, YopM and YopK, which together inhibit Rho GTPases, remodel actin
cytoskeleton (inhibiting phagocytes), dampen pro-inflammatory cytokines, and trigger
apoptosis by multiple sophisticated mechanisms (Demeure et al., 2019). Upon apoptosis,
more virulent bacteria within phagocytes can be released into the lung environment. During
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the pro-inflammatory stage of primary pneumonic plague, when bacterial burden has reached
its peak, infiltrating neutrophils are responsible for the development of fulminant pneumonia
and tissue necrosis. In this context, YopK modulates macrophage apoptosis and promotes
progression of pneumonia (Peters et al., 2013), while YopM “paralyzes” neutrophils,
inhibiting their death in dense inflammatory lesions and preventing the release of their
bactericidal content (Ratner et al., 2016; Stasulli et al., 2015). To overcome host nutritional
immunity, Y. pestis secretes the siderophore yersiniabactin (Ybt) to acquire iron, which is
essential in the pathogenesis of bubonic and pneumonic plague (Fetherston et al., 2010). Ybt
is also necessary for zinc uptake together with the ZnuABC transporter system (Bobrov et
al., 2017; Perry et al., 2015). There are several other novel Y. pestis virulence factors that
have been identified in recent years (Demeure et al., 2019; Huang et al., 2006; Sha et al.,
2016; Tidhar et al., 2009), however, they will not be covered in detail in this review.

3. V and F1 Antigens
Despite numerous potential antigenic targets of Y. pestis, the most promising plague
vaccines almost always target two proteins: F1 and LcrV. LcrV, also known as the virulence
or “V” antigen, is the tip protein of the Y. pestis T3SS, and a pivotal component of virulence
for all pathogenic Yersinia (Derewenda et al., 2004). The pYV/pCD1 plasmid of Y. pestis
contains at least five low-calcium response (lcr) genes, which appear to serve as regulators of
V expression when extracellular [Ca++] is extremely low or absent, and when temperatures
are high (i.e. in a mammalian host). Insertion mutations made into lcr genes causes the loss
of regulated Yop and V antigen expression as well as the loss of calcium dependence for
growth (Goguen et al., 1984). Contact of the bacteria with eukaryotic cells results in

25

secretion of V antigen (35-37kDa) into the surrounding medium, or into the cytosol of
infected host cells (Fields and Straley, 1999). Once released, V antigen may function as a
“diffusor” of host immunity, where it has been shown to suppress IFN-γ and TNF-α
production (Nakajima et al., 1995) via enhancement of IL-10 (Nedialkov et al., 1997; Sing et
al., 2002), and inhibit chemotaxis of neutrophils (Visser et al., 1995; Welkos et al., 1998). V
is indispensable for the targeting of Yops; upon contact with a host cell membrane, V
undergoes conformational changes allowing a structure to form with translocator Yops
(YopB and YopD) that mediates transfer of effector Yops into the host cell (Fields et al.,
1999; Pettersson et al., 1999). This structure resembles the needle-like T3SS discovered in
Salmonella typhimurium (Cornelis, 1998), and is highly conserved and nearly identical
among Salmonella spp., Pseudomonas spp. Shigella spp., enteric hemorrhagic Escherichia
coli (EHEC), and Yersinia spp. The combination of V antigen with F1 antigen (or as a fusion
protein) has been shown to generate high levels of vaccine protection than either component
individually (Amemiya et al., 2009; Heath et al., 1998; Jones et al., 2006; Williamson et al.,
1997). Since V is also essential for Y. pestis virulence, it is frequently referred to as a
protective antigen and continues to be a central target of almost all plague vaccines.
There are advantages to studying the F1 capsule protein in the context of Y. pestis
pathogenesis, particularly as F1’s protective mechanisms showcase the serological arm of
adaptive immunity. Vaccination with F1, but not with V, has been shown to rapidly induce
immunity within several days, in the form of antibodies (Levy et al., 2011; Williamson et al.,
2007). It is thought the F1 capsule obstructs phagocytosis by acting at the level of receptor
interaction with phagocytes (Du et al., 2002) while potentially cloaking other surface features
that would otherwise enable host recognition (Runco et al., 2008). Therefore, blocking this
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interaction remains a worthwhile and strategic goal of vaccination. Indeed, research has
repeatedly supported protective efficacy of F1-specific antibodies in pneumonic and bubonic
models of plague (Andrews et al., 1996; Feodorova and Corbel, 2009; Feodorova and Motin,
2012; Heath et al., 1998; Holtzman et al., 2006; Levy et al., 2011; Levy et al., 2018; Okan et
al., 2010; Titball and Williamson, 2001; Titball and Williamson, 2004; Williamson et al.,
1996; Williamson and Oyston, 2013). Passive transfer of anti-F1 antibodies to naïve animals
and generation of anti-F1 IgG following F1 immunization both lead to high survival rates in
animal models of plague (Williamson and Oyston, 2013). The tendency for recombinant F1
(rF1) to form large molecular-weight polymers also aids in rapid recognition by innate-like B
cells, permitting F1-specific antibody production within 3 days of immunization and
complete protection from bubonic plague (Levy et al., 2018). Additionally, these rF1
polymers can be easily purified from E. coli cultures expressing the caf1 operon (Andrews et
al., 1996). The caf1 operon also encodes for the transcriptional regulator Caf1R, the
chaperon Caf1M, and the usher protein Caf1A (Galyov et al., 1991). In the generation of the
capsule, F1 monomers (15.5-17.5kDa) form polymers that are exported to the outer
membrane of the bacteria, aided by Caf1M and Caf1A (Andrews et al., 1996; Zavialov et al.,
2003). F1 capsule proteins have also been detected in outer membrane vesicles (OMV) of Y.
pestis, which carry other virulence factors (Eddy et al., 2014). Unlike V antigen, F1 is
dispensable for virulence. Naturally occurring F1 mutant strains have been isolated and are
capable of causing fatal disease similar to wild-type strains (Davis et al., 1996; Friedlander et
al., 1995). In these cases, immunization with V alone can still generate protective immunity
against both strains (Quenee et al., 2008).
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4. Immunity to Plague: Vaccines
Most early attempts at plague vaccines utilized killed whole cell (KWC)
formulations. The Cutter vaccine was a formaldehyde-killed Y. pestis 195/P strain; it was
believed to stimulate protection mainly against the F1 protein but is no longer in production
(Friedlander et al., 1995).The Commonwealth Serum Laboratories vaccine was a heat-killed
suspension of Y. pestis that required multiple boosters to maintain protection. It was proven
effective against bubonic plague in U.S. soldiers in the Vietnam War, but was ineffective
against pneumonic plague, as was the Cutter vaccine (Meyer, 1970; SPECK and
WOLOCHOW, 1957). Both KWC vaccines required an intensive prime-boost schedule to
achieve long-term protective immunity (Bramwell et al., 2005). Live vaccines were
approached as a more immunogenic alternative. However, development of a suitable vaccine
was challenged by the genomic instability of Y. pestis (Demeure et al., 2017). Interest
dwindled, largely owing to the unpredictability of the attenuation, as well as the tendency of
the EV76 vaccine (an effective live Y. pestis strain developed by the former Soviet Union) to
produce vaccine adverse reactions in humans and occasionally kill nonhuman primates
(NHP) (Meyer, 1970; Verma and Tuteja, 2016). Studies in the Soviet Union had also shown
that vaccinating baboons by the inhalation route with a live pgm− Y. pestis EV strain
generated immunity, but s.c. injection of F1 still provided better protection against
pneumonic plague (Anisimov et al., 1995; Byvalov et al., 1984). Pgm− Y. pestis strains were
often more immunogenic than killed vaccines, but like EV76, frequently caused local and
systemic reactions in animals and humans (Hallett et al., 1973; Meyer, Smith et al., 1974;
Meyer, Cavanaugh et al., 1974). Reactogenicity also varied with the animal and the route of
inoculation, and several species of NHP were significantly more sensitive to pgm− Y. pestis
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than guinea pigs (Meyer et al., 1974). The Y. pestis CO92pgm− strain was shown to be
virulent to mice and African green monkeys by aerosol route (Welkos et al., 2002). Thus, the
safety of such strains was deemed host-specific and was not recommended for use as a
human vaccine.
The virulence of live strains needed to be reduced further. Efforts focused on
“switching out” various immuno-suppressive elements of the bacterium. For instance, the
replacement of the Y. pestis atypical tetra-acylated lipid A with the E. coli hexa-acylated lipid
A resulted in an immunogenic, highly attenuated live vaccine construct, but still induced IL10 (Sun, W. et al., 2011). Another advantage of live vaccines are the contributions of T cell
immunity for protection. Vaccination with live, replicating Y. pestis strains is one way to
prime CD4+ and CD8+ T cells to respond to antigens distinct from those previously defined
as targets for humoral immunity (e.g. F1 and V) (Smiley, 2008a; Sun et al., 2011). Mice that
were i.n. immunized with live Y. pestis KIM5 and KIM6 strains, indeed, generated T cells
that could respond in vitro to a Y. pestis strain lacking F1, V, and all pCD1/pPCP-encoded
proteins; however, 60% of mice receiving Y. pestis KIM5 as the initial vaccine
administration failed to survive (Philipovskiy and Smiley, 2007). Concern about reversion to
virulence continued to diminish enthusiasm for genetically manipulated (attenuated) virulent
strains as vaccines. KWC vaccines did not generate timely immunity, while live vaccine
strains posed too high of a risk. Researchers needed to strike a balance: a safe vaccine that
also generated the precise “amount” of innate and adaptive immunity needed to eliminate Y.
pestis successfully.
Because of the limitations of KWC and live attenuated vaccines, subunit vaccines
were pursued against plague. Both F1 and V antigens were found to confer high levels of
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protection, and thus success in experimental settings renewed interest in subunit
formulations. Clinical trials of F1 and V subunit vaccines began around a decade ago
(Quenee and Schneewind, 2009). Soluble F1 and V antigens make up the active components
of RypVax™ (PharmAthene Inc.), a recombinant plague vaccine comprising separate rF1
and rV antigens produced in E. coli. Building on RypVax™ clinical data, the rF1-V fusion
protein vaccine was developed by the U.S. Army Medical Research Institute for Infectious
Diseases (USAMRIID) and its use is anticipated in 2021 by the U.S. Army (Demeure et al.,
2019). The rF1-V and RypVax™ vaccines are safe and have passed through Phase I and II
clinical trials, but the results of the Phase II trials are not yet available. To abate V antigen’s
immuno-suppressive actions, a truncated version (recombinant V10) was also created; this
was capable of maintaining protection against pneumonic plague infection in mice, guinea
pigs, and macaques as well as the rF1-V vaccine (Cornelius et al., 2008; DeBord et al.,
2006). However, both the rF1-V fusion and rV10 vaccines failed to protect African green
monkeys against pneumonic plague as uniformly as Cynomolgus macaques, despite eliciting
robust antibody responses (Pitt, 2004; Quenee et al., 2011; Smiley, 2008). The inconsistent
efficacy of these vaccines is speculated to be due to a deficiency in innate or cellular
immunity, resulting in a lack of synergy between humoral and cell-mediated immune
responses (Sun, W. and Singh, 2019). This synergistic effect is considered the optimal
defense against pneumonic plague, since antibodies alone are not a reliable correlate of
protection (Kummer et al., 2008). African green monkeys (Cercopitheus aethiops) are
evolutionarily closer to humans than Asian macaques (Ervin and Palmour, 2002). Thus, there
is reasonable concern that the F1-V vaccines undergoing clinical trials may not protect
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humans against pneumonic plague. Several groups are trying to enhance immunogenicity of
subunit vaccines using different means.
Defining immune correlates of plague protection has proved challenging for over a
century. On one hand, the antibody evidence was abundant. Yersin himself had showed that
horse antiserum to plague could be used to treat plague-infected patients (Yersin, 1897),
demonstrating that antibodies were highly protective. Similarly, sera from F1-immunized
human volunteers can passively protect mice against bubonic plague (Meyer and Foster,
1948; Williamson et al., 2005) as can anti-F1 monoclonal antibodies for bubonic and
pneumonic plague (Anderson et al., 1997). Immunization with V alone (Leary et al., 1995)
or in combination with F1 mainly works through robust production of antigen-specific IgG
(Rocke et al., 2008; Williamson et al., 1999). Antibodies became consistently relied upon as
correlates of vaccine-induced protection, but several studies soon cautioned against this.
While the combination of F1 and V showed promise, any sole F1-based subunit vaccine
would be ineffective against F1-negative Y. pestis strains (Feodorova and Corbel, 2009;
Quenee et al., 2008; Verma and Tuteja, 2016). Additionally, serological studies suggested
that rV-based vaccines may fail to protect against Y. pestis strains expressing functional V
variants (Anisimov et al., 2004; Anisimov et al., 2010; Roggenkamp et al., 1997).
Furthermore, it was found that only anti-V antibodies that promoted phagocytosis directly
could neutralize pneumonic plague; simply blocking the T3SS tip was not enough (Eisele
and Anderson, 2009). Complicating matters further, only a single V epitope generated
antibodies capable of antibody-dependent cellular phagocytosis (ADCP) (Eisele and
Anderson, 2009). It is now generally accepted that levels of anti-F1 and anti-V IgG titers are
not a true correlate of protection. Rather, rapid antibody-mediated clearance of Y. pestis
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during respiratory infection is dependent on the activation of phagocytes (macrophages and
neutrophils), which can be assessed in vitro (Bashaw et al., 2007). This lends further support
to the notion that a coordinated effort between innate, humoral, and cellular immunity is
needed to defend against pneumonic plague (Smiley, 2008b).
IFN-γ, TNF-α, nitric oxide synthase 2, and IL-17 have all been implicated in systemic
host responses to pneumonic plague (Lin et al., 2011; Nakajima and Brubaker, 1993; Parent
et al., 2005; Parent et al., 2006; Szaba et al., 2014), and play important roles in antibodymediated protection generated by the rF1-V fusion protein vaccine (Lin et al., 2010). Smiley
and colleagues were the first to demonstrate that vaccination with live attenuated Y. pestis
protected B-cell-deficient μMT mice against pneumonic infection in a T-cell dependent
manner (Parent et al., 2005; Parent et al., 2006). Moreover, T cells from vaccinated μMT
mice could be primed in vitro and adoptively transferred to naïve mice, conferring protection
against lethal pneumonic plague (Parent et al., 2005). Smiley’s discoveries led subsequent
research to pursue plague subunit vaccines that could potentially “balance” cellular and
humoral immune responses. Adjuvants promoting Th1 cellular responses were explored. A
recent study investigated the addition of SA-4-1BBL, an agonist of the CD137 costimulatory
pathway, to the Alhydrogel® -adjuvanted rF1-V vaccine. Alhydrogel® is a common
aluminum hydroxide-based adjuvant that tends to initiate T helper 2 (Th2)-like humoral
responses (Brewer et al., 1999). Interestingly, addition of SA-4-1BBL did not improve
protection. Mice that received s.c. prime-boost with the added SA-4-1BBL were not as
protected against pneumonic lethal infection compared with a prime-boost of just rF1-V +
Alhydrogel® (75% vs. 90% survival, respectively), despite a robust antigen-specific IFN-γ
response observed in SA-4-1BBL-administered mice (Bowen et al., 2019). Generating
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protective cell-mediated responses against plague using subunit vaccines has not been easy to
accomplish (Smiley, 2008). Importantly, this study implicates there may be unknown or
atypical factors that are critical to protection against pneumonic plague, and simply skewing
the immune response one way or the other (e.g. Th1, Th2, Th17) through various adjuvants is
not sufficient.
For mucosal (oral and nasal) plague vaccines, live attenuated vectors were an ideal
choice as they can overcome the tolerogenic immune environment of the mucosa by
mimicking a real infection (Neutra and Kozlowski, 2006; Wang et al., 2015). Mucosal
vaccines also have the added benefit of stimulating neutralizing secretory IgA (SIgA)
responses, as well as the advantage of being easier and safer to administer than needle-based
delivery (Garmory, Leary et al., 2003; Levine, 2003). The first attempts to express the caf
operon in a live attenuated Salmonella enterica serovar Typhimurium led to suboptimal
expression and immunity (Oyston et al., 1995; Titball et al., 1997), and for V antigen,
multiple doses were required for protection (Garmory, Griffin et al., 2003). However, a S.
Typhimurium vector containing two separate plasmids, one for each antigen, demonstrated
improved and stable expression of F1 and V; orally immunized mice showed 88% protection
against 1000 LD50 bubonic and 100 LD50 pneumonic plague challenges (Yang, X. et al.,
2007). Intranasal vaccination proved to be even more effective. Mice that were i.n.
immunized twice with a F1- and V-expressing S. Typhimurium strain, and boosted once with
V + alum, showed 100% protection against 37 LD50 and 177 LD50 pneumonic challenges
(Galen et al., 2015). Viral vectors were also explored. Ashok Chopra’s group at the
University of Texas Medical Branch successfully generated a replication-defective
adenovirus (Ad5) vector expressing a fusion gene YFV (ycsF, caf1, and lcrV) (Sha et al.,
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2016). Immunization with Y. pestis YcsF (Yop secretion protein F) has been previously
shown to be protective against bubonic plague (Matson et al 2005). A mixed i.n.-i.m. primeboost of mice and Cynomolgus macaques with the trivalent rAd5-YFV vaccine conferred
100% protection against aerosolized, fully virulent Y. pestis CO92pgm+, despite these
animals having pre-existing adenoviral immunity (Sha et al., 2016). Combinations of
vaccines using this new heterologous-route prime-boost strategy might overcome current
limitations of pneumonic plague vaccines. The most promising candidates appear to consist
of a primary i.n. multivalent or live vectored vaccine dose, followed by an i.m. booster dose
of the purified antigen(s) (Sun and Singh, 2019). However, live vectored vaccines are not
safe for everyone and can cause opportunistic infections in certain individuals (e.g. in the
immunocompromised and elderly). Even for replication-defective vectors, safety needs to be
evaluated meticulously in preclinical and clinical studies. For this reason, subunit vaccines
still remain the safest and most attractive approach for largescale vaccine production and
stockpile.
In murine models, i.n. delivery of subunit plague vaccines has been explored using
varying and creative formulations, including Protollin™ (Jones et al., 2006), flagellin
(Honko et al., 2006; Mizel et al., 2009), heat-labile enterotoxin (Glynn et al., 2005),
microspheres (Eyles et al., 2000; Gupta et al., 2010), lipid A mimetics (Airhart et al., 2008),
and more recently, double mutant heat-labile toxin (dmLT) (Heine et al., 2019) and
commensal gut bacteria‐derived OMV (Carvalho et al., 2019). These vaccines usually
displayed good safety profiles and often produced higher levels of protection at mucosal
surfaces compared to their parenteral equivalents. However, each of these formulations has
been met with challenges, particularly, the need to administer booster doses to achieve
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protection. Remarkably, Airhart et al. demonstrated 100% protection against 100 LD50 Y.
pestis CO92pgm+ using a single dose i.n. synthetic lipid A adjuvanted F1 and V vaccine;
however, this protection was not achieved until 150 days after immunization (Airhart et al.,
2008). They were able to achieve 100% protection in as early as 11 days post-immunization,
but only after a prime-boost schedule. As of present, a single-dose i.n. F1 and V-based
subunit vaccine has yet to achieve early complete protection against pneumonic plague.

Hypothesis and Specific Aims
The major goal of this work was to understand the mechanism(s) by which the TMVF1 and TMV-V conjugates enhanced vaccine-specific immunity to a mouse model of plague.
My overall hypothesis stated that: inactivated and rTMV was enhancing the immune
response to the associated subunit proteins through direct uptake of the virus by APCs and
may induce responses analogous to VLP vaccines. Like VLP, the resulting high-density
display of protein antigens on the rTMV virion is more immunogenic compared to their
soluble form, and no adjuvants are needed to boost immunity in our model. When
administered i.n., this particulate vaccine has greater potential to stimulate B cells or DCs at
mucosal surfaces and elicit a potent antigen-specific response to the bound proteins in the
form of neutralizing antibodies and T-cell mediated responses (Fig 4).
To answer this central question, my research was divided into three overarching aims:
(1) the innate response to TMV conjugates, (2) the resulting adaptive response from TMV
conjugate immunization, and (3) the application of the conjugates to a single dose
administration and its effects on bacterial dissemination and inflammation. In two of my
three aims, TMV conjugates had to be studied in the context of infection, and so, challenge
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experiments utilized BSL-2 Y. pestis strains with the chromosomal pgm locus deleted
(CO92pgm−) or mutated (KIM5caf1A). Each aim below lists various hypotheses (sub-aims)
separately or jointly investigated to address specific experimental questions. Each aim
represents its own chapter in this dissertation, and follows the traditional scientific paper
format (Introduction, Methods, Results, Discussion).

SPECIFIC AIM 1: Determine if TMV Conjugates Target Conjugated Antigens to
Antigen Presenting Cells in vitro and in vivo
Aim 1a: Test the hypothesis that TMV promotes uptake into antigen-presenting cells in vitro
(BMDCs) and ex vivo (B-cells)
Aim 1b: Test the hypothesis that TMV is an immunostimulant by upregulating costimulatory
surface markers on dendritic cells in vitro
Aim 1c: Test the hypothesis that TMV targets conjugated protein antigens (F1 and V) to
pulmonary dendritic cells in vivo after intranasal immunization

SPECIFIC AIM 2: Evaluating Efficacy and Correlates of Protection of a Single-Dose
Intranasal TMV Conjugate Vaccine for Pneumonic Plague
Aim 2a: Test the hypothesis that a single intranasal administration of the vaccine is
protective against high-dose pneumonic plague infection
Aim 2b: Test the hypothesis that single administration of the vaccine prevents or reduces
dissemination of Y. pestis in the infected host
Aim 2c: Test the hypothesis that pre-challenge vaccine-specific antibody titers are a correlate
of TMV vaccine-induced protection
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Aim 2d: Test the hypothesis that the TMV vaccine induces a TH1 or TH17 specific response
in the infected host

SPECIFIC AIM 3: Identify the Role of T Cell-Mediated and Antibody-Mediated
Immune Responses of TMV Conjugates as an Intranasal VLP-like Vaccine
Aim 3a: Test the hypothesis that CD4+ T cells and/or CD8+ T cells are required for vaccinemediated protection at the time of infection
Aim 3b: Test the hypothesis that intranasal vaccination induces both virus-specific and
antigen-specific antibody responses
Aim 3c: Test the hypothesis that the antibody response to vaccination is rapid and localized
to the lung after infection
Aim 3d: Test the hypothesis that vaccine-specific immunity is not limited to F1 immunity
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Fig 4. Potential APCs involved in the primary uptake of i.n.-administered TMV-F1 and
TMV-V and the logical subsequent adaptive immune response. This image summarizes
the general hypothesis, which is centered on the necessary uptake of TMV conjugate
vaccines by APCs at the mucosal surface. Based on how the antigen is introduced (i.n.
droplets), the anatomy of the mouse lymphatic system, and the data generated previously in
our laboratory, the particulates are likely being transported by low-affinity B cells or DCs to
a SLO, where naïve antibody production is stimulated in GC reactions, and where naïve T
cells can be primed and activated. Since the F1 capsule is similar in size to TMV CP (1720kDa), its display on the virion more closely resembles the surface structure of TMV and
could explain why F1-specific IgG is almost always produced after single vaccination, while
V-specific IgG is not. High V-specific IgG titers are generated, but only after multiple boosts
of TMV-V. Image created on BioRender.com.
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Chapter 2. Specific Aim 1
AIM 1:
Determine if TMV Conjugates Target Conjugated Antigens to Professional
Antigen Presenting Cells in vitro and in vivo
Aim 1a: Test the hypothesis that TMV promotes uptake into antigen-presenting cells in vitro
(BMDCs) and ex vivo (B cells)
Aim 1b: Test the hypothesis that TMV is an immunostimulant by upregulating costimulatory
surface markers on dendritic cells in vitro
Aim 1c: Test the hypothesis that TMV targets conjugated protein antigens (F1 and V) to
pulmonary dendritic cells in vivo after intranasal immunization
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1.INTRODUCTION
Rationally designed vaccines are comprised of antigen(s) co-inoculated with
adjuvant(s) that elicit predictable and protective immune responses against the targeted
pathogen (Rueckert and Guzman, 2012). A properly formulated vaccine ensures the antigen
is 1) protected from enzymes and degradation, 2) stable in a wide-pH range, and 3) taken up
by antigen presenting cells (APCs). APC recognition is crucial to development of immunity
as professional APCs (collectively macrophages, dendritic cells, and B cells) play a role in
differentiating innocuous particles from microbial intruders via identification of danger- and
pathogen-associated molecular patterns (DAMPS and PAMPs, respectively) through
different receptor families, including toll-like receptors (TLRs), NOD-like receptors (NLR),
RIG-I-like receptors (RLRs), DNA receptors (e.g. STING), C-type lectins, and scavenger
receptors. Dendritic cells (DCs), the most “professional” of the APCs, have the capacity to
internalize, process, and present antigens through both major histocompatibility complexes
(MHC) I and II, and have the predominant role in initiating primary T-cell immune responses
over macrophages and B cells (Foged et al., 2002). Thus, targeting of vaccines to DCs, either
parenterally or mucosally, has great potential to reduce antigen dose, limit side effects, and
directly improve vaccine efficacy.
Mucosally, DCs are less ubiquitous than tissue macrophages, yet are nonetheless
central to vaccine priming. In the lung, the interstitium, terminal bronchioles, and alveoli are
dominantly patrolled by macrophages (>80%), a majority of which are alveolar macrophages
(AMs). AMs have limited APC function (Kunda et al., 2013), but can induce type I
interferons after infection with certain RNA viruses (Kumagai et al., 2007). CD11c is the
marker used conventionally used to identify and distinguish DCs from other immune cells;
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however, several subsets can be identified by expression of specific co-markers. In mice, the
lung contains CD11b+ conventional DCs (cDCs), CD103+ cDCs, and plasmacytoid DCs,
with CD103+ cDCs in the epithelium and CD11b+ cDCs in the lamina propria (Neyt and
Lambrecht, 2013) . Additionally, Ly6Chi monocytes can be recruited to the lung, and have
ability to take up antigen, increase their expression of MHC II, costimulatory molecules, and
CCR7, and migrate to draining lymph nodes (dLN) in a CCR2-dependent manner (Teh et al.,
2019), much like cDCs. In the absence of inflammation, most pulmonary DC display an
immature phenotype and mediate immune tolerance to exogenous and self-antigens
(Lambrecht et al., 2001). Direct detection of PAMPS or DAMPS after antigen internalization
triggers DC maturation and migration to dLN, where they can prime naïve T cells. DCs have
been the target of numerous mucosal vaccines to influenza (Khalil et al., 2014; Wakim et al.,
2015), Chlamydia trachomatis (Stary et al., 2015), HIV (Ruane et al., 2016), Streptococcus
pneumoniae (Kataoka et al., 2017), Mycobacterium tuberculosis (Griffiths et al., 2016), and
Yersinia pestis (Do et al., 2008; Do et al., 2012). These vaccines succeeded in inducing
protective CD4+ and CD8+ T cell responses, enhancing the amplitude and durability of
vaccine-induced immune responses in the mucosal tissue.
We previously reported that complete protection against lethal pneumonic challenge
with Y. pestis CO92pgm- could be achieved with an intranasally (i.n.)-administered vaccine
comprised of F1 and LcrV (V), the capsule protein and the tip protein of the Y. pestis type III
secretion system (T3SS), respectively, covalently linked to recombinant Tobacco Mosaic
Virus (rTMV) (Arnaboldi et al., 2016). TMV is a single-strand (+) RNA plant virus,
consisting of 2,130 copies of a single coat protein (CP) surrounding the RNA core. It is
considered safe to humans because it cannot replicate in mammalian cells (Smith et al.,
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2006). The CP was genetically modified to express a surface-exposed lysine residue that
allows for covalent conjugation of proteins, converting TMV into a highly versatile antigen
presentation platform (McCormick and Palmer, 2008; Smith et al., 2006). Viable TMV (not
chemically inactivated or irradiated) has been shown to target to and upregulate
costimulatory molecules on DCs both in vitro and in vivo (Kemnade et al., 2014; McCormick
et al., 2006) . Interactions between plant viruses and immune cells has been documented
(Balique et al., 2013; Gonzalez et al., 2009; Lacasse et al., 2008) (Gonzalez et al., 2009;
Lacasse et al., 2008) however, there is limited evidence of their direct interactions with
mucosal DCs in vivo. The rTMV used in our vaccine studies (Banik et al., 2015;
Mallajosyula et al., 2014; Mallajosyula et al., 2016; Mansour et al., 2018; McCormick et al.,
2006; McCormick et al., 2018) still contains its RNA core (albeit inactivated). Due to this,
we hypothesize that rTMV is analogous to a virus-like particle (VLP) vaccine, with capacity
to be both an immunostimulant and DC-targeting particulate. In this current study, we extend
previous observations regarding the targeting and immune activating abilities of TMV using
our TMV-conjugated Y. pestis vaccine. We compared uptake and activation of APCs by our
Y. pestis vaccine conjugates (TMV-F1 and TMV-V) to TMV alone as well as their respective
recombinant protein antigens (rF1 and rV) both in vitro and in vivo.

2.MATERIALS AND METHODS
2.1 Recombinant proteins, TMV, and fluorescence labeling
Cloning, expression, and purification of rF1 and rLcrV (rV), and preparation of TMV-F1
and TMV-V conjugate vaccines were performed as described previously (Arnaboldi et al.,
2016). Purified TMV and TMV conjugates were supplied by Alison McCormick. The TMV
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was inactivated via binary ethyleneimine (BEI) prior to the antigen conjugation process
(EDC mediated amine conjugation) and has no replication capacity in plant or mammalian
cells. Each purified protein and conjugate were fluorescently labeled with DyLight™ 488
NHS Ester amine-reactive dye according to the manufacturer’s protocol (ThermoFisher
Scientific). Labeled proteins were aliquoted separately and stored at -20°C. A chromogenic
LAL (limulus amebocyte lysate) endotoxin assay was also performed to assess LPS
contamination from recombinant proteins, as well as TMV and conjugates, according to
manufacturer’s kit protocol (GenScript).

2.2 Mice
Male and female C57Bl/6J mice were obtained from Jackson Laboratories (Bar Harbor,
ME), and maintained by the husbandry staff of the Department of Comparative Medicine at
New York Medical College. All experiments were conducted with the approval of the New
York Medical College Institutional Animal Care and Use Committee (IACUC). All mice
were utilized between 6-25 weeks of age. For protocols that required anesthetization, mice
were anesthetized using 200μL of ketamine/xylazine cocktail (IP injection).

2.3 BMDC isolation, cell culture, and in vitro uptake studies
Murine bone marrow-derived dendritic cells (BMDCs) were prepared and maintained
as previously described (Dong et al., 2016) from adult C57Bl/6J mice, with minor
modifications to the protocol. Bone marrow progenitor cells were obtained by flushing the
femoral bones and cultured in sterile Petri dishes at 37°C in 10mL BMDC media: Advanced
RPMI 1640 (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco), 20mM

61

HEPES (Gibco), 2mM L-glutamine (GlutaMAX, Gibco), 50 U/mL penicillin and
streptomycin (Pen Strep, Gibco), 55 μM 2-mercaptoethanol (Gibco), and 20 ng/mL
recombinant mouse GM-CSF and 10ng/mL recombinant mouse IL-4 (R&D Systems). RBCs
were allowed to die in culture. On Day 3, 10mL fresh BMDC media was added (doubling
volume). On Day 6, a half media change was performed with fresh BMDC media containing
20 ng/mL GM-CSF only (no IL-4). Non-adherent and loosely adherent cells were harvested
from days 7-15 as previously described (Dong et al., 2016). BMDC generation was assessed
by flow cytometry as described below. 5x105 BMDCs/well were seeded in a 12-well cell
culture plate in 2mL of minimal media: Advanced RPMI 1640 medium supplemented with
10% FBS and 50 U/mL penicillin and streptomycin. Wells were treated separately with the
following final concentrations of DyLight™ 488-labeled proteins: 0.5 μg/mL TMV, 0.5
μg/mL rF1, 0.5 μg/mL rV, 1 μg/mL TMV-F1, and 1 μg/mL TMV-V. The concentration of
TMV conjugates was double that of recombinant protein to ensure molar equivalency of rF1
and rV between the groups, since TMV conjugates contain equivalent concentrations of
TMV and recombinant protein. Cells were incubated at 37°C for 1, 4, 24, 48, and 72 hours
and collected into Eppendorf tubes. Cells were centrifuged at 350xg for 5 min, washed with
500μL PBS, and replicate samples were processed for flow cytometry or
immunofluorescence microscopy as described below. As a positive control for BMDC
activation additional wells treated with 1 μg/mL LPS (Sigma-Aldrich).

2.4 Immunofluorescence of BMDCs
Antigen stimulated and control BMDCs, described above, were treated with 4%
paraformaldehyde (PFA) in PBS for 15-20 min at RT. Cells were centrifuged at 350xg for 5
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min and pellets were resuspended in 400μL of 1% BSA in PBS. 60-100μL of each sample
was pipetted into a StatSpin cassette, and cells were spun onto glass microscope slides
(Fisher Scientific) using a StatSpin Cytofuge Cytocentrifuge (Beckman Coulter). Slides were
fixed in 200μL 2.5% PFA in PBS for 10 min and washed by quickly pipetting 1mL of PBS
over the slide (3x). Slides were blocked with 500μL of 1% BSA in PBS for 45 min in the
dark at RT. 200μL of the Alexa Fluor 594 anti-mouse CD11c primary antibody (N418;
BioLegend) or Alexa Fluor 594 Armenian hamster IgG isotype control antibody (HTK888;
BioLegend) was added to each slide (diluted 1:100 in 1% BSA in PBS) for 1 hour in the dark
at RT. Slides were washed again 3x with PBS for 5 min each and allowed to dry. 1-2 drops
of DAPI-Flouromount-G (Southern Biotech) was applied to each slide and immediately
covered with a micro cover glass (No. 1, VWR). Slides were stored in the dark at 4°C until
ready for imaging. Imaging was performed on a Revolve microscope (Echo Inc.).

2.5 B lymphocyte isolation, cell culture, and ex vivo uptake studies
For mucosal B cell isolation, lungs from two naïve adult C57Bl/6J mice were
removed and processed as described below (see 2.7 Isolation of lung cells). For splenic B cells, spleens were removed aseptically from two naïve adult C57Bl/6J mice and placed on
ice in sterile PBS. Single cell suspensions were generated by pressing the organ through a
sterile 40μm cell strainer (Fisher Scientific) with a sterile syringe plunger. Splenocytes were
pelleted by centrifugation at 350xg for 5 min at 4°C, and resuspended and incubated in
0.5mL of filtered red cell lysis buffer (0.8% ammonium chloride) for 5 min in a 37°C bead
bath. The cells were centrifuged again and resuspended in sterile PBS containing 2%FBS and
1mM EDTA. B lymphocytes were isolated using the EasySEP™ Mouse B Cell Isolation Kit
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protocol (STEMCELL Technologies). 5x105 purified B lymphocytes were seeded in a 12well cell culture plate in 2mL of primary lymphocyte media: Advanced RPMI 1640 (Gibco)
supplemented with 10% FBS (Gibco), 1% HEPES (Gibco), 1% penicillin streptomycin Lglutamine (Pen Strep Glutamine, Gibco), and 55 μM 2-mercaptoethanol (Gibco). B cells
were rested for 1 hour and then treated with DyLight™ 488-labeled proteins (as above).

2.6 Intranasal vaccination and in vivo uptake studies
C57Bl/6J mice (8-25 weeks old) were anesthetized in order to preform i.n.
immunization with either: 10µg of TMV-V+10µg of TMV-F1 (total of 20 µg), 5µg rV+5µg
rF1 (total of 10µg), or 10ug of TMV in 40µL volume of saline. Control mice received no i.n.
immunization. Mice were vaccinated with 10μg of TMV-conjugate and 5 μg of recombinant
protein to ensure molar equivalency of rF1 and rV between the two vaccines. Mice were not
vaccinated separately with TMV-F1/rF1 and TMV-V/rV to reduce the number of animals
needed for study. Working concentrations of vaccines were prepared from freezer stocks on
the day of immunization. A total of four mice were used for each time point and included an
even number of males and females (e.g. rF1+rV-male, TMV-F1+TMV-V-female, TMVmale, control-female). A table providing the sexes used for each timepoint is supplied in
Appendix I (Appendix I Table S1).

2.7 Isolation of lung cells
Mice were sacrificed and whole lungs were harvested 1, 2, 4, 24, 48, and 96 hours
after i.n. immunization with labeled vaccine proteins. Before harvest, lungs were gently
perfused via the right ventricle with 5–10mL of PBS to remove leucocytes in the blood from
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the pulmonary circulation. Lungs from each mouse were placed in sterile gentleMACS C
tubes (Miltenyi Biotec) and single cell suspensions were prepared using the mouse Lung
Dissociation Kit and a gentleMACS Dissociator, according to the manufacturer’s protocol
(Miltenyi Biotec). Lung cell suspension was strained through a 70μm cell strainer (Fisher
Scientific) into a 50mL conical tube and flushed with 15mL of PEB buffer (1x PBS, 0.5%
BSA, 2mM EDTA) (the strainer was pre-soaked with 1 mL PEB to assist straining) and then
centrifuged at 300xg for 10 min at 4°C. The supernatant was discarded, and cell pellets were
resuspended in 0.5mL of red cell lysis buffer and incubated in a 37°C bead bath for 4 min.
After, the cells were centrifuged again at 300xg for 10 min at 4°C. The supernatant was
carefully pipetted off and discarded and pellet was gently resuspended in 2-3 mL of cold
PEB buffer. Cells were strained for a second time through a cell strainer snap cap test tube
(BD Falcon) and kept on ice to ensure preservation of surface markers for flow cytometry.
Cell concentration and viability were determined using Trypan Blue solution (0.4%, Gibco)
staining and a hemocytometer.

2.8 Flow cytometry
5x105 - 1x106 cells/well were placed in a 96-well V-bottom plate. Cells were
centrifuged at 350xg for 5 min at 4°C and washed twice with PBS. Cells were stained with
Fixable Viability Dye eFluor™ 450 for 30 min on ice in the dark (1:1000) (eBioscience).
Cells were then centrifuged and washed once with staining buffer (1x PBS, 0.1% sodium
azide, 2% BSA). Cells were incubated with Fc receptor block (anti-mouse CD16/CD32,
clone93; eBioscience) for 20 min in staining buffer and stained with fluorochromeconjugated primary anti-mouse antibodies for 30min at RT (see Table 1). Antibodies were
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titrated to determine optimal concentrations prior to use (data not shown). After staining,
cells were washed twice with staining buffer and fixed in 2% PFA. Extra wells containing
untreated lung/BMDC/B cells were stained with individual antibodies to calculate
compensation. Cells that were treated with DyLight™ 488-labeled proteins (in vitro or in
vivo) acted as compensation control for FITC. All marker and isotype control antibodies were
manufactured by eBioscience unless noted below in Table 1.
In vitro uptake studies: Antibodies used for BMDC activation (marker name followed
by clone in parenthesis): anti-CD11c APC-eFluor 780 (N418), anti-MHC Class II (1-A/I-E)
PE-Cyanine7 (M5/114.15.12), anti-CD86 (B7-2) APC (GL1), anti-CD80 (B7-1) PerCPeFluor 710 (16-10A1). B cells: anti-CD19 APC e-Fluor 780 (1D3), and appropriate isotype
control antibodies. Four wells were stained per sample: staining mix, isotype controls, antiCD11c plus isotype controls for other markers, and an unstained well. Samples were
acquired using a MACSQuant flow cytometer and analyzed using Flowlogic™ software
(Miltenyi Biotec).
In vivo uptake studies: Data was acquired using three different flow cytometers over
the course of the study due to equipment malfunction, and unexpected changes in core
facility availability. Three wells were created per sample: mix, anti-CD45 (see table below)
plus isotype controls for other markers, and an unstained well. Antibody mixes are described
below and were modified based on the channels available on different cytometers. For the
Miltenyi MACSQuant, different mixes had to be used for B cells and DCs. An extra well
containing lung cells was stained with CD45 isotype control (rat IgG2bk PerCP/Cy5.5
(BioLegend) or APC (eBioscience)) to confirm CD45 gating. All samples were analyzed
using Flowlogic™ software (Miltenyi Biotec).
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Table 1: List of primary antibody mixes used for each flow cytometer.
Flow
Cytometer
Miltenyi Biotec
MACSQuant
(7 channel)

Beckman
Coulter MoFlo
XDP
(11 channel)
BD FACS
Celesta
(12 channel)

Primary anti-mouse antibody mixes
Mix 1: anti-CD11c APC-eFluor 780 (N418), anti-MHC Class II (1-A/IE) PE-Cyanine7 (M5/114.15.12), anti-SiglecF (CD170) PE
(1RNM44N), anti-CD45 PerCP/Cyanine5.5 (30-F11, BioLegend), antiCD11b APC (M1/70)
Mix 2: anti-CD19 APC e-Fluor 780 (1D3), anti-CD4 APC (GK1.5),
anti-CD45 PerCP/Cyanine5.5 (30-F11, BioLegend), anti-CD40 PE
(1C10)
Fixable Viability Dye eFluor™ 455UV (1:1000, before antibodies).
anti-CD11c APC-eFluor 780 (N418), anti-MHC Class II (1-A/I-E) PECyanine7 (M5/114.15.12), anti-SiglecF (CD170) PE (1RNM44N), antiCD45 PerCP/Cyanine5.5 (30-F11, BioLegend), anti-CD11b PE-eFluor
610 (M1/70), anti-CD4 APC (GK1.5), anti-CD19 Alexa Fluor 700
(1D3),
anti-CD11c APC-eFluor 780 (N418), anti-MHC Class II (1-A/I-E)
Super Bright 645 (M5/114.15.12), anti-SiglecF (CD170) PE
(1RNM44N), anti-CD45 APC (30-F11), anti-CD11b PE-eFluor 610
(M1/70), anti-CD4 PerCP-Cyanine5.5 (RM4-5), anti-CD19 Alexa Fluor
700 (1D3)
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2.9 Statistical analysis
Means between two groups were compared by unpaired t test. For comparisons of
three or more groups in relation to time, data was analyzed by a repeated measures two-way
ANOVA, with Tukey’s multiple comparisons test as the post-hoc analysis per time point.
Values for significance were set at p<0.05. All values are expressed as the mean ± SD or
SEM, where indicated. Statistical analysis was performed using GraphPad Prism 7 software.

3.RESULTS
Inhaled antigens are taken up largely by AMs, but TMV-conjugates are taken up at a
higher rate by lung DCs compared to unconjugated rF1+rV or TMV
It has been demonstrated that TMV is taken up by DCs and induces upregulation of
costimulatory molecules on the DC surface in dLN following subcutaneous (s.c.) injection
(Kemnade et al., 2014). And when administered intratracheally to mice, TMV was taken up
by macrophages obtained from bronchoalveolar fluid (BAL), presumably AMs (Balique et
al., 2013). However, this study by Balique et al. did not examine other cell populations, and
it has yet to be shown if TMV induces uptake by lung DCs. To gain further insight into the in
vivo uptake of TMV and TMV-conjugated vaccines following mucosal administration, we
analyzed the uptake of DyLight™ 488 (D488)-labeled TMV, TMV conjugates, and soluble
proteins in the lung 1, 2, 4, 24, 48, 96h after i.n. immunization. We evaluated TMVF1+TMV-V together and rF1+rV together, as Y. pestis vaccine formulations commonly
include both antigens.
Following i.n. immunization there was no significant difference in the overall uptake
of the fluorescently labelled antigens in terms of the percent total D488+ staining cells in the
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lung (either CD45+ or CD45-) at any time point (Appendix I Fig S1). Interestingly,
unconjugated TMV also was almost exclusively taken up by CD45+ cells at all time points
(Appendix I Fig S1C), unlike the conjugates and proteins, where a small percentage always
reached CD45- cells (presumably pneumocytes) (Appendix I Fig S1A, S1B). Uptake of the
TMV conjugates by CD45+ cells was consistently higher than uptake of unconjugated TMV,
though these differences were not statistically significant (Fig 1A, 1B). Uptake of rF1+rV
was also higher than unconjugated TMV but only at later time points (ns, Fig 1A, 1B).
Uptake of TMVF1+TMV-V generally higher (but not statistically different) than uptake of
rF1+rV, but only very early (1h and 2h); uptake was similar in CD45+ cells at later time
points. Interestingly, TMVF1+TMV-V and TMV both exhibited smoother and more
consistent uptake in CD45+ cells over the 4 days (though TMV was always <6%), whereas
rF1+rV uptake was spiked and inconsistent (Fig 1A). A striking percentage of CD11c+ cells
took up antigen in the lungs. It is important to note that while CD11c+ cells represent around
20% of total lung CD45+ cells (Yu et al., 2016), CD11c is a marker for more than just DCs in
the lung (see below). Similarly, uptake of both TMVF1+TMV-V and rF1+rV was
consistently higher than uptake of unconjugated TMV at all timepoints assessed, but this did
not reach statistical significance (Fig 1C). Only a small percentage of CD19+ cells took up
fluorescent antigen in the lung, no differences significant or otherwise were observed
between the groups (Fig 1D). In summation, roughly 4-8% of leucocytes were associated
with all antigens (Fig 1A), yet these fractions still represented 20-50% of the CD11c+
population (Fig 1C). Therefore, this data suggests all i.n. immunized antigens – TMV, TMVF1+TMV-V, and rF1+rV – were mostly taken up into CD11c+ cells.

69

Several non-DC myeloid populations express CD11c, including AMs, some
interstitial macrophages (IMs), and resident Ly6Clo monocytes. Therefore, further analysis
was needed to determine which of these cells were participating in antigen uptake. The
gating strategy and cell markers used for flow cytometric analysis is supplied in Appendix I
(Appendix I Fig S2). AMs (CD11c+ SiglecF+ SSChi) represent around 70% of the total
CD11c+ cells in the lung (Yu et al., 2016), and accordingly accounted for >50% of D488+
cells for every antigen assessed (Fig 2A). TMV showed the highest mean uptake in AMs at
all time points, which accounted for >80% of the D488+ cells. Uptake of TMV by AMs was
substantially higher than both TMVF1+TMV-V and rF1+rV at all time points except for 96h,
while uptake of TMVF1+TMV-V by AMs was consistently lower than it was for rF1+rV
(Fig 2A). These were reproducible differences that were statistically significant by two-way
ANOVA (p=0.001), however, the post-hoc analysis did not reveal significant differences in
pairwise comparisons per time point. DCs were defined as CD11c+ MHC II+ and SSClo to
help differentiate from SSChi macrophages that are also CD11c+ MHC II+ (Yu et al., 2016) .
At each time point, particularly early time points, TMV-conjugated vaccine was taken up by
a higher percentage of DCs than either unconjugated recombinant protein or unconjugated
TMV (Fig 2B). As early as 1h and 2h post-immunization with TMV-F1+TMV-V, the mean
percentage of D488+ DCs was more than double that of rF1+rV (9.6% and 6.6% vs. 4.2%
and 2.1%, 1h and 2h TMV-F1+TMV-V vs. rF1+rV respectively) (Fig 2B). DCs continued to
account for a higher percentage of D488+ cells in TMVF1+TMV-V-immunized mice for the
remaining time points (Fig 2B). However, despite consistent, reproducible differences, the
values did not reach statistically significance by two-way ANOVA likely because of
variability inherent to this experiment and technique. IMs (CD11b+ SSChi), APCs that

70

contribute to tissue homeostasis in the lung, could also represent a target for i.n.-administered
vaccine proteins. IMs comprise a heterogenous CD11b+ population, and in our analysis,
>90% of IMs were CD11c- and MHC II- (Appendix I Fig S3). There were no significant
differences between the antigens in regard to uptake into IMs, as analyzed by two-way
ANOVA (Fig 2C).
We also discovered a population of CD11c+ MHCII- CD11b- cells that were taking
up fluorescently labelled antigen, which we identified as probable tissue-resident DC
precursors (pre-DC) (Suda et al., 1998; von Garnier et al., 2017; Wang et al., 2006).
Interestingly, both TMV-F1+TMV-V and rF1+rV were consistently taken up by substantially
more pre-DC than unconjugated TMV at all but the final time point (Fig 2D), however, these
differences did not reach statistical significance by two-way ANOVA. The percentage of
D488+ antigens that were associated with pre-DCs (0-40%) was roughly double of that seen
with cDCs (0-20%) for all antigens. Uptake of antigen in CD11c- CD11b+ monocytes
(presumably Ly6C+ monocytes) was highly variable, and there were no significant
differences between the antigens in regard to uptake into this cell population (Fig 2E). CD19+
B cells demonstrated similar uptake of antigen at all time points (Fig 2F). CD4+ T cells
represented another insignificant target of inhaled antigens; less than 1% of lung CD4+ cells
participated in uptake of all proteins from 1-96h post-immunization (data not shown).
Overall, these data supported that i.n.-administered antigens are largely taken up by AMs in
the lungs, but TMV-F1+TMV-V was associated with a higher percentage of DCs compared
with the unconjugated rF1+rV and TMV, especially in the first 2 hours post-immunization.
We also looked at activation markers on CD11c+ cells in the lung post-immunization, but
preliminary data showed there was no difference in expression of MHC II and CD86 of
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antigen-immunized mice compared to unimmunized control mice (data not shown).
Therefore, we moved to an in vitro system.

TMV conjugation promotes uptake of F1 and V antigens in BMDCs and B cells in vitro,
but does not induce costimulatory molecules
Kemnade and colleagues were the first to demonstrate uptake of TMV into mouse
and human DCs (Kemnade et al., 2014). However, these experiments utilized live TMV
without conjugated antigen. One other in vitro study on TMV solely focused on
macrophages, where they found live TMV localized in the cytoplasm of murine bonemarrow derived macrophages (BMDMs) and persisted for over two weeks, but not
replicating (Balique et al., 2013). We sought to evaluate the uptake of TMV into three other
APCs: bone-marrow derived DCs (BMDCs), splenic B cells, and lung mucosal B cells. In
our studies, TMV was inactivated and conjugated separately to F1 and V antigens. This
allowed us to examine vaccine-APC interactions under more reproducible conditions than is
possible in the mouse.
When conjugated to TMV, uptake of V antigen by BMDCs was significantly
increased at 4, 24, 48, and 72 hours (h), compared to uptake of unconjugated protein, with
the largest difference being at 72h (TMV-V 78.8% ± 2.2% vs rV 58.4% ± 1.9% of BMDC
population) (Fig 3A). Uptake of TMV-F1, conversely, was not significantly different from
rF1 over the time course (Fig 3A). The F1 capsule is known to possess anti-phagocytic
properties, and therefore, coating the TMV particle in F1 proteins could theoretically inhibit
uptake into phagocytic cells. This was further supported by the fact that TMV uptake in
BMDCs was significantly higher than TMV-F1 at all time points, and uptake was parallel to
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that of TMV-V (Fig 3A). Microscopically, TMV could be seen internalized by CD11c+
BMDCs as early as 1h of incubation, as well as by CD11c- macrophages/monocytes in
culture (Fig 3B). For both splenic and mucosal B cells, the percentage of cells participating
in uptake (<3%) was much smaller compared to that of BMDCs (20-80%). Since B cells
internalize antigen through the B cell receptor or other surface receptors, this indicated there
is likely no PRR specific for TMV on B cells, and there are only few B cells with BCRs
capable of binding TMV. Unlike with BMDCs, uptake of TMV-V and rV antigen in splenic
B cells was not significantly different at any timepoint, although TMV-V was associated with
a greater percentage of B cells (≥1%) at all timepoints (Fig 3C). On the other hand, uptake of
TMV-F1 was significantly higher than that of rF1 beginning at 24h (TMV-F1 0.77% ±
0.03% vs rF1 0.24% ± 0.05%), and the difference increased at each subsequent timepoint
(Fig 3C). In lung B cells, the reverse was observed, uptake of TMV-F1 and rF1 antigen was
not significantly different at any timepoint, although TMV-F1 was associated with a greater
percentage of B cells at most timepoints (Fig 3D). However, uptake of TMV-V was
significantly higher compared to rV at all time points (Fig 3D). Uptake of unconjugated
TMV negligible in both splenic and lung B cells (Fig 3C, 3D). This suggests that the uptake
of antigens by B cells is utterly independent of the antigenicity of TMV. Enhancement of
TMV conjugates compared to protein antigens in both BMDCs in vitro and B cells ex vivo is
likely due to increased particle size, and not directly related to properties of the virus itself.
It has been previously shown that CD11c+ DCs isolated from dLN that had taken up
fluorescently-labeled TMV following s.c. footpad injection had increased surface expression
of the T cell costimulatory molecules CD54, CD40, CD86, MHC I, and MHC II compared to
DCs from PBS-injected mice (Kemnade et al., 2014). This suggested that TMV uptake
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induced the immune-activating potential of these cells; however, this was a live, noninactivated TMV (Kemnade et al., 2014). We therefore asked whether inactivated TMV
conjugated to either F1 or V antigen, could also trigger DC activation. LPS, a TLR4 agonist,
significantly increased the mean fluorescence intensity (MFI) of all costimulatory molecules
compared to unstimulated BMDCs, as expected (Fig 3E, 3F, 3G). MFI increased from 24 to
72h before decreasing at 144h. There was no significant difference in the surface expression
of any costimulatory molecule following incubation of BMDCs with any antigen at any time
point assessed, compared to unstimulated cells (Fig 3E, 3F, 3G). We also assessed possible
E. coli endotoxin (LPS) contamination in recombinant proteins, as LPS upregulates
costimulatory molecules in APCs and would interfere with the interpretation of this data.
Purified TMV contained no endotoxin, as expected, and rF1 and rV had similar levels of
endotoxin as molar equivalent concentrations of their respective TMV conjugates (Appendix
I Fig S4). This indicated that any inadvertent effects resulting from endotoxin-contaminated
proteins would also be seen by their respective TMV conjugates, and the effects would be
similar. Despite the detectable contamination, we did not observe any differences in
activation compared to unstimulated BMDCs, as already stated. Altogether, these data
suggested that neither inactivated TMV itself, or as part of a conjugate, directly stimulates
the maturation of DCs in vitro, supporting our in vivo findings.

4. DISCUSSION
DCs are professional APCs that are present throughout the respiratory tract and play a
vital role in the initiation of immune responses, whether those responses may be allergenbased, or directed at replicating viral, bacterial, or fungal pathogens. In healthy lungs, the
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majority of DC are immature and mediate immune tolerance to various innocuous antigens in
both mice and humans (Kuipers and Lambrecht, 2004). Exposure of antigens to the lung,
therefore, often leads to induction of tolerance rather than immunization. Effective
respiratory vaccines have to overcome this tolerance so that a protective immune response
can be generated. The addition of an adjuvant is key in a mucosal vaccination setting.
Vaccine delivery systems, while less potent than toxoid-based adjuvants, have the advantage
of facilitating the uptake of soluble antigens into APCs with low risk of damaging mucus
tissue. These systems include nano- and micro-particles, liposomes, particulates (e.g. VLPs),
and emulsions (Kunda et al., 2013). Based on the findings of the current study, we propose
that TMV can be classified as such an adjuvant. We reported 100% protection against lethal
pneumonic plague challenge could be achieved with i.n. administration of TMV-F1+TMVV, but not rF1+rV, and that TMV-F1- and/or TMV-V-immunized mice had greater
production of antigen-specific antibodies compared to mice immunized with rF1 and/or rV
(Arnaboldi et al., 2016). Although the success of the vaccine was apparent, the mechanism of
how TMV enhances vaccine-specific immunity had not been identified.
To define cell populations involved in uptake of vaccine antigens in vivo, we
analyzed the uptake of fluorescently labeled TMV, TMV-F1+TMV-V, and rF1+rV in the
lung for 1-96h post-immunization. Viable TMV has been known to persist in lung
macrophages when administered to mice intratracheally (Balique et al., 2013). In the current
study, TMV was primarily found in AMs (>80% of the D488+ cells were AMs). AMs
represent a significant macrophage population in the lung: 14% of all CD45+ cells (Yu et al.,
2016). It is unclear why TMV is preferentially associated with AMs. TMV is relatively small
at 300nm, compared to a bacterium or fungus, yet is stable enough to endure the harsh
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environment of phagocytes, and that of the surrounding mucosa. Preliminary data showed
TMV and our TMV conjugate vaccine was detected in lungs at 10 days post- i.n.
administration (data not shown). We think this stability could be its most important feature,
as this would greatly increase likelihood of APC detection. All antigens – TMV, TMVF1+TMV-V, and rF1+rV – were mostly taken up into CD11c+ cells, a majority of which were
AMs. TMV-F1+TMV-V was the only group consistently taken up by less AMs and more
DCs compared to unconjugated protein and TMV alone (Fig 3). This suggests that
TMVF1+TMV-V conjugates can overcome the immune tolerant threshold mediated by AMs,
the first line of defense against invading microorganisms, to reach a greater number of lung
DCs. However, further studies would need to determine the fate of these TMV-F1+TMV-V+
DCs in dLN, the type of DC (CD11b+ or CD103+), and whether they are capable of
stimulating antigen-specific CD4+ T cell proliferation in secondary lymphoid organs (SLO).
We also observed that lung-resident DC precursors represented a significant target of
inhaled antigens. These DC precursors can generate into fully functional CD11c+ CD11b+
DCs but are not considered APCs themselves due to lack of MHC II and costimulatory
molecules (Wang et al., 2006). Both TMVF1+TMV-V and rF1+rV were consistently taken
up by a higher percentage of pre-DC compared to TMV, although the biological relevance of
this is questionable given that pre-DCs are poor APCs and their purpose is to replenish the
resident lung DC population. The percentage of D488+ pre-DCs was roughly double that of
D488+ cDCs for all antigens, which is interesting given that pre-DCs make up a similar cell
percentage as cDCs in the naïve mouse lung (6% and 5% of CD45+, respectively) (Wang et
al., 2006; Yu et al., 2016). IMs were also associated with all vaccine proteins, and uptake of
D488+ proteins by IMs was the highest at days post-immunization, as opposed to hours.
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Most studies on murine IMs have focused on their immunoregulatory nature, and human and
murine IMs have been shown to express IL-10 at steady state (Schyns et al., 2018).
Therefore, it is unlikely that IMs are key players in vaccine-induced protection. B cells,
which act as APCs for follicular DCs in germinal centers (GC) to enable GC class switching
and affinity maturation, were also a smaller but significant target of the TMV-F1+TMV-V
conjugates. From this, we can infer that B cells do bind the conjugates, but there are likely
not high numbers of TMV-, V-, and F1-specific B cells in the naïve lung, as mentioned
previously. In vivo, B cell data is difficult to interpret without the use of fluorescently labeled
tetramers, which can identify rare antigen-specific B cells. It is also possible these proteins
were interacting with low-affinity B cells generated against other antigens with cross-reactive
epitopes. This process could be occurring beyond 4 days, and thus beyond the scope of these
experiments. Further studies will need to look at conjugates individually (TMV-F1 vs TMVV) and investigate conjugate uptake into B cell responses in the lung mucosa.
Considering the prior report of viable TMV activating DCs in vivo (Kemnade et al.,
2014), we hypothesized that TMV had the potential to be both an immunostimulant and
stable vaccine delivery system targeted to DCs. To test this hypothesis, we cultured BMDCs
in the presence of fluorescently labeled proteins (TMV, TMV-F1, TMV-V, rF1, rV) and
analyzed their uptake by flow cytometry. While TMV-V showed significantly greater uptake
into BMDCs compared to rV, the same was not true for TMV-F1. The F1 capsule is known
to possess anti-phagocytic properties (Runco et al., 2008). Therefore, coating the TMV
particle in F1 proteins could theoretically create the same protective effect exerted by the
bacterial capsule. This was further supported by the fact that TMV uptake in BMDCs was
significantly higher than TMV-F1 at all time points, but no different compared to TMV-V.
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This suggests addition of F1 to the TMV particle could limit its uptake capacity into DCs in
vivo, potentially dampening anti-F1 CD4+ T cell responses.
Uptake of TMV-V and TMV-F1 into lung B cells ex vivo was generally higher than
both rV and rF1 proteins. Mucosa-associated B lymphocytes largely represent effector or
memory cells (Allie et al., 2019). Thus, we did not expect there to be a high number of
TMV-, V-, and F1-specific B cells in the naïve lung, since these antigens are not encountered
there normally in mice. For splenic B cells, uptake of TMV-F1 was significantly higher than
rF1, and this difference increased with each day of incubation. TMV alone was barely taken
up by splenic B cells, indicating there are more splenic B cells that are cross-reactive with F1
than TMV. Overall this suggests that the uptake of antigens by B cells is utterly independent
of the virus and is likely due to the random presence of B cells with BCRs capable of binding
to F1 or V with high avidity. BCR interaction would also explain why such a low percentage
of B cells (<3%) were involved in uptake; BCR binding must precede internalization of the
antigen. A spleen also contains a higher proportion of naïve B cells. If presented at a high
frequency in SLO, our data suggests there is potential for direct or indirect (BCR
crosslinking) activation of naïve B cells by TMV-F1.
Mature APCs upregulate the expression of MHC class II and costimulatory molecules
before or as they drain to dLN where they then interact with antigen-specific B or T-cells to
trigger immune responses. In vivo, viable TMV is known to induce costimulatory molecules
on CD11c+ DCs from dLN (Kemnade et al., 2014). We investigated whether TMV, if
conjugated to F1 and V antigen, could also trigger DC activation. However, we could not
show that TMV conjugates are immunostimulants. Incubation of TMV conjugates in vitro
failed to upregulate MHC II, CD80, or CD86 over that of unstimulated BMDCs, while LPS
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alone did. This may be because the TMV RNA is altered via BEI prior to the antigen
conjugation process, which could negate any agonist interactions with PRRs (e.g. endosomal
TLR7 ligation). We looked at activation markers on D488+ CD11c+ lung cells in vivo, posti.n. immunization, but preliminary data showed there was no differences in expression of
MHC II and CD86 compared to unimmunized mice.
In summary, although inactive TMV conjugates do not appear to induce DC
activation, TMV conjugation to the whole protein antigens increased their uptake into splenic
and mucosal B cells, BMDCs, as well lung DCs in vivo. This process seemed dependent on
the vaccine particulate’s size and characteristics, and not due to any TMV-specific
mechanism. While AMs were the primary cell of uptake in the lung for TMV, TMVF1+TMV-V, and rF1+rV, the dual vaccine conjugates were consistently taken up by less
AMs and more DCs compared to unconjugated protein and TMV alone. Our data suggests
that rTMV is an efficient vaccine delivery platform by targeting antigens to APCs, even in
the mucosal respiratory tract where overcoming immune tolerance is challenging (Neutra and
Kozlowski, 2006). TMV conjugation to protein antigens can increase their uptake into
murine DCs, indicating potential for antigen-specific T-cell proliferation and long-term
vaccine-induced protection.
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Fig 1. Protein antigens, TMV conjugates, and TMV are taken up by <16% of lung
CD45+ cells in vivo, a majority of which are CD11c+. Uptake of DyLight™ 488-labeled
proteins (FITC+) proteins into the lung after 1, 2, 4, 24, 48, and 96 hours post- i.n.
immunization, shown as the percent of CD45+ cells (A) and the absolute number of FITC+
CD45+ cells (B). Uptake of FITC+ proteins, as a percent of the total CD11c+ cells (C) and
total CD19+ cells (D) in the lung, was also measured by flow cytometry. For each panel, a
line and bar graph of the same data are shown to highlight overall trends (line) and variation
between the groups (bars). For each graph, significance was analyzed by repeated-measures
two-way ANOVA, with Tukey’s multiple comparisons test, however, at no time point were
the groups statistically different from one another. All errors bars represent mean±SEM.
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Fig 2. Protein antigens, TMV conjugates, and TMV are mostly taken up by AMs, but
conjugates are associated with more lung DCs at earlier time points than proteins and
TMV. Uptake of DyLight™ 488-labeled (FITC+) proteins into different lung immune cell
types after 1, 2, 4, 24, 48, and 96h post- i.n. immunization. Percent of the FITC+ cells that
represented AMs (A), conventional DCs (B), IMs (C), pre-DC (D), CD11c- monocytes (E),
and CD19+ B cells (F) were measured by flow cytometry. For each graph, differences
between the groups were analyzed by a repeated-measures two-way ANOVA, with Tukey’s
multiple comparisons test, however, at no time point were the groups statistically different
from one another. All errors bars represent mean±SEM.
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Fig 3. TMV conjugation promotes uptake of F1 or V antigens in BMDCs and B cells in
vitro but does not induce costimulatory molecules on BMDCs. (A) Uptake of
DyLight™488-labeled (FITC+) proteins into BMDCs in vitro as measured by flow
cytometry. Blue and red asterisks indicate statistical significance for TMV-V vs rV and TMV
vs TMV-F1, respectively. (B) Image of CD11c+ BMDCs (red) after 1h incubation with 488labeled TMV (green) with DAPI-stained nuclei (20x). Uptake of FITC+ proteins into splenic
B cells (C) and lung B cells (D) ex vivo as measured by flow cytometry. Green and blue
asterisks indicate statistical significance for TMV-F1 vs rF1 and TMV-V vs rV, respectively.
Mean fluorescence intensity (MFI) of surface MHC II (E), CD86 (F), and CD80 (G) on
CD11c+ BMDCs in vitro as measured by flow cytometry. Purple and green asterisks indicate
statistical significance for LPS vs untreated cells (control) and TMV-F1 vs rF1, respectively.
For each graph, significance was analyzed by multiple t tests. **** p<0.0001, ***p<0.001,
**p<0.01, *p<0.05. All errors bars represent mean±SD.
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Chapter 3. Specific Aim 2
AIM 2:
Evaluating Efficacy and Correlates of Protection of a Single-Dose Intranasal
TMV Conjugate Vaccine for Pneumonic Plague
Aim 2a: Test the hypothesis that a single intranasal administration of TMV vaccine is
protective against high-dose pneumonic plague infection
Aim 2b: Test the hypothesis that single administration of TMV vaccine prevents or reduces
dissemination of Y. pestis in the infected host
Aim 2c: Test the hypothesis that pre-challenge antigen-specific titers are a correlate of TMV
vaccine-induced protection
Aim 2d: Test the hypothesis that the TMV vaccine induces a TH1 or TH17 specific response
in the infected host
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1.INTRODUCTION
Yersinia pestis is the causative agent of plague, an acute febrile illness with a high
mortality if left untreated. Most natural infections occur through the bite of infected fleas,
resulting in bubonic plague, where lymphohematogenous dissemination of the bacteria
typically results in infection, and characteristic swelling, of draining lymph nodes (termed
buboes). In rare cases, direct blood dissemination can occur resulting septicemic plague,
which is often associated with a blackening of the hands and feet (necrosis) and a very high
mortality rate if treatment is not administered rapidly (Perry and Fetherston, 1997). In
addition, Y. pestis can disseminate to the lung and be transmitted via inhalation of infectious
aerosol droplets, which enables person-to-person transmission. Pneumonic plague is one of
the deadliest diseases known to mankind; death is almost certain if antibiotic treatment is
delayed past the first 24 hours. Plague is still endemic in many regions of the world,
particularly in central Africa and Madagascar where outbreaks are not uncommon.
Madagascar experienced a large urban outbreak in 2017, with 76% of the nearly 2,400
reported cases were confirmed, probable, or suspected pneumonic plague
(Andrianaivoarimanana et al., 2019; Nguyen et al., 2018; Rabaan et al., 2019; Randremanana
et al., 2019; WHO, 2017). Among confirmed pneumonic cases, the fatality rate was 25%,
and over 80% of confirmed or probable pneumonic cases were concentrated in two major
cities (Randremanana et al., 2019). Despite sensitivity of Yersinia ssp. to a range of
antibiotics, the recent increases in the number of worldwide annual cases, findings of multidrug resistant (MDR) strains from clinical isolates, and potential for local outbreaks to evolve
into a pandemic – whether natural or intentional – have prompted global efforts to develop
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effective plague vaccines. Despite decades of ongoing research, an FDA-approved vaccine
does not currently exist.
Most current efforts are focused on developing recombinant subunit vaccines against
pneumonic plague. Top vaccine candidates include the well-characterized F1 and LcrV (V)
antigens, the Y. pestis capsule protein and the tip protein of the type III secretion system
(T3SS), respectively. Despite its success in small animal models (Anderson et al., 1998;
Bowen et al., 2019; Heath et al., 1998; Jones et al., 2000; Williamson et al., 1995;
Williamson et al., 1996; Williamson et al., 1997), intramuscular (i.m.) administration of
F1/V generated mixed results in NHP models of pneumonic plague (Smiley, 2008). Over the
last few decades, numerous approaches have sought to improve the efficacy of the F1/Vvaccines (Demeure et al., 2019; Sun and Singh, 2019; Titball and Williamson, 2004) to
generate rapid mucosal and systemic immunity against plague.
We previously reported that complete protection against lethal pneumonic challenge
with Y. pestis CO92pgm- could be achieved using three doses (prime + two boosts) of an
intranasal (i.n.) vaccine comprised of V and F1 covalently linked to recombinant Tobacco
Mosaic Virus (TMV) (Arnaboldi et al., 2016). TMV is a single-strand RNA virus that
cannot replicate in mammalian cells. Despite this, TMV has adjuvant-like properties,
targeting antigen to dendritic cells, upregulating MHC and co-stimulatory molecules, and
capable of inducing antigen-specific CD8+ T cells in vivo in mice (Kemnade et al., 2014).
Due to ubiquitous exposure, most, if not all humans have serum antibodies to the virus,
regardless of their tobacco use (Liu et al., 2013). In addition to our own studies, others have
demonstrated that TMV-based vaccines also induce protective immunity against tularemia
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(Banik et al., 2015)(Mansour et al., 2018) , as well as influenza H1N1 (Mallajosyula et al.,
2014) and H5N1 (Mallajosyula et al., 2016).
Although the 3-dose vaccine regimen was protective, it would be impractical to use in
the setting of an outbreak. In the present study, we tested i.n. administration of a single dose
of TMV-F1+TMV-V (abbr. TMV-F1/V), with no other adjuvant, 5 weeks prior to challenge
with a pigmentation locus-deficient (pgm-) strain of Y. pestis (CO92pgm−). Mice
immunized with the dual antigen TMV conjugate mixture rapidly cleared bacteria from distal
tissues and reduced inflammatory cytokine production compared to mice immunized with
unconjugated rF1+rV. Our study showed that a single dose of vaccine provided protection to
mice that was superior to unconjugated protein (rF1+rV), irrespective of comparable F1
antibody titers prior to challenge.

2.MATERIALS AND METHODS
2.1 Bacterial strains, recombinant protein, and TMV
Yersinia pestis CO92pgm− was a generous gift of Dr. James Bliska (Stonybrook
University, NY), and was cultivated as previously described (Arnaboldi et al., 2016).
Cloning, expression, and purification of rF1 and rLcrV (rV), and preparation of TMV-F1 and
TMV-V conjugate vaccines were performed as described previously (Arnaboldi et al., 2016).
Briefly, rF1 and rLcrV (rV) proteins were conjugated independently to rTMV by EDC
mediated amine conjugation to generateTMV-F1 and TMV-V. Conjugation efficacy was
measured by SDS-PAGE, with little or no free rF or rV measurable by using the same
reaction conditions. The TMV is inactivated via binary ethyleneimine (BEI) prior to the
antigen conjugation process (EDC mediated amine conjugation) and has no replication
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capacity in plant or mammalian cells. The TMV-F1 and TMV-V conjugates used in this
study were from the same lot.

2.2 Mice and intranasal vaccination
Adult (6-week-old) male and female C57Bl/6J mice were obtained from Jackson
Laboratories (Bar Harbor, Maine), and maintained by the husbandry staff of the Department
of Comparative Medicine at New York Medical College. All experiments were conducted
with the approval of the New York Medical College Institutional Animal Care and Use
Committee (IACUC). All mice were vaccinated at 6 weeks old and challenged at 11 weeks
of age. Equal numbers of male and female mice were tested in all groups. Mice were
anesthetized using ketamine/xylazine cocktail in order to preform i.n. vaccination with either:
10µg of TMV-V+10µg of TMV-F1 (total of 20 µg) or 5µg rV+5µg rF1 (total of 10µg) in
40µL volume of saline. TMV-conjugated vaccines contain equivalent concentrations of
TMV and recombinant protein (5μg TMV+5μg protein). Mice were vaccinated with 10μg of
TMV-conjugate and 5 μg of recombinant protein to ensure molar equivalency of the Y. pestis
antigens between the two vaccines. Control mice were unvaccinated. We have previously
observed that TMV-vaccination alone does not impart protection to mice (Banik et al., 2015).
Therefore, we did not include a TMV-alone vaccine group to minimize the number of
animals needed for study. Working concentrations of vaccines were prepared from freezer
stocks on the day of immunization.

2.3 Bacterial Challenge
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All mice were challenged on day 35 post-immunization with Y. pestis CO92pgm− as
previously described (Arnaboldi et al., 2016). Briefly, Y. pestis CO92pgm− was grown to an
OD620 of 0.9 in heart infusion broth supplemented with 2.5mM CaCl2 and 0.2% Xylose at
37°C in a shaking incubator (225 RPM). Culture medium was removed by centrifugation and
the bacterial pellet was washed 3× with sterile saline. Bacteria were resuspended in normal
saline to an OD620 of 1.1, assuming a concentration of 1x109 CFU. The LD50 of Y. pestis
CO92pgm− in C57Bl/6J mice was previously determined to be 2.5x104 CFU (Arnaboldi et
al., 2016). Bacteria were diluted accordingly, and anesthetized mice were intranasally (i.n.)
administered 10 LD50 or 100 LD50 in 50µL saline in a class II biosafety cabinet. 10-fold
dilutions of the bacteria were streaked on HI agar and incubated for 2 days at 28°C to
confirm the number of bacterial CFU administered for each challenge. After challenge (D0),
mice were weighed and checked daily for signs of morbidity (ruffled fur, hunched posture,
reduced activity, weight loss). Mice that lost more than 20% of their pre-challenge body
weight, or were severely moribund, were euthanized. Survival was monitored for 21 days,
and mice were euthanized according to approved IACUC guidelines.

2.4 Tissue collection
In a separate experiment, mice that were immunized and challenged as described
above (2.3) were euthanized daily for the first 5 days following challenge and lungs, spleen,
liver, and blood were collected (n=6/group). The left lobe of the lung, half of the spleen and
~150mg of liver tissue were placed in 1.5ml centrifuge tubes filled with ~100uL of ceria
stabilized zirconium oxide beads (2mm diameter, Next Advance, Inc.) and 0.5mL of sterile
PBS on ice. The tissues were homogenized using a BioSpec Mini-BeadbeaterTM. Six 10-
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fold dilutions of the homogenates were generated in sterile PBS, and 10uL of each dilution
was pipetted onto replicate HI plates (6 dilutions per petri dish). Plates were incubated for 2
days at 28°C. CFUs were calculated as described previously (Wang, N. et al., 2011). Counts
per dilution were averaged from plates per mouse. Briefly, calculations were performed using
the formula: CFU/tissue= CFU/100uL x dilution factor x 0.5mL. This number was then
divided by 0.5 for the spleen and lung, and 0.2 for the liver (the percentage of the total organ
mass used for homogenization). Therefore, if no CFUs were recovered on HI plates, these
values were assigned for the indicated mouse. For blood plating, ~500uL of whole blood
was collected, and dilutions were plated as described above. Because whole tissues were not
processed, the limit of detection for each tissue was calculated as follows: lung 10
CFUs/organ, liver 25 CFUs/organ, spleen 10 CFUs/organ, blood 100 CFUs/mL. Serum was
collected from the remaining blood by centrifugation at 2500xg for 15 min and stored at 20°C. Remainder of tissue homogenates were centrifuged at 10,000rpm x 10 min, and the
supernatants were aliquoted and stored at -80°C.

2.5 Histology
Formalin fixed lung, liver, and spleen tissue was processed, paraffin-embedded, and
stained with hematoxylin and eosin (H&E). For quantification of pathology, tissues were
scored in a blinded fashion for severity of inflammation and necrosis (0-4) (see Appendix II
Table S1 for scoring). Imaging of the sections was performed on a Revolve microscope
(ECHO, San Diego, CA). Images were collected at 4x magnification, with exception of
naïve lung (2x).
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2.6 Antibody measurements
Blood was collected via retroorbital bleed twice prior to challenge, at days 14-18 and
28-32 post-immunization. Sera were collected by centrifugation at 2500xg for 15 min and
stored at -20°C. 96 well ELISA plates (Nunc MaxiSorpTM flat bottom or Immulon® 2 HB
Flat Bottom MicroTiterTM) were coated with rV or rF1 (2 µg/ml) in 0.1M Carbonate Buffer,
pH 9.4 overnight at 4°C. Plates were blocked with 1% BSA in PBS for 1h at RT, and
washed 3x with 0.05% Tween in PBS. Sera were diluted in blocking buffer and were
incubated for 1h at RT. Plates were washed 3x again, and HRP-labeled goat anti-mouse Ig
heavy and light (H+L) chain or IgG2b (Southern Biotech) diluted 1:5000 in blocking buffer
was added to each well for 1h at RT. The plates were washed and developed with TMB
substrate (KPL) for 30 min at RT. The reaction was stopped by addition of 2N sulfuric acid,
and absorbance was read at 450nm and 570nm on a SpectraMax Plus 384 microplate reader
(Molecular Devices). Absorbance was plotted vs. reciprocal serum dilution and 50%
maximal binding titers were calculated using GraphPad Prism 7.0 software.

2.7 Cytokine measurements
Cytokine concentrations in lung and spleen supernatant from tissue homogenates
were evaluated with the Invitrogen/eBioscience uncoated ELISA kits according to
manufacturer’s instructions: TNF-α (cat # 88-7324-77), IL-17 (cat # 88-7371-77), and IFN-γ
(cat # 88-7314-77). All homogenates were diluted in assay diluent. Samples were analyzed in
duplicate.

2.8 Statistical analyses
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Statistical analyses were performed using Prism 7.0 GraphPad software. Survival
curves were compared using a log-rank (Mantel-Cox) test. Differences in means were
analyzed using an unpaired student’s t-test or one-way ANOVA. Multiple t tests were used to
analyze mean differences between ELISA serum dilutions. Linear correlations were analyzed
by Pearson’s correlation coefficient. P values of <0.05 were considered statistically
significant.

3.RESULTS
A single i.n. administration of TMV-F1+TMV-V enhances survival and bacterial
clearance compared to recombinant protein alone
We previously demonstrated that conjugating V and F1 to a rTMV vaccine delivery
platform imparts complete protection against lethal challenge with 10 LD50 of Y. pestis
CO92pgm- after a minimum of three doses (Arnaboldi et al., 2016) If this vaccine were to be
used as a countermeasure for a potential biological attack, fewer doses would be optimal. In
the present study, we evaluated a single dose of TMV-F1/V against challenge with both 10
and 100 LD50 Y. pestis CO92pgm−.
A single i.n. dose of TMV-F1+TMV-V imparted a mean survival of 88% (23/26
mice) over two studies following i.n. challenge with 100 LD50 of Y. pestis CO92pgm−. This
was significantly higher than the survival rate of mice immunized with rF1+rV- (11.5%,
3/26) or unimmunized mice (11.5%, 3/26) (Fig 1A). Similar results were obtained when a
challenge dose of 10 LD50 was utilized (Appendix II Fig S1). Importantly, conjugation of V
and F1 to TMV was required for protection as mice immunized with rF1+rV mixed with
TMV demonstrated similar protection to mice immunized with rF1+rV alone (Appendix II
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Fig S1). Mice vaccinated with TMV-V+TMV-F1 showed initial weight loss. However,
weight loss was significantly reduced in TMV conjugate-immunized mice compared to
unimmunized mice as early as day 3 (D3) post-infection (PI) and was reduced compared to
mice immunized with rF1+rV, though this difference was not statistically significant (Fig
1B). Morbidity, defined as the subjective condition and activity level of the mice, was also
reduced compared to mice that received rF1+rV. Three unimmunized mice, all female, and
three rF1+rV immunized mice, two females and one male survived the infection. Three
TMV-conjugate immunized mice, two males and one female, succumbed to the infection.
Although three unimmunized mice managed to survive infection, these mice took longer to
recover compared to rF1+rV- and TMV-conjugate immunized mice, as evidenced by a delay
in returning to pre-challenge weight (Appendix II Fig S2). It has been reported that up to
50% of naïve C57Bl/6J mice can survive a similar i.n. dose of a nonpigmented Y. pestis
strain (Olson and Anderson, 2019), however, the reason for this is not fully understood, as
we have observed lower doses (e.g. 10 LD50) remain fully lethal (Appendix II Fig S1).
Lungs, spleens, and livers were collected from mice during the first five days of
infection to determine the kinetics of bacterial clearance. Bacteremia was also assessed using
peripheral blood. In the lungs, the mean bacterial burden decreased in TMV-F1+TMV-V
immunized mice daily; the same trend was not observed in unimmunized or rF1+rV
immunized mice (Fig 2A). In the liver and spleen, bacterial burden peaked at D3 PI in TMVF1+TMV-V immunized mice, and bacteria were cleared by D5 (Fig 2B, 2C). In rF1+rV
immunized mice and unimmunized mice, bacterial burden peaked a day later (D4), and also
began to decrease by D5 (Fig 2B, 2C); however, most of these mice had succumbed to
infection by D5 (Fig 1A). Bacterial burdens were significantly higher in rF1+rV immunized
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mice D4-D5 in the spleen, D4 in the liver, and D4 in the lung compared to TMV-F1+TMV-V
immunized mice. Bacterial burdens were significantly higher in unimmunized mice at D3D4 in liver, D2-D5 in the spleen (D3 p=0.05), and D3-D4 in the lungs compared to TMVF1+TMV-V immunized mice. Bacterial burdens were similar in all rF1+rV immunized and
unimmunized mice. In peripheral blood, Y. pestis was not detected in any TMV-F1/V
immunized mice, however, bacteria were found in the bloodstream of the other groups of
mice beginning on D3 PI (Fig 2D). Statistical analyses were not performed since bacteremia
was only detected in a few mice.
We performed a histological analysis of lung, liver, and spleen tissue obtained from
the same mice used for bacterial burden studies. Inflammation was scored in a blinded
fashion for severity of tissue necrosis, and edema (Fig 3A, Appendix II Table S2) in
comparison to a naïve mouse (Fig 3B). Differences in disease severity were most apparent at
D5 PI (Fig 3C-E). On this day, unimmunized mice showed signs of severe inflammation, as
evidence by the loss of rich red pulp in the spleen, inflammatory foci in the liver, and dense
neutrophilic infiltrates and edema throughout the lung tissue (Fig 3C). rF1+rV immunized
mice demonstrated similar disease severity; lung tissue was marked by edema, perivascular
inflammation, and loss of the alveolar architecture; the liver contained several inflammatory
foci; and spleen germinal centers (GC) were distorted by large neutrophilic lesions (Fig 3D).
TMV-F1/V immunized mice showed signs of moderate inflammation at D5 in the lung, but
not necrosis, and overall inflammation was significantly reduced in the spleen and liver
compared to the other groups (Fig 3A, 3E). A time course of D1-D4 histology for each
tissue is presented in Appendix II figures S3-S5. At no point was lung tissue severity of
TMV-F1/V immunized mice significantly different from the other groups (Appendix II Fig
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S3, Fig 3A). By D4 and D5, disease severity in TMV-F1/V immunized mice was
significantly reduced in the spleen (Appendix II Fig S4, Fig 3A) and liver (Appendix II Fig
S5, Fig 3A), as compared to either unimmunized or rF1+rV immunized mice. This would
indicate that, here, clearance of bacteria first occurs systemically, while clearance and tissue
repair in the lung occurs more slowly, and likely extends beyond 5 days.

A stronger F1-specific humoral response is associated with survival
Serum antibody production was limited following single dose immunization. Only
antibodies against F1 were detected at 2- and 4-weeks post-immunization (Fig 4A). Vantigen-specific antibody titers were below the limits of detection in both TMV-F1+TMV-V
and rF1+rV immunized mice. V-antigen specific antibodies were not detected by ELISA in
serum or tissue homogenates even after infection, indicating anti-V antibodies may not be
necessary for survival in the presence of anti-F1 antibodies (data not shown). Significantly
higher mean total F1 antibody titers were observed in mice immunized with TMV-F1+TMVV compared to mice vaccinated with rF1+rV at both week 2 and 4 post-vaccination, with a
statistically greater difference seen at week 4 (Fig 4A). Interestingly, this was not due to an
increase in F1 titers among TMV-F1+TMV-V immunized mice, but rather a decline in these
titers in rF1+rV immunized females from the second to fourth week. At week 2, there was a
higher mean F1 titer in female mice immunized with rF1+rV as compared to males (p=0.05),
however, antibody titers diminished from week 2 to 4 and this was no longer apparent. F1
antibody titers were similar between male and female mice immunized with TMV-F1+TMVV at either timepoint (Fig 4A). Mice that survived infection had significantly higher week 2
F1 titers compared to mice that died (Fig 4B). Interestingly, a small proportion of surviving
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TMV-F1+TMV-V immunized mice produced little anti-F1 antibody (titer <50), while
surviving rF1+rV immunized mice all had relatively high F1 titers prior to infection.
Correspondingly, there was a positive moderate correlation between this F1 titer and percent
body weight for rF1+rV immunized (r2=0.5214, p<0.01) and TMV-F1+TMV-V immunized
mice (r2=0.411, p<0.01) at D3 PI (Fig 4C). This was the timepoint when differences in
weight loss between groups reached statistical significance (Fig 1B). Together this data
showed that TMV-F1+TMV-Vimmunized mice had increased F1 titers prior to challenge,
and higher F1 titers were moderately associated with survival.
We also evaluated antibody isotype levels D1-D5 PI. TMV-F1+TMV-V immunized
mice demonstrated a rapid increase in anti-F1 IgG2b antibody within the first 5 days PI (Fig
5A-E). This increase was not observed in unimmunized mice or mice immunized with
rF1+rV. Up until D2 PI, there was no difference in serum F1-specific IgG2b (Fig 5A-B);
however, beginning D3 PI, significant differences could be seen between TMV-F1+TMV-V
immunized mice and unimmunized mice (Fig5C-E). We also detected anti-F1 IgG1, but not
IgG2a, in serum at D5 PI. Absorbance curves for IgG1 at D5 were virtually identical to D1
IgG2b (Fig 5A) and group differences were not significant (data not shown). Overall the data
showed a strong trend between the quantity of pre-challenge F1-specific antibody and better
survival outcomes. TMV-F1+TMV-V immunized mice exhibited faster anti-F1 IgG2b
production upon infection relative to the other groups, likely indicating a larger pool of F1specific memory B cells generated by immunization.

TMV-F1+TMV-V vaccinated mice have reduced IFN-γ, TNF-α, and IL-17 cytokines
after challenge
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In a pilot study examining cytokine expression in the lungs of vaccinated and
unvaccinated mice in the first 72h after infection we observed a very large induction of
inflammatory cytokines and chemokines. Strikingly, inflammatory cytokine and chemokine
expression was reduced in mice vaccinated with TMV-F1+TMV-V compared to
unvaccinated mice with rF1-rV vaccinated mice falling between (data not shown). We
extended this observation by assessing production of IFN-γ, IL-17, and TNF-α in lung,
spleen, and serum of mice after infection (Fig 6 and 7). IFN-γ production peaked at D2 PI in
lungs of all three groups of mice but was reduced in TMV-F1+TMV-V immunized mice
compared to rF1+rV immunized and unimmunized mice (Fig 6A, n.s.). IFN-γ levels
progressively decreased in the lungs of all mice after D2 and were virtually undetectable by
D5 PI (Fig 6A). In the spleen, IFN-γ peaked at D3 in unimmunized mice, decreasing
thereafter, but levels remained elevated at D5; by comparison, IFN-γ levels were reduced in
rF1+rV-vaccinated mice (n.s.) and were virtually undetectable in most TMV-F1+TMV-V
immunized mice (Fig 6B). TNF-α was elevated at D1 in lung tissue of TMV-F1+TMV-V
immunized and unimmunized mice, compared to rF1+rV- immunized mice (Fig 6C). In the
spleen, TNF-α levels were similar between treatment groups at all timepoints assessed (Fig
6D), perhaps moderately reduced in TV-conjugate immunized mice at D4 compared to the
other groups; however, total TNF-α levels in the spleen were at or below the average levels
observed in naïve untreated mice (dotted line, Fig 6D). Very low concentrations of IL-17A
were found in all tissues, compared to mean levels found in naïve unvaccinated, uninfected
mice (dashed lines), with no discernable differences between immunization groups (Fig 6EF).
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Serum levels of IFN-γ and TNF-α were also elevated only in unimmunized and
rF1+rV immunized mice beginning on D3 PI, highly suggesting the onset of sepsis in those
mice. IFN-γ levels were highest at D3 PI and decreased steadily through D5; by comparison;
IFN-γ was negligible in all but one TMV-F1+TMV-V immunized mouse (Fig 7A). Serum
TNF-α levels were elevated in unimmunized mice at D3, D4, and D5 without decreasing, and
at D4 in rF1+rV immunized mice, although this was not significantly different from the
TMV-F1+TMV-V immunized group, where levels were undetectable in most mice (Fig 7B).
These data suggest that the TMV-F1+TMV-V vaccine induces immunity marked by a highly
regulated inflammatory environment immediately following challenge. In our model, the
absence of a hyper-inflammatory environment appears more helpful than harmful and may
actually be sparing the animals from tissue destruction, sepsis, and ultimately death.

4.DISCUSSION
Y. pestis remains a significant public health threat due to the potential for the natural
or intentional spread of antibiotic resistant strains. Even in the presence of appropriate
antibiotic treatment, mortality remains high. Stockpiled antibiotics will be of little use
against MDR Y. pestis, necessitating the development of a preventative vaccine. Previously
explored killed whole cell (KWC) and live attenuated vaccines for plague were discontinued
in the U.S. because they either did not provide long-term protection, had negative sideeffects, or were not protective against pneumonic plague (Smiley, 2008; Wang, X. et al.,
2013). A protein subunit vaccine consisting of F1+V was very effective at protecting mice
from pneumonic plague but produced mixed results when tested in Cynomolgus macaques
and African green monkeys, raising doubt that this formulation would produce widespread
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protection in humans (Smiley, 2008). Additionally, parenteral administration of protein
antigens induces only limited protection at mucosal surfaces, whereas, at least
experimentally, mucosal introduction of such antigens provides strong immunity at both
mucosal surfaces and systemically (Srivastava et al., 2015; Woodrow et al., 2012) .
We previously demonstrated that conjugating F1 and V to TMV induced complete
protection against lethal challenge with i.n. dosing of 10 LD50 Y. pestis CO92pgm- after a
minimum of three vaccine doses (Arnaboldi et al., 2016). That study was limited to
evaluating protection and antibody production in response to vaccination with TMV. In the
current study, we evaluated against one vaccine dose and further extend our previous
findings by evaluating dissemination, histopathology, the kinetics of bacterial clearance, and
cytokine production. In the present study we found that a single i.n. administration of the
TMV-conjugate vaccine protected 88% of mice challenged with 100 LD50 and 100% of mice
challenged i.n. with 10 LD50 of Y. pestis CO92pgm-. rF1+rV immunized mice challenged
with 10 LD50 of bacteria exhibited 40% protection while less than 10% of mice challenged
with 100 LD50 survived. This suggests that with higher-dose challenges, rF1+rV i.n.
immunization alone cannot control the infection any better than unvaccinated mice,
supporting the addition of an adjuvant or carrier to improve the mucosal response to
vaccination. Furthermore, we demonstrated for the first time that conjugation of the proteins
to TMV was critical for vaccine protection, as co-administration of unconjugated rF1+rV
mixed with TMV could not protect mice any better than those vaccinated with rF1+rV alone.
Some reports have suggested that pigmentation locus deficient (pgm-) strains of Y.
pestis do not cause pneumonia when administered i.n., in contrast to fully virulent strains of
Y. pestis (Galvan et al., 2010; Lee-Lewis and Anderson, 2010). In the present study we find
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that i.n. administration of Y. pestis CO92pgm- seeds the lung causing the development of
pneumonia that also rapidly disseminates to other tissues, including the spleen and the lung
resulting in fulminant bacteremia by D3 PI. In TMV-F1+TMV-V mice, systemic
distribution of the bacteria is cleared by D5 and is associated with a significant decline in
bacterial numbers in the lung. Surviving mice fully clear the infection. It is not clear why
this discrepancy in the literature exists; however, differences among strains of Y. pestis used
(KIM vs. CO92) (Galvan et al., 2010; Lee-Lewis and Anderson, 2010), as well as differences
in the volume of the i.n. dose may contribute to discordant outcomes (Olson and Anderson,
2019) .

Interestingly, following a single i.n. vaccination, antibodies were only detected
against the F1 portion of the vaccine. In our previous study, we did observe serum antibodies
to V (Arnaboldi et al., 2016) , though the data here suggest multiple immunizations are
required for this. Overall, antibody titers were low, with mean F1 titers between 1:100 and
1:125. F1 titers correlated with both a reduction in weight loss and survival. In addition,
there was a rapid increase in anti-F1 antibody within the first five days of infection in TMV
immunized mice compared to rF1+rV immunized mice, presumably from memory B cell
populations. Despite this, it is not clear if pre-challenge antibody is protective in this model,
or if it simply serves as an indication that a protective immune response has developed.
Passive transfer of anti-F1 antibodies to naïve animals and generation of anti-F1 IgG
following F1 immunization both lead to high survival rates in animal models of plague
(Williamson and Oyston, 2013). The tendency for rF1 to form large molecular-weight
polymers also aids in rapid recognition by innate-like B1b cells, resulting in a protective anti-
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F1 antibody response in just 3 days (Levy et al., 2018). However, despite a well-documented
role for anti-F1 antibodies in protection from plague in mice, primate challenge demonstrated
discordant survival results between Cynomolgus macaques (protected) and African green
monkeys (poorly protected), which could not be explained by differences in antibody levels
(Bashaw et al., 2007; Pitt, 2004; Smiley, 2008). Thus, it is not clear if antibody plays a
significant role in protection from pneumonic plague or is only a component of a more
complex process. Since pneumonic plague in African green monkeys rapidly progresses to
septicemia in as early as 3 days (Layton et al., 2011), and F1/V-based vaccines could not
fully protect this species against aerosolized Y. pestis in multiple trials (Smiley, 2008),
further study is needed to determine this. Furthermore, F1 is not required for virulence, and
F1- strains are still lethal and found in nature (Quenee et al., 2008). This has led other
researchers to suggest that mucosal and serum anti-V antibodies are the best correlates for
survival against pneumonic plague in mice, as V antigen is a critical virulence factor (Reed
and Martinez, 2006). Further study is needed to determine which components of host
immunity are critical for rapid protection.
Recently, Bowen et al. reported a sex bias in protection against fully virulent
pneumonic plague following s.c. immunization with rF1-V in Alhydrogel®. This vaccine
better protected female mice (C57Bl/6J and BALB/c) against fully virulent pneumonic
plague, irrespective of rF1-V-specific titers, which were comparable between male and
female mice (Bowen et al., 2019). In our study, males and females were equally protected
when immunized with either TMV-F1+TMV-V or rF1+rV, though of the total unimmunized
and rF1+rV immunized survivors (n=6), almost all were female (5/6). There were also higher
F1 titers in our rF1+rV vaccinated females at 2 weeks following vaccination as compared to
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males (n.s., p=0.05). Nonetheless, these data reinforce the importance of using both sexes in
plague vaccine studies, as this can reveal disparities that would otherwise be hidden in allfemale experiments.
Several studies have implicated TH1 and TH17 cell-mediated immunity in protection
in mouse models of pneumonic plague. IFN-γ, TNF-α, and IL-17 have all been proposed to
play critical roles in vaccine-mediated protection (Lin et al., 2011; Nakajima and Brubaker,
1993; Parent et al., 2006). In the present study we found that the majority of TMV-F1+TMVV immunized mice showed diminished levels of IFN-γ in the lung, spleen, and blood,
compared to unimmunized and rF1+rV unimmunized mice. This suggests the presence of a
more highly regulated inflammatory response in mice that survive infection, particularly as
bacteria disseminated from the lungs in all mice during the first 3 days of infection regardless
of prior vaccination. The role of antigen-specific T cells in vaccine-mediated immunity to
plague needs further study.
In conclusion, TMV-F1+TMV-V is capable of mediating single-dose protection
against high-dose pneumonic challenge of Y. pestis CO92pgm-. Protection moderately
correlated with F1 serum antibody titers. TMV-F1+TMV-V immunized mice were able to
rapidly clear disseminated bacteria from the spleen and liver in the presence of a wellregulated inflammatory response. Though further study is needed to determine whether this
protection is conferred against fully lethal strains of Y. pestis bacteria, these results warrant
further investigation into TMV conjugate vaccines for severe respiratory infections.
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Fig 1. Single TMV-F1+TMV-V i.n. immunization is protective against pneumonic
plague challenge. 26 mice (13 males, 13 females) were i.n. immunized with either TMVF1+TMV-V, rF1+rV, or not immunized (controls) and monitored for 21 days post-infection
with 100 LD50 Y. pestis CO92pgm-. (A) Kaplan-Meier curve showing comparison of
survival between TMV-F1+TMV-V -immunized mice and the other groups. Asterisks
indicate statistical significance by the Mantel-Cox log-rank test. (B) Average percent body
weight (from initial weight on day of challenge). Asterisks indicated statistical significance
between TMV-F1+TMV-V- and un-immunized groups by unpaired student’s t test for each
day post-infection (DPI). Data pooled from two separate experiments. **** p<0.0001,
**p<0.01, *p<0.05. All errors bars represent mean±SEM.
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Fig 2. TMV-F1+TMV-V immunized mice experience a decrease in bacterial burden in
lung, spleen, and liver, and no sepsis, in the 5 days post-infection. Bacterial burden was
quantified from the lungs, spleens, and livers of infected mice for days 1-5 following
challenge. Individual mice are indicated by their respective symbol (n=6/group) for lung (A),
spleen (B), and liver (C). For septicemic burden, the number of mice/group where CFUs
were retrievable from peripheral blood is shown as fraction (D). Asterisks and pound
symbols indicate statistical significance by Mann-Whitney test for each DPI. *= TMVF1+TMV-V vs. unvaccinated, #= TMV-F1+TMV-V vs. rF1+rV. Data pooled from two
separate experiments. **p<0.01, *p<0.05. All errors bars represent min to max values, with
lines indicating the median.

111

A

Fig 3. Comparison of tissue inflammation in the lung, spleen, and liver of TMVF1+TMV-V immunized, unimmunized, rF1+rV-immunized mice at D3 post-infection.
Representative spleen (left), liver (center), and lung (right) sections were collected from mice
challenged with 100 LD50 Y. pestis CO92pgm-. Formalin-fixed tissues were sectioned and
stained with hematoxylin and eosin (H&E). Pathological severity scoring (0-4) ± SEM vs.
day post-infection is shown in (A). No errors bars indicate mice for that group received the
same score. Asterisks symbols in (A) indicate statistical significance by two-way ANOVA
between the indicated group and TMV-F1/V, *<0.05, **<0.01, and ***<0.001.
Fig 3. Continued on next page: Images represent sections from a (B) naïve (uninfected), (C)
unvaccinated, (D) rF1+rV vaccinated, and (E) TMV-F1/V vaccinated mouse sacrificed at D5
PI. Arrows indicate neutrophilic foci. The inlays (20x) represent the black boxed region in
each larger image (4x). Scale bar represents 550µm in all 4x images and 110µm in all 20x
images.
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Fig 4. TMV-F1+TMV-V immunized mice have increased anti-F1 titers prior to
challenge, and higher F1-specific titers are correlated with survival for both vaccines.
(A) Serum F1-specific antibody titers (total Ig) week 2 post-immunization for unvaccinated,
rF1+rV-vaccinated, and TMV-F1+TMV-V-vaccinated mice, and serum total F1-specific
titers for these groups week 4 post-immunization. Unvaccinated mice sera were not collected
week 4, as past experiments have shown they remain unchanged. (B) Comparison of the
week 2 total serum F1-specific titers between the deceased and surviving mice. (C)
Correlation of week 2 serum F1-specific titers and percent body weight D3 post-infection.
Pearson r correlation was significant for rF1+rV-immunized mice (p<0.01, r2=0.5214), and
for TMV-F1+TMV-V-immunized mice (p<0.01, r2=0.411). Asterisks indicated statistical
significance compared by unpaired student’s t test between indicated groups. Data is
representative of two experiments. Individual mice are indicated by their respective symbol.
****p<0.0001, **p<0.01. All errors bars represent mean±SD.
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Fig 5. F1-specific IgG increases rapidly in response to plague infection in TMVF1+TMV-V immunized mice. Comparison of ELISA curves measuring serum IgG2b. Sera
was obtained from mouse peripheral blood collected 24HPI (A), 48HPI (B), 72HPI (C),
96HPI (D), and 120HPI (E) for each experimental group. Asterisks indicated statistical
significance compared by multiple t tests. *= TMV-F1+TMV-V vs. unvaccinated, #= TMVF1+TMV-V vs. rF1+rV. *** p<0.001, **p<0.01, *p<0.05. All errors bars represent
mean±SEM.
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Fig 6. TMV-F1+TMV-V i.n. vaccine does not induce Th1 or Th17 cytokine response
post-infection. Tissue cytokine levels of the lung and spleen D1-D5 post-challenge for (A-B)
IFN-γ, (C-D) TNF-α, and (E-F) IL-17A. Dashed lines represent the average tissue cytokine
measurement of naïve male and female mice (n=10). Asterisks indicated statistical
significance compared by one-way ANOVA for each time point. Individual mice are
indicated by their respective symbol. *= vs. unvaccinated, #= vs. rF1+rV. *p<0.05. All error
bars represent mean±SEM.
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Fig 7. Single immunization with TMV-F1+TMV-V vaccine protects against secondary
plague sepsis. Serum cytokine levels obtained from mouse peripheral blood collected D3-D5
post-infection for IFN-γ (A) and TNF-α (B). Cytokine levels were minimal and similar for
D1-D2 post-infection, and so are not shown. Asterisks indicated statistical significance
compared by one-way ANOVA for each time point. Individual mice are indicated by their
respective symbol. *p<0.05. All errors bars represent mean±SEM.
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Chapter 4. Specific Aim 3
AIM 3:
Identify the Role of T Cell-Mediated and Antibody-Mediated Immune
Responses of TMV Conjugates as an Intranasal VLP-like Vaccine
Aim 2a: Test the hypothesis that CD4+ T cells and/or CD8+ T cells are required for
protection from TMV vaccine at the time of infection
Aim 2b: Test the hypothesis that intranasal immunization with TMV induces both virusspecific and antigen-specific antibody responses
Aim 2c: Test the hypothesis the TMV vaccine induces a rapid and localized mucosal
antibody response after lung infection
Aim 3d: Test the hypothesis that vaccine-specific immunity is not limited to F1 immunity

118

1.INTRODUCTION
Most infectious pathogens enter the body through mucosal surfaces. Optimal
protection is usually triggered by local secretory IgA (SIgA) production at the mucosal
barrier but can include other isotypes such as IgG (Chen, K. et al., 2020). Intranasal (i.n.),
oral, vaginal, and rectal vaccines typically achieve higher levels of neutralizing antibody
responses at mucosal surfaces than intramuscular (i.m.) or subcutaneous (s.c.) administered
vaccines (Neutra and Kozlowski, 2006) and have the added advantage of being needle‐free
(Levine, 2003). However, such vaccines must also possess features that can get around
mucosal tolerance. Many subunit vaccines routinely fail to induce mucosal immunity. With
the exception of toxins, most soluble proteins are ignored or even induce immunosuppression
through tolerogenic dendritic cells (DCs), induction of regulatory T cells (Treg) cells, as well
as inducing anergy or clonal deletion of responsive T cells at mucosal barriers (Weiner,
2001). Successful experimental mucosal vaccines have thus been described as possessing the
following: (1) they are particulate, (2) they directly stimulate innate immunity (e.g. TLR
activation), or, (3) they target underlying antigen-presenting cells (APCs) in the mucosa
(Neutra and Kozlowski, 2006) . Virus‐like particles (VLP) are unique antigen carriers that
fulfill all of these requirements.
VLP are devoid of an intact virus genome, and thus incapable of infection and
replication; but their repetitive immunogenic surface structure still enables the retention of
cell uptake and immune processing pathways normally associated with live viruses (AlBarwani et al., 2014). VLP vaccines are often described as possessing the safety of a subunit
vaccine, but with efficacy and outcomes that can be comparable to live attenuated or live
vectored vaccines (Bessa et al., 2008). One of these outcomes is the induction of mucosal
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immunity. VLP vaccines approved for clinical use have utilized various administration
routes, including mucosal vaccination (Herzog, 2014). I.n. vaccination with VLP in mice has
shown protection against norovirus (Tamminen et al., 2016), respiratory syncytial virus
(RSV) (Jiao et al., 2017), and hepatitis B (Huang et al., 2006). Specifically, i.n.
immunization with VLP has been shown to be protective by inducing high systemic (IgG)
and mucosal antibody (SIgA) titers in mouse models without the need for adjuvants
(Balmelli et al., 1998; Sedlik et al., 1999).
The success of human VLP vaccine programes, such as Gardasil® and Cervarix™ for
human papillomavirus, have encouraged the development of novel VLP platforms.
Recombinant VLP, also termed chimeric VLP, was explored as a “new generation” VLP that
went beyond the basic, first-generation capsid VLP vaccines resembling the parent virus.
Genetic fusion and chemical conjugation are two experimental approaches used to create
chimeric virus particles. Chemical conjugation has two advantages over a genetically
engineered virus: (1) diverse sizes and types of whole antigens can be displayed, and (2) the
antigen-virus binding site can be manipulated to maximize exposure of the conjugated
antigen (Chen, Q. and Lai, 2013). These features prove crucial for pathogens with antigenic
variations, as larger proteins are more potent than short peptides in provoking neutralizing
antibodies that recognize a broad range of liner and conformational epitopes on the pathogen
(Chen and Lai, 2013; Jennings and Bachmann, 2008).
Antigens can be linked to viruses or virus particles through either covalent or
noncovalent chemical bonds. We use an inactivated and recombinant plant virus, Tobacco
Mosaic Virus (rTMV), that enables covalent linkage of whole proteins. Our rTMV virion has
been genetically engineered to display a lysine on the coat protein (CP) that allows for amine
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conjugation of exogenous proteins containing lysine or cysteine (McCormick and Palmer,
2008; Smith et al., 2006). We reported complete protection in a pneumonic plague mouse
model using an i.n. vaccine comprised of Yersinia pestis virulence proteins, LcrV (V) and F1,
separately linked to rTMV (Arnaboldi et al., 2016). In this aim, I sought to identify the
humoral and cellular mechanisms that support rTMV’s classification as a mucosal vaccine
that enables high-density, VLP display of protein antigens. These include the conjugates’
ability to generate TMV-specific as well as antigen-specific high titer antibodies in
circulation. It also includes its potential contribution of CD8+ cytotoxic T cell (CTL) or CD4+
T cell responses to plague defense. Our findings suggest that rTMV represents an efficient
vaccine delivery platform for the generation of IgG antibody‐based, but not T cell-based,
immunity that can be administered i.n. safely without the need for adjuvants.

2.MATERIALS AND METHODS
2.1 Bacterial strains
Yersinia pestis CO92pgm− was a gift of Dr. James Bliska (Stonybrook University,
NY), and was cultivated as previously described (Arnaboldi et al., 2016). The Y. pestis
KIM5caf1A (Δpgm Δcaf1A, Ampr Kanr) F1 negative (F1-) mutant strain was also a gift of
Dr. Bliska and was cultivated as previously described, with the exception that cultures were
incubated shaking at 37°C overnight instead of 26°C (Ivanov et al., 2008). All cultures were
revived from frozen glycerol stocks.

2.2 Recombinant proteins and TMV
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Cloning, expression, and purification of rF1 and rLcrV (rV), and preparation of
TMV-F1 and TMV-V conjugate vaccines were performed as described previously
(Arnaboldi et al., 2016) . Purified TMV and TMV conjugates were created and supplied by
Alison McCormick. The TMV was inactivated via binary ethyleneimine (BEI) prior to the
antigen conjugation process (EDC mediated amine conjugation) and has no replication
capacity in plant or mammalian cells.

2.3 Mice and intranasal vaccination
Adult (6-week-old) male and female C57Bl/6J mice were obtained from Jackson
Laboratories (Bar Harbor, Maine), and maintained by the husbandry staff of the Department
of Comparative Medicine at New York Medical College. All experiments were conducted
with the approval of the New York Medical College Institutional Animal Care and Use
Committee (IACUC). All mice were vaccinated at 6-8 weeks. Equal numbers of male and
female mice were tested in all groups. Mice were anesthetized using ketamine/xylazine
cocktail in order to perform i.n. vaccination with the following in 40µL volume of saline:
10µg of TMV-V+10µg of TMV-F1 (total of 20 µg), 5µg rV+5µg rF1 (total of 10µg), 5µg
rV, or 10µg of TMV-V. TMV-conjugated vaccines always equivalent concentrations of
TMV and recombinant protein (5μg TMV+5μg protein). Mice were vaccinated with 10μg of
TMV-conjugate and 5 μg of recombinant protein to ensure molar equivalency of the antigens
between the two vaccines. All control mice were unvaccinated. For the challenge with Y.
pestis KIM5caf1A, mice were boosted i.n. with the indicated vaccines 21 days after the prime
vaccination.
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2.3 Bacterial Challenge
Mice were challenged on day 35 post-immunization with Y. pestis CO92pgm−.
Briefly, Y. pestis CO92pgm− was grown to an OD620 of 0.9 in heart infusion broth
supplemented with 2.5mM CaCl2 and 0.2% Xylose at 37°C in a shaking incubator (225
RPM). Culture medium was removed by centrifugation and the bacterial pellet was washed
3x with sterile saline. Bacteria were resuspended in saline to an OD620 of 1.1, assuming a
concentration of 1x109 CFU. The LD50 of Y. pestis CO92pgm− in C57Bl/6J mice was
previously determined to be 2.5x104 CFU (Arnaboldi et al., 2016). Bacteria were diluted
accordingly, and anesthetized mice were i.n. administered 10 or 100 LD50 in 50µL saline in
a class II biosafety cabinet. 10-fold dilutions of the bacteria were streaked on HI agar and
incubated for 2 days at 28°C to confirm the number of bacterial CFU administered for each
challenge. After challenge (D0), mice were weighed and checked daily for signs of
morbidity (ruffled fur, hunched posture, reduced activity, weight loss). Mice that lost more
than 20% of their pre-challenge body weight, or were severely moribund, were euthanized.
Survival was determined at 21 days, and mice were euthanized according to approved
IACUC guidelines.
The i.n. LD50 of Y. pestis KIM5caf1A F1- strain was determined to be 1.1-1.5x106
CFU in our laboratory (data not shown). For this experiment, mice were challenged i.n. with
2.58x107 CFU in 50µL saline 15 days after the boost. Determination of bacterial CFU and
mouse morbidity were made as described above, with the exception that survival was
determined at 14 days.

2.4 CD4+ and CD8+ T cell depletion
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Mice were injected i.p. with either anti- mouse CD4 (clone GK1.5; BioXCell) or rat
IgG2bk isotype control antibody (clone LTF-2; BioXCell) 2 days prior to challenge and
weekly thereafter. In a separate experiment, mice were injected i.p. with anti-mouse CD8α
(clone YTS 169.4; BioXCell) or the isotype control described above (clone LTF-2;
BioXCell) 2 days prior to challenge and weekly thereafter. The dose for all antibody
injections was 100µg in 200µL PBS per mouse.

2.5 Lung collection
Mice that were immunized and challenged with 100 LD50 Y. pestis CO92pgm− as
described above (see 2.3) were euthanized daily for the first 5 days following challenge to
collect infected organs. The left lobe of the lung was placed in 1.5ml centrifuge tubes filled
with ~100uL of ceria stabilized zirconium oxide beads (2mm diameter, Next Advance, Inc.)
and 0.5mL of sterile PBS on ice. The tissues were homogenized using a BioSpec MiniBeadbeaterTM, were centrifuged at 10,000rpm x 10 min, and supernatants were aliquoted
and stored at -80°C. In a separate experiment, the same was done for all survivors of a 10
LD50 Y. pestis CO92pgm− challenge.

2.6 Antibody measurements
All serum antibodies were determined from blood samples collected via retroorbital
bleed week 2 or 3 post-immunization. Sera was allowed to sit at RT for at least 30 min before
being centrifuged at 2500xg for 15 min and stored at -20°C. Antibodies were also determined
from lung tissue homogenate supernatant that had been stored at -80°C (see 2.4). 96 well
ELISA plates (Nunc MaxiSorp™ flat bottom or Immulon® 2 HB Flat Bottom MicroTiter™)
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were coated with rV or rF1 (2 µg/ml) in 0.1M Carbonate Buffer, pH 9.4 overnight at 4°C.
Plates were blocked with 1% BSA in PBS for 1h at RT, and washed 3x with 0.05% Tween in
PBS. Sera or supernatant were diluted in blocking buffer and were incubated for 1h at RT.
Plates were washed 3x again, and HRP-labeled goat anti-mouse Ig heavy and light (H+L)
chain, IgM, IgG1, IgG2a, IgG2b, IgG3, IgE, or IgA (Southern Biotech) diluted 1:5000 in
blocking buffer was added to each well for 1h at RT. The plates were washed and developed
with TMB substrate (KPL) for 30 min at RT. The reaction was stopped by addition of 2N
sulfuric acid, and absorbance was read at 450nm and 570nm on a SpectraMax Plus 384
microplate reader (Molecular Devices). Absorbance was plotted vs. reciprocal serum
dilution and 50% maximal binding titers were calculated using Prism 7.0 (GraphPad).
Samples were analyzed in duplicate.
Antibody specific for TMV was measured using a modified sandwich ELISA
protocol. Anti-TMV coating antibody reagent (Agdia®, Catalog# SRA 57400), was applied
to 96 well ELISA plates overnight according to the manufacturer’s protocol. The next day,
plates were washed 3x with 0.05% Tween in PBS, blocked with 1% BSA in PBS for 1h at
RT, and then washed 3x again. The protocol continued as described above for sera and
supernatant samples.

2.7 Statistical analysis
Unpaired student’s t test was used to analyze means between two groups. Multiple t
tests were used to analyze differences between groups at various time points or dilutions (e.g.
body weight, ELISA dilutions). One-way ANOVA was used to compare means of three or
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more groups, with Tukey’s multiple comparisons test as the post-hoc analysis. Statistical
analyses were performed using GraphPad Prism 7 software.

3.RESULTS
CD4+ and CD8+ T cells are not required for vaccine-induced protection against lethal
pneumonic plague infection
Arnaboldi et al. previously showed that i.n. immunization with TMV-F1 and TMV-V
conjugates effectively protected against pneumonic plague most likely through augmentation
of an F1-specific humoral response (Arnaboldi et al., 2016). However, the role of CD4+ and
CD8+ T cells in vaccine-induced protection was not assessed in that study. Using antibodymediated depletion of CD4+ and CD8+ T cells, we sought to determine if these two
populations were critical for protection mediated by TMV-F1+TMV-V. Groups of 12 mice
(6 males + 6 females) were i.n. immunized once with TMV-F1+TMV-V and challenged i.n.
with 9-15 LD50 Y. pestis CO92 pgm- 5 weeks later. Unimmunized mice were used as a
control.
For the first experiment, we evaluated the contribution of CD4+ T cells to TMV
vaccine-induced protection. In each group, half (3 males + 3 females) of mice were injected
intraperitoneally (i.p.) with anti-CD4 antibody (clone GK1.5), and other half with a “mock”
non-specific isotype control antibody 2 days prior to challenge (Fig 1A). Prior to conducting
this experiment, we had confirmed the anti-CD4 mediated antibody depletion was effective
at 2 days post-depletion and lasted until day 7 post-depletion in the peripheral blood, lung,
and spleen (Appendix III Fig S1). At the one-week time point, mice were injected weekly to
maintain CD4+ T cell depletion. As predicted, all non-immunized mice succumbed to
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pneumonic plague infection by day 6, while 83% of all TMV-F1+TMV-V-immunized mice
were protected (Fig 1B). For both groups of immunized mice (mock and CD4-depleted), only
one mouse succumbed to infection in each group (5 out of 6 mice, 83% survival) (Fig 1B).
The presence of CD4+ T cells did, however, increase the mean time to death by 2 days
compared to mice lacking CD4+ T cells (Fig 1B). Both of these groups also showed no
significant weight loss relative to each other over the 21 days post-challenge (Fig 1C). It may
be important to note that two TMV-F1+TMV-V-immunized mock females accidentally
became pregnant and had to be separated from their offspring just prior to challenge while
nursing. These two females never returned to their initial body weight, and we assumed is
what kept the average weight of-immunized mock mice consistently below that of the CD4depleted immunized mice (Fig 1C). There was no significant difference in the pre-challenge
total F1-specific immunoglobulin (Ig) serum titers between deceased and surviving
immunized mice, indicating that F1-specific antibody levels were not a reliable correlate of
vaccine-induced protection (Fig 1D). Although all immunized mice did generate an anti-F1
humoral response from single vaccination, this did not assure protection from plague
infection in the presence or absence of CD4+ T cells. Total V-specific antibody titers were
below the limit of detection (<20) at week 3 post-challenge, and therefore, are not reported
here (data not shown). Focusing solely on the survivors’ weight loss, it is evident that a
single-vaccination of TMV-F1+TMV-V effectively kept these mice from experiencing
morbidity post-challenge; mice were able to maintain their initial body weight on the day of
infection (Fig 1E). For the reason explained above, the immunized mock group contained
two surviving females which kept the average weight below that of the CD4-depleted
immunized group. It is assumed the percent body weight of these groups would have been
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comparable if these females were of normal weight on day of challenge. Overall, we can
conclude from these data that for 3 weeks post-infection, CD4+ T cells do not play a crucial
role in the protection from plague that is generated by a single i.n. administration of the
TMV-F1+TMV-V vaccine.
For the second experiment, we evaluated the contribution of CD8+ T cells to TMV
vaccine-induced protection. As with the CD4+ T cell-depletion experiment, in each group
(immunized or control), half of mice (3 males + 3 females) were injected i.p. with anti-CD8α
antibody (clone YTS 169.4), while the other half were treated with the “mock” isotype
control antibody 2 days prior to challenge, and weekly for the 21 days post-challenge (Fig
2A). Prior to conducting this experiment, we again confirmed the anti-CD8α mediated
depletion was effective at 2 days depletion and 7 days post-depletion in the peripheral blood,
lung, and spleen (Appendix III Fig S2). To keep consistent with the CD4+ depletion
experiment, we continued weekly antibody injections to maintain depletion of CD8+ T cells.
The survival results obtained from this experiment were identical to the CD4+ T celldepletion experiment. All non-immunized mice succumbed to pneumonic plague by day 6,
while 83% of all immunized mice were protected (Fig 2B). For both groups of immunized
mice (mock and CD8-depleted), 5 out of 6 mice survived infection (83% survival) (Fig 2B).
The presence of CD8+ T cells increased the mean time to death by 4 days compared to mice
lacking CD8+ T cells (Fig 1B). Both of these groups also showed no significant body weight
loss relative to each other over the 21 days post-challenge (Fig 2C). There was no significant
difference in the pre-challenge total Ig F1-specific serum titers of between the deceased and
surviving immunized mice, although deceased mice did have a lower mean titer (Fig 2D). Of
note, one immunized mouse did not produce a detectable anti-F1 titer prior to challenge and
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died from infection (Fig 2D). Surviving mice also showed no morbidity and maintained their
initial weight on the day of infection (Fig 2E). Total V-specific antibody titers were below
the limit of detection (<20) at week 3 post-challenge, and therefore, are not reported here
(data not shown). Interestingly, the absence of CD8+ T cells in recovering survivors appeared
to elevate the mean percent body weight above that of survivors with CD8+ T cells, although
this difference was not statistically significant at any day post-infection (Fig 2E). Again, we
can conclude that, like CD4+ T cells, CD8+ CTL do not play a crucial role in TMVF1+TMV-V vaccine-induced protection for pneumonic plague and sepsis.

TMV-F1+ TMV-V i.n. immunization auguments serum IgG against TMV and F1+V
One question that had not yet been addressed until this point was if immunization
with the TMV conjugates was inducing TMV-specific IgG production. Using archived prechallenge serum from our published challenge and immunization study (Arnaboldi et al.,
2016), we wanted to identify the isotypes of the anti-TMV antibody response – if there was,
in fact, a response. This serum was collected on 56 days after the prime immunization (day 0)
and after the second and final boost (day 35) from TMV-F1+TMV-V i.n.-immunized mice.
We found that i.n. immunization with TMV conjugates did generate an anti-TMV
antibody response in mice, and this response was dominated by IgG2b, followed by IgM and
IgG3 (Appendix III Fig S3). We adapted a commercial TMV sandwich ELISA in order to
quantify serological levels of TMV-specific antibody in our mice. We first asked if there was
any possible sex bias in the anti-TMV antibody response. Upon immunization with TMVF1+TMV-V, female mice generally had higher anti-TMV IgG2b and IgG3 serum titers;
however, these were not significantly different than that of immunized males (Appendix III
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Fig S4B). A prime immunization and two boosters of TMV-F1+TMV-V produced an antiTMV IgG2b serum titer of nearly 1:200,000 (Fig 3A) and an anti-TMV IgG3 serum titer of
about 1:15,000 (Fig 3B). In each case, this titer was significantly greater than that of mice
immunized with recombinant proteins only (rF1+rV) and unimmunized mice (Fig 3A, 3B).
We also examined anti-TMV antibody in other naïve mice and found titers were below our
detection limits (data not shown). In our 2016 study, F1- and V-specific IgG1 was elevated in
response to the three vaccine doses; however, anti-TMV IgG1 was not elevated in response
to these vaccinations, nor was IgG2a (Appendix III FigS3). The more interesting observation
was that these same predominant IgG subclasses (IgG2b and IgG3) were also specific for F1
and V – the antigens conjugated to TMV. For this ELISA, the plate was coated with both
antigens (rF1+rV) since it was previously shown the sera contained both F1-specific and Vspecific IgG (Arnaboldi et al., 2016). A prime immunization and two boosts of TMVF1+TMV-V produced an F1/V-specific IgG2b serum titer of about 1:6,000 (Fig 3C) and an
F1/V-specific IgG3 serum titer of 1:600 (Fig 3D). Both of these titers were, again,
significantly greater than that of mice i.n. immunized with recombinant free antigens and
unimmunized mice (Fig 3C, 3D). Interestingly, unimmunized mice had a higher – but not
statistically different – mean F1/V-specific IgG3 serum titer than mice immunized with rF1 +
rV (Fig 3D). Overall, the data suggests that the same IgG subclasses directed against TMV
(IgG2b, IgG3) are also directed against the proteins bound to TMV.

F1-specific IgG generated by i.n. TMV-F1+TMV-V is not localized to the lung
Now that we had a better understanding of antigen-specific antibody enhancement
induced by our vaccine, we next wanted to see where this response was occurring. We have
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shown that vaccination with TMV-F1+TMV-V induced F1-specific IgG production in
circulation by the third day following i.n. challenge with Y. pestis, implying a vaccineinduced central memory B cell pool (see Aim 2). However, i.n. vaccination and the induction
of SIgA production is also an important outcome for vaccines against pathogens that infect
through mucosal surfaces. Mediastinal lymph nodes (MLN) drain the lung in mice and
humans and are usually the site where mucosal immune responses (IgG or SIgA) are initiated
against antigens reaching the lung (Bessa et al., 2008).
We evaluated the F1-specific IgG2b antibody levels in the lung post-infection to
signify a local mucosal immune response. Mice had been immunized once with a mixture of
rF1+rV, TMV-F1+TMV-V, or not immunized at all (control) 5 weeks prior to i.n. challenge
with 100 LD50 of Y. pestis CO92pgm−. Little IgG2b was detected in lung homogenates for 5
days post-challenge in any of the three groups, indicating this was likely residual serum from
circulation (Fig 4A-E). It was not until day 5 post-infection (120HPI) that F1-specific IgG2b
levels could be seen increasing for only TMV-F1+TMV-V-immunized mice, but this was not
a statistically significant difference (Fig 4E). This was in contrast to anti-F1 IgG2b serum
levels, where TMV-F1+TMV-V-immunized mice were producing significantly more
antibody than unimmunized mice as early as day 3 post-infection (72HPI) (see Aim 2). F1specific IgA and IgG2b were detected in the lungs of surviving mice from a separate
challenge experiment (10 LD50 of Y. pestis CO92pgm−) (Appendix III Fig S5A, S5B). In
this experiment, mice received a single-dose vaccine prior to challenge. The majority of
TMV-F1+TMV-V-immunized survivors did produce F1-specifc IgA titers (7 out of 9 mice),
however, it was also detected in both surviving rF1+rV-immunized mice, and in one mouse
immunized with an unconjugated mix (TMV+rF1+rV) (Appendix III Fig S5B). Since these
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lung samples were collected 21 days after infection, it was not possible to determine how
soon these IgA or IgG2b responses were initiated in the lung. TMV-specific IgG2b titers of
roughly 1:160 were detected in all mice except those immunized with rF1+rV (Appendix III
Fig S5C), as predicted. On the other hand, anti-TMV IgA in the lung was not high enough to
report a titer, indicating that there is not a strong localized IgA response upon i.n.
administration of TMV (Appendix III Fig S5D). Anti-F1 IgG2a levels were also extremely
low in all immunized groups, indicating that F1-specific IgG2a is not critical in protection
against pneumonic plague using our model vaccines (Appendix III Fig S5E). Likewise, Vspecific IgG2a, IgG2b, and IgA titers were below the limit of detection (<50) in these lung
samples, and therefore, are not reported here (data not shown). Overall, this data suggests
that i.n. administration of the TMV conjugate vaccine does not induce a localized F1-specific
IgG response in the lung immediately after infection with Y. pestis.

Unconjugated rV antigen provides optimal protection against lethal pneumonic
infection with F1- Y. pestis
Until this point, our investigation of TMV conjugate vaccine-induced immunity has
focused on the humoral response to the F1 capsule, since this is evidently the
immunodominant antigen for this vaccine. Next, we wanted to evaluate the role of V-specific
antibody in protection against a Y. pestis strain lacking F1, where contribution of F1-specific
immunity is nullified. We selected the Y. pestis KIM5caf1A mutant strain (Δpgm Δcaf1) for
i.n. challenge to see if the enhanced production of anti-V responses in co-immunized mice
(TMV-F1+TMV-V) (Arnaboldi et al., 2016) translated to enhanced protection against lethal
pneumonic plague.
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Groups of 10 mice, each containing males and females, were i.n. immunized and
boosted once with rV, TMV-V, rF1+rV, TMV-F1+TMV-V, or not immunized (control) and
challenged i.n. with 20 LD50 Y. pestis KIM5caf1A (~2.5x107 CFU/mouse) 15 days after the
boost (Fig 5A). Survival was assessed at day 14 post-challenge. Interestingly, mice
immunized and boosted with rV alone all failed to survive i.n. challenge with F1-wild-type Y.
pestis CO92pgm- strain (Arnaboldi et al., 2016). However, in the present study, mice
immunized and boosted with rV were the best protected against the F1- strain (55%
survival), followed by immunization with rF1+rV (37% survival), TMV-F1+TMV-V (30%
survival), and lastly, TMV-V (12% survival) (Fig 5B). All unimmunized mice succumbed to
infection by day 3 (Fig 5B). Combining TMV-F1 and TMV-V into a co-administered vaccine
provided better protection than vaccination with TMV-V (Fig 5B). However, the free
recombinant protein, rV, or a mixture of the recombinant proteins, rF1+rV, still provided
better protection than the TMV conjugates (Fig 5B). All groups showed a decline to about
80% of their initial body weight in the first 3 days of infection; however, mice that recovered
eventually regained 90-100% of their initial weight (Fig 5C). There were no significant
differences in percent body weight loss between groups over this time period (Fig 5C). The
rapid plunge in body weight was also seen in survivors, although, a majority of these mice
began regaining their weight by day 3 (Fig 5D). Finally, the potential contribution of V- and
F1-specific antibody responses to protection was assessed. None of the vaccinated groups
produced detectable F1-specific titers (<50) other than TMV-F1+TMV-V-vaccinated mice,
as predicted (Fig 5E). Surprisingly, none of the groups produced detectable V-specific titers
(<50) other than two TMV-V vaccinated mice (Fig 5E). These two mice (1 male and 1
female) did not survive infection, whereas the one TMV-V male that did survive (1 out of 8
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mice) did not produce anti-V antibodies prior to challenge. Therefore, although coimmunization of TMV-F1+TMV-V protected mice better than TMV-V immunization against
F1- Y. pestis, their survival was not associated with a greater V-specific antibody response.

4.DISCUSSION
For mucosal vaccines, in particular, live vaccines are frequently preferred over
subunit, killed, or particulate vaccines as they can circumvent the tolerogenic environment of
mucosal tissues by creating a benign infection (Neutra and Kozlowski, 2006; Wang et al.,
2015). VLPs are a unique category of non-replicating vaccines that can balance safety and
potency significantly better than live vaccines. While the induction of high titers is typical of
VLP vaccines, it is not always sufficient for protection. The induction of CTL responses can
be an added benefit for specific pathogens, including Y. pestis (Parent et al., 2005; Smiley,
2007; Smiley, 2008). A potent cell-mediated response to VLP vaccines is dependent upon
DC cross-presentation of VLP-derived antigens on MHC Class I, which then trigger CTL
through interaction with the TCR (Donadson et al., 2018). In the literature, viable TMV has
been shown to target and activate DCs in vitro and in vivo (Kemnade et al., 2014;
McCormick et al., 2006), and my own observations have shown that the TMV conjugates are
also capable of targeting to DCs in vitro and in vivo (see Aim 1). DC-targeting inherently
increases chances of naïve T cell activation in secondary lymphoid organs (SLO), and thus,
contribution of cell-mediated immunity.
The data presented here demonstrated that neither CD4+ T cells nor CD8+ CTL are
required for vaccine-induced protection against pneumonic plague. With the exception of
mice that succumbed to the disease, all TMV-F1+TMV-V-immunized mice showed no
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evident weight loss or other outward signs of illness post-challenge, even as CD4+ and CD8+
T cells were continually depleted until day of sacrifice. This was surprising, given that TMV
conjugates were shown to target DCs. This data shows that a humoral immune response is
sufficient for protection. Further work might wish to experiment with adjuvants in help TMV
conjugates activate DCs as well as viable TMV can in vivo to induce CTL responses
(Kemnade et al., 2014). Other studies have showed that i.n. administration of VLP did not
induce strong effector CTL responses (Bessa et al., 2008; Bessa et al., 2012), providing some
support of our findings. Adoptive transfer of CD4+ and CD8+ T cells from TMV-F1 and/or
TMV-V vaccinated mice to naïve mice remains the best method to confirm T cells are
sufficient for vaccine-mediated protection against plague.
Specific immune responses are mounted against replicating viruses, but it is generally
thought such responses are not elicited by plant viruses (Mandal and Jain, 2010). Effective
VLP vaccines induce the production of antiviral antibodies specific for the virus surface
proteins, which are neutralizing and protective by nature (Chen and Lai, 2013; Donaldson et
al., 2018). In the present study, we have confirmed that i.n. exposure to whole, inactivated
TMV at vaccine-comparable doses generates systemic anti-TMV IgG2b titers. This response
is magnitudes higher compared to mice not immunized with TMV, and unexposed mice
appear to have no anti-TMV antibody (but they likely still do) (Fig 3). Most viruses and VLP
consist of structurally identical capsid proteins arranged in a repetitive quasi-crystalline
pattern; this structure naturally crosslinks BCRs and promotes MHCII presentation of
peptides to T cells (Donaldson et al., 2018). If foreign epitopes or proteins are displayed on
the virus in this high-density display (genetically or chemically), immune responses can also
be directed at those epitopes. Indeed, our data shows that the dominant IgG subclasses
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directed against TMV (IgG2b, IgG3) are also directed against the CP-bound proteins: F1 and
V. Like IgG2a, IgG2b fixes complement and binds to all activating Fcγ receptors (FcγR)
(Collins, 2016). IgG1, on the other hand, does not fix complement and only binds well to the
inhibitory FcγRIIb (Nimmerjahn and Ravetch, 2005), and so its contribution to protective
immunity in mice is still unclear and was not examined here. F1/V-specific IgG3 is likely not
critical for plague defense in mice, as this isotype does not exhibit high-affinity for FcγR
(Bruhns and Jonsson, 2015; Collins, 2016). Also, the fact that unvaccinated mice had a
higher IgG3 titer compared to rF1+rV vaccinated mice suggested binding to F1/V in these
samples is nonspecific and perhaps due to contamination from E. coli, since LPS alone is
sufficient to induce isotype switching to IgG3 (Deenick et al., 1999).
I.n. administration of TMV-F1 can completely protect mice against the F1 wild-type
Y. pestis CO92pgm- strain as well as mice given i.n. TMV-F1+TMV-V, which can likely be
attributed to a strong antibody response against F1 in both groups (Arnaboldi et al., 2016).
However, the role of V antigen in vaccine-induced protection was still unclear. The best way
to evaluate this role, we believed, was to use a Y. pestis strain lacking F1, where we could
confirm contribution of V-specific adaptive immunity from the conjugate vaccine (TMVF1+TMV-V) in the absence of the immunodominant F1. The KIM5caf1A mutant of Y. pestis
(Δpgm Δcaf1) was selected; this strain cannot assemble the F1 capsule on its surface due to
the lack of the Caf1A protein, which is required for secretion of F1 (Andrews et al., 1996;
Ivanov et al., 2008; Zavialov et al., 2003). Interestingly, mice i.n. immunized with rV, a mix
of rF1 and rV (rF1+rV), or TMV-F1+TMV-V had no measurable V-specific serum titer prior
to challenge, yet all of these groups fared better in survival against pneumonic plague than
mice immunized with TMV-V alone, in which two mice did produce anti-V antibodies. Both
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of those mice (a male and female) succumbed to infection while the one surviving TMV-Vimmunized male had no titer prior to infection. The number of mice sampled in this
experiment is small, and some mice were lost after the boost due to issues with the i.n.
immunization, and therefore, should be repeated. The data thus far suggests that V-specific
immunity may be T cell-mediated and not antibody-dependent. All immunized mice
drastically lost body weight in the first 2-3 days after challenge, but then eventually
rebounded if they survived. Activation of T memory cells in this case could be delayed in
comparison to the rapid recall responses seen with F1-based humoral immunity (see Aim 2).
This also involved a different Y. pestis strain (KIM5) and the lethal inoculation dose required
two orders of magnitude of bacteria (~2.5x107 CFU) higher than that established for Y. pestis
CO92pgm- (~2.5x105). This could be why dramatic weight loss was not observed in any of
our 10 LD50 Y. pestis CO92 challenges. The data also clearly indicated that, for Y. pestis
strains lacking F1, linking V to TMV for i.n. vaccination does not offer any benefit over V
alone. Further experiments should seek to understand how rV as a vaccine could contribute
to cell-mediated immunity better than TMV-V.
Another interesting observation was that the mixed TMV-F1+TMV-V vaccine
offered better protection (30% survival) compared to TMV-V (12% survival). This finding
echoes those of our laboratory, which reported that mean F1- and V-specific titers were
elevated in mice co-immunized with TMV-F1 and TMV-V, compared to mice that received
TMV-F1 or TMV-V alone (Arnaboldi et al., 2016). Addition of TMV-F1 did not detract
from the immune response to V, and vice versa. This is seen in cases, here, where antibody
may not be critical to survival. In the aforementioned study, i.n. co-immunization of rF1 and
rV did not increase V-specific IgG1, IgG2a, or IgG2b titers compared with i.n. rV
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immunization alone (Arnaboldi et al., 2016). Therefore, I hypothesized that the added
presence of TMV was likely responsible for the enhanced anti-V response. These results
encourage the addition of viable TMV as an adjuvant to the TMV-V vaccine. Our rTMV is
replication-defective; the RNA is inactivated by BEI and cannot be translated, but is still
intact. Since it is unclear how this inactivation affects RNA interaction with PRRs, addition
of active TMV (with replication-capable RNA) is worth exploring. Active RNA may boost
the antiviral-like response to TMV, and thus the anti-V response, since these are one-in-thesame during VLP-driven immunity. Further experiments looking at V-specific immunity may
wish to add viable TMV to bolster CD4+ T helper or CTL cell responses, since our data
suggests V-specific antibodies are not a correlate of protection of TMV-V.
In summary, we show that TMV conjugates are a potent and safe chimeric mucosal
vaccine that initiates VLP-like immune responses. Any mouse immunized i.n. with TMV-F1,
specifically, usually developed high F1-specific serum IgG titers after single or multiple
administrations. When applied to an infection model, we find that this response is protective
against pneumonic infection with a Y. pestis strain expressing the F1 capsule protein, and this
memory recall response is T-cell independent. This protection is lost against F1- Y. pestis,
even when the TMV-V vaccine is also administered. Taken together, our results indicate the
potential usefulness of rTMV as a carrier for VLP immunogenic presentation and mucosal
delivery of whole protein antigens.
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Fig 1. CD4+ T cell depletion prior to lethal pneumonic infection with Y. pestis
CO92pgm- does not affect survival in immunized mice. 12 mice were i.n. immunized once
with TMV-F1+TMV-V or not immunized (control), challenged i.n. with Y. pestis 5 weeks
later, and monitored for 21 days post-infection. In each group, half of mice were injected IP
with anti-CD4 antibody, and other half with rat IgG2bk isotype antibody, 2 days prior to
challenge and weekly thereafter. (A) Immunization and challenge timeline. (B) Kaplan-Meier
curve showing comparison of survival. Statistical significance was analyzed by the MantelCox log-rank test (p<0.0001). (C) Average percent body weight (from initial weight on day
of challenge). (D) Comparison of the pre-challenge total serum F1-specific titers between
deceased and surviving TMV-F1+TMV-V-immunized mice. Unpaired t test analysis
revealed no significant difference between the two groups. (E) Survivors’ weight loss during
the critical period of infection (D1-D8). Multiple t test analysis for each day post-infection
revealed no significant difference between the two groups. All errors bars represent
mean±SD.
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Fig 2. CD8+ T cell depletion prior to lethal pneumonic infection with Y. pestis
CO92pgm- does not affect survival in immunized mice. 12 mice were i.n. immunized once
with TMV-F1+TMV-V or not immunized (control), challenged i.n. with Y. pestis 5 weeks
later, and monitored for 21 days post-infection. In each group, half of mice were injected IP
with anti-CD8α antibody, and other half with rat IgG2bk isotype antibody, 2 days prior to
challenge and weekly thereafter. (A) Immunization and challenge timeline. (B) Kaplan-Meier
curve showing comparison of survival. Statistical significance was analyzed by the MantelCox log-rank test (p<0.0001). (C) Average percent body weight (from initial weight on day
of challenge). (D) Comparison of the pre-challenge total serum F1-specific titers between
deceased and surviving TMV-F1+TMV-V-immunized mice. Unpaired t test analysis
revealed no significant difference between the two groups. (E) Survivors’ weight loss during
the critical period of infection (D1-D8). Multiple t test analysis for each day post-infection
revealed no significant difference between the two groups. All errors bars represent
mean±SD.
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Fig 3. I.n. immunization with TMV-F1+TMV-V generates robust serum IgG response
of the same subclasses (IgG2b, IgG3) against TMV and conjugated antigens. Serum
antibody titers for anti-TMV IgG2b (A), anti-TMV IgG3 (B), anti-F1+V IgG2b (C), and antiF1+V IgG3 (D) following i.n. vaccinations with rF1+rV, TMV-F1+TMV-V, or no vaccine
(control). For all groups, serum was collected on day 56 post-prime immunization (day 0)
and after the second and final boost (day 35). One-way ANOVA analysis revealed TMVF1+TMV-V immunized mice had a significant increase in IgG2b and IgG3 titers for both
TMV and F1+ V antigens compared to unvaccinated and rF1+rV-immunized mice.
****p<0.0001, ***p<0.001. n=4 mice/group. All errors bars represent mean±SD.
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Fig 4. F1-specific IgG2b production is not localized to lung following infection.
Comparison of ELISA curves for F1-specific IgG2b collected from lung homogenates 24
(A), 48 (B), 72 (C), 96 (D), and 120 (E) hours post-infection (HPI) with i.n. dose of 100
LD50 Y. pestis CO92pgm-. Multiple t test analysis for each dilution revealed no significant
difference between the groups. n=6 mice/group. All errors bars represent mean±SD.
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Fig 5. I.n. immunization and boost with rV provides the best protection against lethal
pneumonic infection with a Y. pestis F1-mutant strain. 10 mice (5 males, 5 females) were
i.n. immunized and boosted once with rV (red), TMV-V (green), rF1+rV (blue), TMVF1+TMV-V (orange), or not immunized (black), and challenged i.n. with 20 LD50 Y. pestis
KIM5caf1A. (A) Immunization and challenge timeline. (B) Kaplan-Meier curve showing
comparison of survival. Statistical significance was analyzed by the Mantel-Cox log-rank test
(p<0.05). (C) Average percent body weight (from initial weight on day of challenge). (D)
Survivors’ weight loss during the critical period of infection (D1-D8). Multiple t test analysis
for each day post-infection revealed no significant differences between groups. Pre-challenge
total serum F1-specific titers (E) and V-specific titers (F) for all groups, collected 4 days
before challenge. Individual mice are indicated by their respective symbol. All errors bars
represent mean±SD.
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Chapter 5. Overall Discussion
The implementation of global vaccination in the 20th century is undoubtedly one of
humanity’s greatest medical achievements. Communicable diseases that once ravaged
communities – smallpox, polio, diphtheria, pertussis, measles, rubella, mumps, hepatitis B,
Haemophilus influenzae type b, tuberculosis, rotavirus, tetanus, meningococcal disease – are
now considered vaccine-preventable diseases. The success of global vaccination programmes
and eradication of smallpox in 1977 inspired the idea of disease eradication – an idealistic
concept that a selected disease could be eradicated from all human populations through
global cooperation (CDC, 1999). The discovery of antibiotics was yet another breakthrough
in the fight against infectious diseases in the 20th century. However, overuse of these
medicines in livestock, fish farming, and the clinic have contributed to multi-drug resistant
(MDR) bacteria. The emergence of MDR bacterial infections has underscored the importance
of disease prevention using vaccines.
In the event of a biological attack, antibiotics cannot be relied upon as the first, or
even last, line of defense. Weaponized plague (Yersinia pestis) bacteria, for instance, would
be expected to be MDR. Thus, routine antibiotics could not be used, and the bioweapon
would successfully infect a densely populated city, aided by human-to-human transmission
of airborne Y. pestis. To envision such a scenario is unsettling. Currently, there is no FDAapproved vaccine against plague for mass vaccination to protect the general public, although
one is anticipated for use by the U.S. Army in 2021 (Demeure et al., 2019). Vaccination
would not only protect civilians before a bioterror attack, but it would also be a way to
minimize casualties and deter future attacks. Since the anthrax attacks of September 2001,
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our nation has prioritized and supported academic and government-led research of multibiothreat vaccines, for example, a dual vaccine for Bacillus anthracis and Y. pestis (Tao et
al., 2017), or a trivalent vaccine for B. anthracis, Y. pestis, and Francisella tularensis (Jia et
al., 2018).
Whatever the target pathogen(s) may be, vaccines for biothreats should aim to have
four key features: (1) broadly neutralizing ability against multiple or predicted antigenic
variants, (2) capacity to induce rapid or sufficient protection after a primary dose, (3)
capacity to generate long-lived memory in the host, and (4) above all, a good safety profile.
Subunit vaccines containing pure recombinant antigens are the best option in regard to safety.
Many laboratories utilize non-replicating vector platforms engineered to express antigens, or
a fusion protein of two or more antigens. While this approach is feasible in small-scale
laboratory experiments, such vectors could prove laborious to produce on a massive scale.
For use in vaccines, fusion proteins – despite the advantage of multivalence – run the risk of
concealing neutralizing epitopes that are accessible when individual antigens are
administered. Singular proteins have better success at provoking antibodies against a wider
range of linear and conformational epitopes, and antigen-specific responses can be further
teased out experimentally.
Additionally, subunit vaccines typically require adjuvants to increase antigen-specific
immunogenicity and maximize effectiveness. For instance, in the study by Tao et al., their
subunit vaccine against anthrax and plague required the use of Alhydrogel® for protection
(Tao et al., 2017). This vaccine could never be administered mucosally to people, as alum
induces a strong proinflammatory immune response that will damage vital mucosal tissue.
Non-replicating vectors and purified antigens commonly stimulate responses dominated by
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antibodies; however, antibodies may not always provide optimal protection (Savelkoul et al.,
2015). This was the major limitation of KWC plague vaccines used on soldiers during the
Vietnam War, where high antibody titers were effective against bubonic plague, but
ineffective against pneumonic plague. A growing body of evidence supports that cellmediated immunity, in cooperation with humoral immunity, is the best defense against
pneumonic plague infection in NHP, and this method of protection likely extends to humans
(Smiley, 2008). While this is not impossible with subunit vaccination, it has nonetheless
proved challenging.
In the early-mid 2000s, McCormick, Palmer, and colleagues at Large Scale Biology
Corp. created a novel recombinant virus delivery vehicle capable of binding whole protein
antigens (McCormick and Palmer, 2008; Smith et al., 2006). Our own version of this
platform has been made to separately “carry” Y. pestis virulence proteins, LcrV (V) and F1
(TMV-V and TMV-F1, respectively). The proteins become covalently bound to the rTMV
CP; they are not expressed by the virion. The unique structure of rTMV-protein conjugates
gives it subunit, whole-inactivated virus, and VLP vaccine classification: it is an inactivated
natural virus that carries subunit proteins in a high-density, repetitive display (similar to a
viral capsid). It is worth noting that several discoveries were made with TMV-F1 and TMVV prior to this dissertation. Most importantly, it was shown that the conjugates could be
safely administered i.n. while retaining immunogenicity in mice. Additionally, covaccination of the TMV conjugates did not detract from the immune response to either
antigen. In fact, F1- and V-specific titers were consistently elevated in mice co-immunized
with TMV-F1+TMV-V, compared to mice that received TMV-F1 or TMV-V alone (with
exception of anti-V IgG2b, IgG2a), as discussed previously (Arnaboldi et al., 2016). It was
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first thought by my lab that the combination of F1 and V was responsible for this effect, as is
often reported with F1/V based vaccines (Amemiya et al., 2009; Heath et al., 1998; Jones et
al., 2006; Williamson et al., 1997) . However, in our model, i.n. vaccination with rF1+rV did
not significantly increase V- or F1-specific titers compared with i.n. rF1 or rV alone.
Therefore, I hypothesized that the TMV was directly responsible for the enhancement of
vaccine-specific immunity and protection in these mice. It was unclear at the time how TMV
conjugates were accomplishing this. The initial hypothesis proposed by my PI stated that
increased uptake of the TMV conjugates into DCs promoted T cell-mediated responses over
that of the unbound antigens. However, this had yet to be formally established.
This dissertation made several new discoveries that have built upon the initial work of
my lab and support further development of this unique carrier platform. A single i.n. dose of
TMV-F1+TMV-V was capable of mediating 100% protection against 10 LD50 Y. pestis
CO92pgm-, and physical linkage of proteins to rTMV (i.e. conjugation) was necessary for
protection. When applied to a high-dose infection (100 LD50), a single i.n. dose of TMVF1+TMV-V was capable of mediating 88% protection against this Y. pestis strain by the i.n.
route, while i.n. immunization with rF1+rV protected <12% of mice. TMV conjugate
immunization additionally showed reduction in histopathology, bacterial burden, and IFN-γ,
TNF-α, and IL-17 tissue levels in the days following challenge. Pneumonic challenge
resulted in systemic dissemination of Y. pestis bacteria in all groups, but only TMVF1+TMV-V immunized mice rapidly cleared bacteria from the spleen and liver 4-5 days into
infection. Additionally, I found that TMV conjugation to F1 and V increased their uptake
into splenic and mucosal B-cells, and BMDCs in vitro, as well lung DCs in vivo. Neither
TMV-F1 nor TMV-V were classic immunostimulants, as they did not upregulate
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costimulatory markers (MHC II, CD80, CD86) over that of unstimulated CD11c+ DCs.
Finally, I demonstrated that generation of antibody‐based, but not T cell-based, immunity
could be attributed to vaccination with TMV conjugates. Mice administered with TMV-F1
i.n. predictably produced anti-F1 IgG after a single vaccine dose. When applied to an
infection model of F1+ Y. pestis, we observed that the protective memory response induced
by TMV vaccination did not require CD4+ or CD8+ T cells. This protection is lost against F1Y. pestis KIM5caf1A, where mice vaccinated with TMV-F1+TMV-V demonstrated poor
protection (30% survival).
In summary, my research has uncovered mechanisms by which rTMV platform is
enhancing vaccine-specific immunity and protection against plague through i.n. vaccination.
I have demonstrated the usefulness of rTMV as a carrier for VLP immunogenic presentation
of some, but perhaps not all, antigenic proteins. Although these studies have revealed a
considerable amount of information about the immune response to TMV and conjugates, we
are left with a number of questions.

1.How important is the F1 antibody response induced by TMV-F1 vaccination?
A major finding of this dissertation was that higher F1-specific serum antibody levels
correlated significantly with the weight of mice challenged i.n. with Y. pestis, regardless of
the i.n. vaccine used: TMV-F1+TMV-V (conjugates) or rF1+rV (proteins) (Aim 2, Fig 4).
This suggested to us that a higher F1 titer prior to challenge signified a better chance of
survival. Although my Aim 2 results showed that TMV-F1+TMV-V immunized mice had
increased F1 titers compared to the other groups, higher F1-specific titers were only
moderately associated with percent body weight at D3 PI, and pre-challenge titers were not
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required for survival. In fact, conjugate-vaccinated mice survived challenge despite a low F1
titer (<50); and conversely, two protein-vaccinated mice and one conjugated-vaccinated
mouse died despite an F1 titer of 100-125 (comparable to titers of survivors) (Aim 2, Fig 4).
Interestingly, only a small proportion of surviving TMV-F1+TMV-V immunized mice
produced little anti-F1 antibody, while all surviving rF1+rV immunized mice had relatively
high anti-F1 titers prior to infection.
When comparing the F1 titers of only TMV-F+TMV-V vaccinated mice in Aim 3, we
found no significant difference in the pre-challenge total F1 serum antibody titers between
the deceased and surviving mice (Aim 3, Fig 1 and 2). T cells were depleted weeks after
blood collection and should have had no effect on immune responses to immunization.
Although this finding seems contradictory to that of the Aim 2 challenge, these analyses
answered separate questions. The above Pearson’s’ correlation asked if F1 antibody levels
correlated with the overall health and recovery of mice, to which the answer was yes. In the
newer sets of experiments, since no unimmunized mice survived, the titer comparison
specifically asked if the quantity of F1 antibodies (titer) could explain the discordant
outcomes from TMV conjugate immunization. Here, survivors had a mean serum F1 titer of
at least 50 prior to challenge, however, the titers of the decreased mice were only slightly
less. So, while it can be said that F1 antibody is predictably generated in response to TMVF1+TMV-V vaccination, the antibody level itself is not a determinant of vaccine-mediated
protection. It is more likely that the quality – not quantity – of the antibody response is
correlative of protection. Further work should utilize in vitro neutralization, ADCP, and CDC
assays to evaluate functionality of vaccine-specific antibodies. Does antibody function
(neutralization, opsonization, cytolysis) improve with boosts? What host factors may

152

negatively influence antibody production from vaccination? These questions need to be
addressed. Therefore, although we found a significant correlation between post-infection
recovery and serum F1 titers, the results obtained by the later set of challenge experiments
show that the correlation may not be biologically relevant. Further work needs to elucidate
what other factors are critical for vaccine-mediated protection and how to better characterize
and predict vaccine efficacy.

2.What is the contribution of DCs vs. B cells to TMV-F1-mediated immunity?
Although my work has shown that TMV-F1+TMV-V were increasingly taken up
DCs in the lung, compared to TMV and unconjugated rF1+rV, other results of my
dissertation do not support a strong role for DCs in vaccine-mediated immunity. Both
conjugates failed to upregulate costimulatory markers on DCs in vitro. These molecules are a
major requirement for activation of naïve T cells, and thus, T cell-mediated responses. I also
failed to see the same effect in vivo with CD86 and MHC II. It is still possible that if MLNs
were isolated, instead of the lungs, costimulatory molecules would be upregulated on DCs
that internalized the conjugates, although this would not explain why we did not see the
effect in vitro. As previously mentioned, the TMV as part of the conjugate is inactivated and
has lost the ability to replicate. Further experimentation is needed to determine if BEI
inactivation interferes in the RNA’s interaction with PRRs in DCs, although the literature
provides evidence for T cell activation when viable (non-inactivated) TMV is used in
immunization strategies (Kemnade et al., 2014)
Results of Aim 1 also showed no significant difference in uptake of TMV-F1 and F1
into DCs (Aim 1, Fig 3), yet the primary immune responses found and investigated in this
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dissertation were against F1. Coating the TMV virion in F1 proteins could limit its uptake by
phagocytosis, as F1 protein naturally accomplishes this in Y. pestis as part of the bacterial
capsule. DCs cannot initiate anti-F1 T cell responses if they are unable to first process the
antigen. Yet, a structure that prevents uptake by phagocytes could simultaneously promote
endocytosis by B cells, on account of the specialization of professional APCs (Bachmann et
al., 1993). Unlike DCs, repetitive protein displays naturally crosslink BCRs on B cells and
promotes MHCII presentation of peptides to T cells (Donaldson et al., 2018). Aim 1
demonstrated that uptake of antigens by B cells is independent of the virus and is likely due
to the random presence of BCRs capable of binding to F1 or V antigens. For splenic B cells,
uptake of TMV-F1 was significantly higher than rF1, and this difference increased with each
day of incubation, indicating potential for activation of naïve B cells by TMV-F1, but not
soluble rF1 (Aim 1, Fig 3). However, due to the specificity of antigen internalization, few
naïve B cells participate in uptake of novel antigens. The lung showed high variability in
uptake of all antigens into B cells that made it difficult to infer significant uptake (Aim 1, Fig
1 and 2). The variation can be attributed to at least two sources: (1) the vast repertoire of
BCR that can exist between individual mice, and (2), the nature of i.n. instillation, as inhaled
material deposits asymmetrically in both lungs and inoculums can vary in size/volume
between subjects, as opposed to uniform aerosol inhalation (Mizgerd and Skerrett, 2008).
Despite these limitations, B cells may represent the primary APC involved in uptake of
TMV-F1, and further in vivo studies should seek to improve experimental conditions where
B cell uptake of this conjugate can be more accurately measured.
If B cells are key APCs, what is their fate? Since lungs were not perfused when
sampled, the presence of F1-specific IgG2b in the lung post-infection was likely due to
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transudation from circulation and not local production (Aim 3, Fig 4). Upon re-exposure to
antigen, memory B cells immediately differentiate into plasma cells in a manner that is faster,
stronger, and more specific than the naïve response (Palm and Henry, 2019). Some also
retreat to SLO to undergo further affinity maturation and proliferate to create more memory
cells. Although it seems critical in pneumonic plague infection that memory B cells would
home to the lung, to maximize their chances of encountering antigen mucosally, our data
suggests F1-specific IgG+ memory B cells do not reside there. Rather, the spleen, cervical
LN (CLN), MLN, or nasal-associated mucosal tissue (NALT) are the likely sites of germinal
center (GC) responses generated by i.n. immunization with TMV-F1 (Fig 1). One study in
mice identified low-affinity lung B cells as the key APCs that shuttle inhaled VLP from the
lung to the spleen via the circulation to initiate GC antibody responses (Bessa et al., 2012).
The marginal zone of the spleen serves as a major reservoir of memory B cells in mice, as
does the subcapsular sinus of LNs (Tangye and Tarlinton, 2009). Going forward, F1-specific
IgG+ memory B cells should be isolated from TMV-F1 immunized mice. If identification of
such memory cells is possible, future experiments can adoptively transfer B cells from TMVF1 vaccinated mice to naïve mice to demonstrate conferred protection against plague.
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Fig 1. Potential immune inductive sites and memory T and B cell locations generated by i.n.
immunization in mice. Various SLO and organized lymphoid tissues could serve as sites of immune
responses to i.n. immunization. The aqueous droplet inhaled by the mouse may stimulate an immune
response to TMV conjugates in the NALT, if volume is retained in the nasal tissue. In this case,
antigen-specific and TMV-specific memory cells would likely be stored in the downstream cervical
LNs (CLN). Due to the large droplet volume used (40µL), the inhaled TMV conjugates are also
absorbed in the lungs, in which case downstream mediastinal LNs (MLN) would serve as the site of
immune induction and memory cells. If the TMV conjugates reach circulation, the spleen could also
serve as additional inductive site and pool of antigen-specific memory cells. There is also a chance a
small volume of the conjugates bypasses the trachea and enters the gastrointestinal tract, where there
could be generation of intestine-resident memory cells if immune responses were initiated there.
Image created on BioRender.com.

156

3.What is the role of T cells in vaccine-mediated immunity, if these cells are not
required for protection against plague?
One of the major findings of this dissertation was that the predominant IgG subclass
in the humoral response to TMV (IgG2b) mirrored the response to F1 and V. Conjugation of
these proteins to TMV significantly increased both viral titers and antigen-specific IgG2b
titers compared to mice given rF1+rV i.n. (Aim 3, Fig 3). This suggests that the TMV
conjugate is enhancing humoral responses by exploiting a phenomenon known as linked
recognition, where B-cells internalize the highly repetitive TMV surface structure, degrade
and process the whole conjugate, and present both virial and antigen peptides to cognate TH
cells. The cognate interaction between T follicular helper (TFH) cells and B cells is necessary
for T cell-dependent (TD) Ig class switching and high-affinity antibodies (Shinomiya et al.,
1989). TH1 or TH17 cellular responses were not required to eliminate the bacteria (Aim 3, Fig
1 and 2). Therefore, the main contribution of T cells in our vaccine model is likely in the
“priming phase,” helping B cells make specific antibody to TMV CP and Y. pestis proteins,
as opposed to the “effector phase,” where T cells would be directly or indirectly killing
infected cells.
TFH-secreted IL-21 and ligation of CD40L to CD40 promotes differentiation of B
cells into long-lived memory cells and plasma cells – a hallmark of TD B cell responses.
Generation of TFH cells is thought to be driven by DCs in vivo, where signals downregulate
CCR7 on CD4+ T cells allowing them to migrate to B cell follicles (Fazilleau et al., 2009). In
GC, cognate activated B cells are also thought to provide similar signals that drive the full
development of TFH cells, such as secretion of IL-6 and IL-27 (Ma et al., 2012). However,
naïve antigen‐specific B cells are rare in vivo, as previously mentioned, and are not available
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as APCs for CD4+ T cells as readily as DCs are (Kolenbrander et al., 2018). Thus, DCs play
a principal role in initiating potent TFH responses. T cell-independent (TI) activation of B
cells can also occur and requires synchronized BCR and TLR signaling. It has been shown
that TLR7 stimulation by a ssRNA-containing VLP (Qβ-VLP) can overcome the requirement
of TFH-derived IL-21 to generate IgG responses in GC (Bessa et al., 2010). rTMV – while a
whole virus and not a VLP –contains intact ssRNA as well. The conjugated protein antigens
(rF1 and rV) are additionally LPS-contaminated due to expression in E. coli (Appendix I, Fig
S4). It would be interesting to see whether TLR7 and/or TLR4 signaling in B cells with TMV
conjugates translated to a TI response in vivo. TD responses usually follow initial TI
responses to viral proteins and contribute to affinity maturation and memory B cell
maintenance. Despite the robust TI response to Qβ-VLP i.p. immunization, T cells were
ultimately needed to induce long-lived Qβ-specific memory IgG+ B cells that were detected
in the spleen for >1 year (Liao et al., 2017). Thus, CD4+ TFH cells would be expected to play
a key role in the generation of long-term TMV (vaccine)-specific memory; although, we
found that CD4+ T cells may not be required for re-activation of memory B cells from a
single vaccination (Aim 3, Fig 1). Adoptive transfer of T cells from TMV-F1 and/or TMV-V
vaccinated mice to naïve mice can confirm if T cells are still sufficient for vaccine-mediated
protection against plague.

4.How are mucosal tissue and SIgA contributing to vaccine-mediated immunity?
The nasal route represents the best method of delivery for non-replicating chimeric
plant virus particles, as i.n. delivery of these vaccines has been shown to optimally induce
both mucosal and systemic IgA and IgG responses in mice, without the requirement of
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adjuvants (Brennan et al., 1999). Humoral immune responses at mucosal surfaces have
historically focused on SIgA. With i.n. vaccination, SIgA production could take place in the
lung, MLN, and also at distal mucosal sites such as the intestinal and vaginal tracts.
Unfortunately, the lungs collected in the 5 days post-infection were not perfused, so it could
not be determined if there were F1-specific IgA+ B cells in the lung mucosa. Other mucosal
sites (e.g. intestine) were not assessed for vaccine-specific memory cells or Ig in our model.
Antigen-specific SIgA can be difficult to detect and usually requires specialized techniques
because there is so little antigen-specific IgA compared to the total IgA content.
Possible contribution of the NALT to immunity could not be determined in the course
of this project. Groups have pointed to the NALT as the major site for priming B cells
following i.n. infection or immunization (Brandtzaeg, 1999; Kiyono and Fukuyama, 2004;
Liang et al., 2001; Zuercher et al., 2002). However, the NALT in mice lacks memory cells
and afferent lymphatics, and thus, is an irrelevant source of antibody production. Prior work
in our laboratory has shown B cells of the NALT are positive for fluorescently labeled TMV
upon i.n. immunization within hours (data not shown), but these experiments did not clarify
the fate of these B cells, nor the requirement of NALT to vaccine-induced protection. My
work attempted this but the NALT ablation surgical procedure was not successful in our
mice, and so the results of that challenge study were scraped. Our VLP-like vaccine is
administered i.n. as droplets, which can be retained in both the upper and lower respiratory
tracts of the mouse depending on the volume used (Mizgerd and Skerrett, 2008) . However, a
large droplet, such as the 40μL volume used in our studies, is mostly inhaled to trigger B-cell
responses preferentially in MLN or lower respiratory tract (Bessa et al., 2008). I.n.
immunization may also lead to induction of B cell responses in the CLN which drain the nose
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and upper airways. However, observations comparing the number of VLP-specific B cells in
the CLN and MLN have shown that the murine lower respiratory tract is the major site
draining particulate vaccines for the induction of antibody responses in MLN (Bessa et al.,
2008). Further investigation is needed to identify where antigen-specific memory B cells
reside (in LNs or spleen) after i.n. immunization with TMV conjugates. The use of ELISPOT
(ex vivo), BCR transgenic mice (in vivo), multiphoton microscopy (in vivo), or fluorescently
labeled antigen tetramers and anti-idiotypic antibodies in flow cytometry (ex vivo) are some
potential methods for identification of antigen-specific B cells in mice.
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Appendix I.
Table S1. Total number of randomly selected male and female mice used per time point for
in vivo replicate experiments.
Immunization
1h
2h
4h
24h
48h
96h
Group
Control
2 males
1 male
1 male
1 male
2 males
2 males
(unimmunized) 1 female
2 females
2 females 2 females 1 female
1 female
rF1+rV

1 male
2 females

2 males
1 female

2 males
1 female

2 males
1 female

2 males
1 female

1 male
2 females

TMVF1+TMV-V

1 male
2 females

1 male
2 females

2 males
1 female

1 male
2 females

1 male
2 females

1 male
2 females

TMV

2 males
1 female

2 males
1 female

1 male
2 females

2 males
1 female

1 male
2 females

2 males
1 female
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Fig S1. General uptake of i.n.-administered protein antigens, TMV conjugates, and
TMV represents <8% of total viable lung cells. Uptake of 488-labeled proteins (FITC+)
proteins into different immune cell populations in the murine lung after 1, 2, 4, 24, 48, and 96
hours post- i.n. immunization. Uptake of FITC+ rF1+rV proteins (A), TMV-F1+TMV-V
conjugates (B), and unconjugated TMV (C) into leucocytes (CD45+) and non-leucocytes
(CD45-) are shown as the percent of total viable lung cells. CD45- bars (white) are
superimposed onto CD45+ bars (grey). (D) Flow cytometry analysis and gating for general
lung uptake. Example plots shown: a control and TMV-F1+TMV-V-immunized lung
sacrificed at 24-hour time point. Significance between all three immunization groups was
analyzed in one graph (not shown) by repeated-measures two-way ANOVA with Tukey’s
multiple comparisons test, however, at no time point were the groups statistically different
from one another. All errors bars represent mean±SEM.
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Cell type

Surface markers and cell scatter

Alveolar macrophage (AM)

CD11c+ SiglecF+ SSChi MHCII- CD11b-

Dendritic cell (DC)

CD11c+ MHCII+ SSClo CD11b+/- SiglecF-

Interstitial macrophage (IM)

CD11b+ CD11c+/- SSChi MHCII+/- SiglecF-

Monocyte (Ly6C+ presumed)

CD11c- CD11b+/- MHCII+/- SSClo SiglecF-

B cell

CD19+ SSClo

DC precursor (pre-DC)

CD11c+ CD11b- MHCII- SSClo SiglecF-

Fig S2. Gating strategy and cell markers used for analysis of FITC+ protein uptake into
lung CD45+ cells in vivo. Flow cytometry analysis and gating used to define CD45+ cell
populations, as well as cells associated with FITC+ proteins. FITC+ cells could be clearly
separated into AMs and non-AMs. Boolean gates were created (e.g. DC gate + FITC+ gate =
FITC+ DCs) to accurately determine all CD45+ cell populations involve in uptake, using
Flowlogic™ analysis software. The table lists the surface markers and scatter used to identify
the various cell populations used in this study. SSChi was defined as >50 and SSClo as ≤50.
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Fig S3. Most interstitial macrophages (IMs) (CD11b+ SSChi) are CD11c- MHC II-. Flow
cytometry analysis and gating used to define IMs in vivo. CD11b+ IMs can represent a
heterogenous population of CD11c- MHCII-, CD11c+ MHC IIlo, and CD11c+ MHC IIhi cells.
Example plots shown: rF1+rV, TMV-F1+TMV-V, and TMV immunized lung sacrificed at
48-hour time point.
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Fig S4. rF1 and rV contain similar levels of endotoxin as corresponding TMV
conjugates. A chromogenic LAL endotoxin assay was performed to assess endotoxin (LPS)
contamination from rF1 and rV antigens, and TMV-F1 and TMV-V conjugates. The
concentration of TMV conjugates was double that of the recombinant protein to ensure molar
equivalency of rF1 and rV between the groups, since TMV conjugates contain equivalent
concentrations of TMV and recombinant protein. Molar equivalent pairs of TMV conjugate
and corresponding protein are color-matched (e.g. TMV-V 10μg/mL and rV 5μg/mL are both
teal). Purified TMV contained no endotoxin.
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Appendix II.

Fig S1. Conjugation to recombinant TMV (rTMV) for protection against pulmonary
challenge with 10 LD50 Y. pestis CO92pgm-. Mice were i.n. vaccinated once with either
TMV-F1/V, rF1+rV, rF1+rV+rTMV, or not vaccinated (controls) and monitored for 21 days
post-infection (n=5 mice/group, mix of male/female). (A) Kaplan-Meier curves showing
comparison of survival. Asterisks indicate statistical significance by the Mantel-Cox log-rank
test. (B) Average percent body weight (from initial weight on day of challenge). ***
p<0.001. All errors bars represent mean±SEM.
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Fig S2. Survivors’ weight loss during the critical period of infection (D1-D8). Asterisks
indicated statistical significance between TMV-F1+TMV-V vaccinated and unvaccinated
mice, compared by unpaired student’s t test for each day post-infection. Data is pooled from
two separate experiments. Unvaccinated n=3, rF1+rV n=3, TMV-F1/V n=23. **p<0.01,
*p<0.05. All errors bars represent mean±SEM.
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D1

D2

D3

D4

A

B

C

Fig S3. Representative lung sections D1-D4 post-infection with 100 LD50 Y. pestis
CO92pgm-. Formalin-fixed tissues were sectioned and stained with hematoxylin and eosin
(H&E). Images represent sections from a (A) unvaccinated, (B) rF1+rV-immunized, and (C)
TMV-F1/V-immunized mouse sacrificed at D1-D4 post-infection (left to right). Scale bar
represents 550µm; all images taken at 4x magnification.
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D1

D2

D3

D4

A

B

C

Fig S4. Representative spleen sections D1-D4 post-infection with 100 LD50 Y. pestis
CO92pgm-. Formalin-fixed tissues were sectioned and stained with hematoxylin and eosin
(H&E). Images represent sections from a (A) unvaccinated, (B) rF1+rV-immunized, and (C)
TMV-F1/V-immunized mouse sacrificed at D1-D4 post-infection (left to right). Scale bar
represents 550µm; all images taken at 4x magnification.
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D1

D2

D3

D4

A

B

C

Fig S5. Representative liver sections D1-D4 post-infection with 100 LD50 Y. pestis
CO92pgm-. Formalin-fixed tissues were sectioned and stained with hematoxylin and eosin
(H&E). Images represent sections from a (A) unvaccinated, (B) rF1+rV-immunized, and (C)
TMV-F1/V-immunized mouse sacrificed at D1-D4 post-infection (left to right). Arrows
indicate locations of inflammation. Scale bar represents 550µm; all images taken at 4x
magnification.
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Table S2: Histopathology Scoring System for Tissue Sections
Severity
Spleen
Lung
Liver
Score
0
Vibrant red pulp, neat Largely eosinophilic
Light pink-purple
germinal center (GC) (pink) staining, alveoli staining, sinusoids are
boundaries, GCs stain are clear, no
clear and free of
rich blue-purple
perivascular
lymphocytes, hepatocytes
lymphocytes
appear “foamy”
1
Some disorganization Some lymphocyte
Some lymphocyte
of GCs, number of
infiltration, 1 or 2
infiltration (dark purple
lymphocytes is
inflammatory foci, lung staining is apparent),
increased, red pulp
architecture and alveoli hepatocyte morphology
still present
remain intact
and sinusoids appear
undisturbed
2
Disorganization of
Neutrophil infiltration, Neutrophil infiltration in
GCs,
increased numbers of
small clusters, some
neutrophil/granulocyte lymphocytes, 3-5
sinusoids are closed
infiltration, some red
inflammatory foci,
and/or surrounded by
pulp is still present
alveoli remain intact,
lymphocytes, edema
edema possible
possible
3
Most GCs have
Neutrophil infiltration, Multiple neutrophilic foci
amalgamated, large
increased numbers of
(>5) are evident, some
neutrophilic lesions,
lymphocytes, >5 large
necrosis, edema, many
necrosis, loss of most inflammatory foci,
sinusoids are closed
or all red pulp
areas of alveoli still
and/or surrounded by
visible, edema in some lymphocytes, hepatocytes
areas
no longer appear “foamy”
4
Over 80% has
Over 80% is inflamed, Over 80% has necrotic
necrotic and/or
architecture and alveoli and/or inflammatory
inflammatory lesions, severely altered,
lesions. This was not
red pulp has
edema, necrosis,
observed in this study.
disappeared
inflammatory foci are
completely
too large to distinguish
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Appendix III.
Day 2 Post-Depletion

Day 7 Post-Depletion

Fig S1. Confirmation of anti-CD4 antibody (GK1.5) depletion 2- and 7-days postinjection. Mice were injected intraperitoneally (IP) with a 100ug dose of anti-mouse antiCD4 antibody (clone GK1.5) in 200ul volume of PBS. Peripheral blood, whole spleen, and
whole lung were collected and processed by flow cytometry for markers CD3 and CD4. Plots
that indicate “ISOTYPE” were mice given a non-specific rat IgG2bk isotype control antibody
at the same time and same dose/volume as the anti-CD4 antibody. Plots that indicate “CD4-“
are mice given the anti-CD4 antibody.
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Day 2 Post-Depletion

Day 7 Post-Depletion

Fig S2. Confirmation of anti-CD8α antibody (YTS 169.4) depletion 2- and 7-days postinjection. Mice were injected intraperitoneally (IP) with a 100ug dose of anti-mouse antiCD8α antibody (clone YTS 169.4) in 200ul volume of PBS. Peripheral blood, whole spleen,
and whole lung were collected and processed by flow cytometry for markers CD3 and CD8.
Plots that indicate “Mock” were mice given a non-specific rat IgG2bk isotype control
antibody at the same time and same dose/volume as the anti-CD8 antibody. Plots that
indicate “CD8-“ are mice given the anti-CD8 antibody.
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Fig S3. I.n. immunization with TMV conjugates generates anti-TMV antibody
consisting of IgG2b, IgG3, and IgM isotypes. (A) ELISA curves showing serum
absorbance for detection of anti-TMV antibody isotypes. Serum was collected on day 56
post-prime immunization (day 0) and after the second and final boost (day 35) from a TMVF1+TMV-V-immunized mouse.
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Fig S4. Single i.n. immunization with TMV conjugates generates similar anti-TMV IgG
titers in females and males, while naïve mice lack a detectable titer. Pilot experiment
showing pre-challenge anti-TMV titers (week 2 post-immunization) of the isotype IgG2b (A)
and IgG3 (B) in TMV-F1+TMV-V-vaccinated and unvaccinated (naïve) mice. One-way
ANOVA analysis revealed no significant difference between titers for panels (A) and (B).
Unvaccinated (control) n=2; TMV-F1+TMV-V females n=3; TMV-F1+TMV-V males n=2.
All errors bars represent mean±SD.
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Fig S5. Titers of survivors show anti-F1 IgG2b and IgA, but not IgG2a, are generated
in response to lethal pneumonic plague infection, regardless of vaccine. Post-challenge
lung homogenate antibody titers for F1-specific IgG2b (A) and IgA (B), and TMV-specific
IgG2b (C) following single i.n. vaccination with rF1+rV (red), TMV-F1+TMV-V (blue), or
TMV+rF1+rV (green). Titers were determined from respective ELISA curves (right-hand
panel) for survivors 21 days after i.n. challenge with 10 LD50 Y. pestis CO92pgm-. Titers
were below the limit of detection (<50) for TMV-specific IgA (D) and F1-specific IgG2a (E),
so only ELISA curves are shown. One-way ANOVA analysis revealed no significant
differences between titers shown in (A) and (B). Unpaired t test revealed no significant
differences in (C). Note: TMV-specific IgG2b was not detected in rF1+rV-immunized mice,
as expected, and was excluded. All errors bars represent mean±SD.
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